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ABSTRACT 
DEAN PATRICK STAUS: The Diaphanous-Related Formins, Dynamic Regulators of 
Smooth Muscle Cell-Specific Gene Transcription 
(Under the direction of Christopher P. Mack, PhD) 
 
 We and others have previously shown that RhoA-dependent actin polymerization 
stimulates SMC-specific gene transcription by promoting the nuclear accumulation of the 
myocardin-related transcription factors (MRTF)-A and -B.  Very little is known about the 
downstream RhoA effectors that mediate this response, and the goal of the studies described 
herein was to define the role of the diaphanous-related formins (DRFs) in regulating smooth 
muscle cell (SMC) differentiation.  The DRFs mDia1 and mDia2 are highly expressed in 
cultured SMCs and in tissues containing a high smooth muscle component. Activation of 
mDia1 or mDia2 by RhoA stimulated actin polymerization, MRTF nuclear accumulation, 
and SMC-specific gene transcription.  Interestingly, we found that phosphorylation of the 
Diaphanous Autoregulatory Domain (DAD) by Rho-kinase also stimulated mDia2 activity 
and SM-marker gene expression.  Knockdown of mDia1/2 using siRNA significantly 
attenuated expression of numerous SM-marker genes in primary aortic SMCs.  While we 
originally attributed these findings to the regulation of cytoplasmic actin dynamics by the 
DRFs, recent evidence linking nuclear globular (G)-actin to MRTF nuclear export led us to 
investigate a possible role for the DRFs in the nucleus.  We found that mDia2, but not mDia1 
or FHOD1, accumulated in the nucleus following treatment with leptomycin, an inhibitor of 
Crm-1 dependent nuclear export.  Deletion and mutation analyses identified nuclear 
iv 
localization sequences (NLS) in the core formin homology 2 (FH2) domain and extreme N-
terminus, and a leucine-rich nuclear export sequence (NES) was identified in the C-terminus 
of mDia2.  Importantly, mDia2 variants that were excluded from the nucleus did not 
stimulate SMC-specific gene transcription and MRTF-B nuclear accumulation as well as 
wild-type mDia2.  Taken together, these data support a model in which mDia2 activity in the 
nucleus and cytoplasm depletes cellular G-actin pools resulting in MRTF nuclear 
accumulation and activation of SMC-specific gene transcription.   
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CHAPTER 1
 
 
BACKGROUND AND SIGNIFICANCE 
Vascular Development 
The vascular system encompasses a complex network of capillaries, arteries and 
veins to efficiently deliver oxygen and nutrients to all bodily tissue.  Since oxygen diffusion 
is limited to approximately 100-200 µM, vasculature formation begins very early in 
development [1].  Vasculogenesis is the earliest process in blood vessel formation and is 
characterized by the differentiation of vascular endothelial cells from mesodermal 
angioblasts (figure 1.1A) [2] .  These cells form primitive hollow tubes that give rise to the 
vascular plexus, which serves as a scaffold for future circulation [3].  Shortly thereafter, new 
capillaries sprout from preexisting vessels in a process called angiogenesis [4].  Since this 
vasculature remains immature and poorly functional, additional vascular remodeling is 
required to meet the high metabolic needs of the embryo.  
An increase in blood flow and pressure within these primitive vascular networks 
likely triggers the recruitment of pericytes and smooth muscle cells (SMCs) by the 
endothelium.  These supportive cells enable the vasculature to withstand increases in 
hemodynamic forces that would otherwise induce vessel rupture or regression.  Platelet-
derived growth factor B (PDGF-B) is produced by the endothelium during this process, and 
acts as a potent stimulator of SMC migration and proliferation.  Indeed, vessels in PDGF-B-
deficient mice exhibit failed vascular recruitment of pericytes and SMCs, and these animals 
 2
 
 
 Figure 1.1. Vascular Development and the role of SMCs in atherosclerosis. A) Mesodermal 
angioblasts give rise to the vascular plexus through the process of vasculogenesis.  Angiogenesis 
leads to vascular remodeling and further vessel maturation requires the recruitment of pericytes and 
SMCs.  B) Normal artery consisting of three main layers; intima, media and adventitia.  The intima is 
composed of a single layer of endothelial cells and is separated from the media by the internal elastic 
lamina. SMCs are the main component of the media and are critical for maintaining blood flow and 
vessel tone. The external elastic lamina is the boundary between the media and adventitia. This 
adventitia is primarily derived from extracellular matrix and fibroblasts. C) SMCs play atherogenic 
roles by migrating and proliferating into the vessel lumen. They further aid in plaque development by 
enhancing the deposition of lipids (as foam cells), calcium, extracellular matrix and inflammatory 
cytokines in the intima.  SMC can also have a protective role in atherosclerosis by contributing to the 
fibrous cap, which may help to stabilize the lesion by preventing rupture and subsequent thrombosis. 
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die in early gestation due to multiple capillary microaneurysms [5, 6].  In addition to 
providing physical support, the medial SMC layer will also facilitate vascular contractility to 
dynamically regulate blood flow and pressure (figure 1.1B). The adventitial layer, which 
mainly consists of fibroblasts and extracellular matrix, is recruited to provide additional 
metabolic and structural support for larger vessels.  
It is worthy of note that SMCs can differentiate from multiple distinct progenitor 
populations during development.  While SMCs have traditionally been regarded as 
mesenchymal in origin, genetic fate mapping has identified at least eight different origins of 
vascular SMCs [7]. These regions include: the neural crest, which gives rise to SMCs of the 
pharyngeal arch and ascending aorta; the secondary heart field, which gives rise to SMCs of 
the pulmonary trunk and base of the aorta; and the proepicardium, which gives rise to 
coronary artery SMCs.  Other identified SMC origins include somites, stem cells, 
mesoangioblasts, splanchnic mesoderm and mesothelium (see [8] for a comprehensive 
review).  
 Once integrated into the vasculature, these different SMC populations, although 
morphologically indistinguishable, can exhibit distinct characteristics.  For example, they 
display spatial separation; while SMCs derived from separate progenitors can occupy the 
same vessel, they rarely intermix within vessels.  Additionally, they can respond 
differentially to extracellular agonists [9]. These distinctions indicate that variance between 
SMC origins has clear functional consequences in the developed organism.  Indeed, SMC 
progenitors were recently discovered within the walls of adult arteries, suggesting that 
differentiation of SMCs may not be exclusive to the developing embryo [10].  Identifying the 
signaling mechanisms and environmental cues that regulate differentiation of distinct SMC 
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progenitors will be essential to determine the contribution of each subtype to the vascular 
network.  
 
Smooth Muscle Cells in Vascular Disease 
 Differentiated SMCs proliferate at a very low rate, are mainly non-migratory, and are 
characterized by the expression of multiple contractile-associated proteins, including SM22, 
SM α-actin, SM myosin heavy chain (MHC), vinculin, calponin, smoothelin and aortic 
carboxypeptidase-like protein (ACLP) [11].  Unlike skeletal and cardiac muscle, smooth 
muscle is not terminally differentiated; rather, SMCs exhibit a specialized plasticity that 
allows them to revert to a more proliferative and synthetic state.  This unique process of 
phenotypic switching has been closely associated with the vascular diseases atherosclerosis 
and restenosis.    
 Atherosclerosis is the number one cause of illness and death in the U.S. as 
determined by the National Heart, Lung, and Blood Institute.  Although the etiology of 
atherosclerosis is not completely understood, diets high in cholesterol and fat, cigarette 
smoking, high blood pressure and diabetes have been closely linked to its development and 
progression [12].  During atherosclerosis, a plaque develops within the intimal layer of the 
vessel as a result of interactions between many cells, including endothelial cells, SMCs, 
lymphocytes and monocytes [13].  As this inflammatory lesion progresses in size and 
severity, it can occlude the arterial lumen, resulting in myocardial infarction or stroke. Early 
atherosclerotic lesions are often described as “fatty streaks”, due to an accumulation of lipid-
rich macrophages and lymphocytes within the vessel wall [14].  Late-stage atherosclerotic 
lesions are characterized by an abundance of necrotic debris, SMCs, and extracellular matrix 
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proteins (figure 1.1C). Interestingly, many studies have shown that SMCs within 
atherosclerotic lesions, which have invaded the arterial intima in response to various 
extracellular cues, are phenotypically distinct from normal medial SMCs [15-17].  These 
phenotypically switched intimal SMCs contribute to the progression of the lesion by 1) 
depositing extracellular matrix within the neointima; and 2) endocytosing lipid deposits to 
form foam cells [18, 19].  However, intimal SMCs can also serve a protective function by 
forming a fibrous cap over the plaque, which acts to stabilize the lesion by preventing 
rupture and subsequent thrombosis.     
 Atherosclerotic blockage is most commonly treated using balloon angioplasty and 
stent placement.  In brief, a balloon attached to a catheter is placed over the plaque and 
inflated to increase lumen diameter. To prevent closure of the artery after catheter removal, a 
stent (wire mesh tube) is inserted. While this procedure temporarily relieves vessel 
occlusion, approximately 30-50% of the 400,000 angioplasties performed each year will 
undergo restenosis, or re-narrowing of the artery [20].  The mechanical injury induced by 
stent placement, especially to the endothelium, triggers SMC phenotypic modulation 
(dedifferentiation, migration and proliferation) leading to intimal hyperplasia and luminal 
narrowing [21].  While it is well established that SMCs play a critical role in atherosclerosis 
and restenosis, their contribution to other pathologies, such as cancer, hypertension and 
asthma, is less clear.        
 
 Extracellular Cues that Regulate SMC Growth and Differentiation 
 The differentiation state of SMCs is influenced by many environmental cues, 
including growth factors, contractile agonists, extracellular matrix proteins, endothelial cell 
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interactions, mechanical forces, and vascular injury (reviewed in [22]). PDGF is a growth 
factor produced by platelets, macrophages and endothelial cells that potently stimulates SMC 
migration and proliferation in vitro and in vivo, while it dramatically suppresses expression 
of multiple SM-specific marker genes [23, 24].   These cellular responses require PDGF-β 
receptors on the SMC surface, and antibody-mediated blockage of these receptors reduces 
intimal SMC invasion in an atherosclerotic mouse model [25].  Taken together, these data 
suggest that PDGF stimulates SMC growth and migration by affecting phenotypic 
modulation.   
 Conversely, other growth factors have been shown to promote SMC differentiation. 
For example, transforming growth factor (TGF)-β is a potent stimulator of SM-specific 
marker gene transcription [26-28].  Genetic deletion of TGF-β or its receptors results in early 
embryonic lethality, partially due to defects in vascular development [29-31].  Furthermore, 
TGF-β is required for the upregulation of SM marker genes in SMC precursors co-cultured 
with endothelial cells [32].  Interestingly, new agonists have been identified that are capable 
of inducing both SMC differentiation and proliferation, suggesting these processes are not 
mutually exclusive. Our laboratory previously showed that Sphingosine-1-Phosphate (S1P) 
can increase both SM α-actin expression and SMC proliferation by activating the RhoA 
GTPase and ERK MAP kinase, respectively [33]. Recent studies have shown that the 
differential regulation of SMC biology by S1P is accomplished through the activation of 
different S1P receptors. S1P2 receptor activation elicits SMC differentiation, whereas the 
S1P1/3 receptors facilitate SMC proliferation and phenotypic modulation in vitro and in vivo 
[34, 35].    
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Several other less extensively studied cues can also modulate SMC phenotype. 
Angiotensin II and arginine vasopressin are potent contractile agonists that increase 
expression of SM α-actin, myosin heavy chain (MHC), vimentin, and tropomyosin [36]. 
Extracellular matrix signaling can also regulate SMC differentiation. Culturing SMCs on 
fibronectin decreases SM α-actin levels, while SMCs plated on matrigel exhibit a more 
differentiated morphology than those grown on tissue culture plastic [37, 38].  Furthermore, 
a recent study by Orr et al. demonstrated that collagen I located within the arterial wall 
enhances SM α-actin and SM-MHC expression more potently than collagen I found within 
atherosclerotic lesions [39].  Finally, mechanical forces can also determine the phenotypic 
state of SMCs.  It has previously been shown that blood flow commencement correlates with 
vascular SMC investment, and that exposure to stretch increases expression of SM-marker 
genes [40, 41].  This evidence suggests that arterial shear stress may play important roles in 
determining the phenotypic status of vascular SMCs.    
 
CArG Boxes are Required for SMC-Specific Gene Transcription 
 Cellular differentiation is ultimately regulated at the level of gene transcription.  
Curiously, the DNA element responsible for effecting SMC-specific gene transcription was 
first identified in the ubiquitously expressed early growth gene, c-fos [42].  An enhancer was 
discovered within the c-fos promoter that was regulated by serum and growth factor 
stimulation.  Further mapping studies identified a 23 base pair element 
(aggatgtccatattaggacatct) possessing dyad symmetry (underlined regions) that was critical for 
this response; thus, this region was later named the serum response element (SRE) [43].  
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Shortly after this discovery, an element was identified in the cardiac α-actin gene that 
resembled the SRE but lacked its dyad symmetry; this sequence was termed the CArG box 
(CC(A/T)6GG) [44].  Mutations within the CArG boxes of cardiac α-actin were shown to 
attenuate its expression, demonstrating the functional importance of these elements [45]. 
Interestingly, additional promoter analysis studies have identified CArG boxes in nearly all 
SMC-specific genes [46].  In vitro studies demonstrated that these CArG boxes are essential 
for transcriptional activation of numerous SM-specific genes in cultured SMCs [11, 47, 48].  
Furthermore, in vivo studies utilizing lacZ transgenes driven by different SM promoters 
demonstrated that mutation of CArG elements within SM-MHC, SM22α and SM α-actin 
results in dramatic promoter inactivation [49, 50].  These studies indicate that the integrity of 
CArG boxes within SMC-specific genes is essential to their expression.  There are currently 
more than 60 characterized genes containing functional CArG boxes, all of which are either 
growth-related or from the skeletal, smooth, or cardiac muscle lineages [51].   
 
Serum Response Factor 
 Serum response factor (SRF) was first purified from HeLa nuclear extracts by virtue 
of its interaction with the c-fos SRE [52, 53].  SRF is a 62-67 kDa protein that is a member 
of the MADS box family of transcription factors [54].  The MADS box is located on the N-
terminus of SRF, and contains a basic DNA-binding domain and a region predicted to 
promote protein-protein interactions (figure 1.2A).  This region also contains a dimerization 
domain (DD) that is required for the homodimerization of SRF on CArG boxes (figure 1.2B) 
[55].  The C-terminus of SRF contains the transactivation domain, which is indispensable for  
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Figure 1.2.  Regulation of SMC-specific gene transcription by serum response factor (SRF) and 
the myocardin related transcription factors (MRTF).  A) Domain structure of SRF; transactivation 
domain (TAD) B) SRF (as a homodimer) regulates nearly all SMC-specific genes by binding to 
CArG elements located in their promoter or intronic regions. C) MRTF domain schematic.RPEL, 
amino acids (AA) RPXXXEL where X is any AA; +, basic region; Q, glutamine rich region; SAP 
(SAF-A/B, Acinus, PIAS) domain; LZ, leucine zipper-like domain. D) 10T1/2 cells were transfected 
with the SM22-luciferase reporter gene (125ng) in the presence of empty vector (EV) or flag-tagged 
myocardin family members (125ng). Data compiled from three independent experiments and 
represented as fold over EV.   
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its transcriptional activity, and many conserved phosphorylation sites that are extensively 
modified after serum stimulation [56].    
 There is strong evidence that SRF is essential to proper embryonic development.  
Mice with a non-functional SRF allele do not develop past gastrulation due to defects in 
mesoderm formation [57].  More specifically, several in vivo studies suggest that SRF plays 
an important role in cardiac development.  Proepicardial cells derived from quail embryos, 
which normally give rise to coronary SMCs, exhibit attenuated differentiation in the 
presence of two different dominant negative SRF constructs [58].  In mice, cardiac-specific 
conditional mutagenesis or restricted inactivation of SRF results in severe cardiovascular 
defects and significant reduction of cardiac and SM-marker gene expression [59, 60].  
Specific cardiovascular defects include: abnormal heart looping, chamber maturation, and Z-
disk organization, failed SMC recruitment to the dorsal aorta, and aberrant cytoskeletal 
structure in vascular SMCs.  In addition, skeletal muscle-specific deletion of SRF results in 
death during the perinatal period as a result of severe skeletal muscle hypoplasia [61].  Since 
SRF is ubiquitously expressed and regulates the expression of a number of muscle-specific, 
cytoskeletal, and early response growth genes, it is likely that additional mechanisms are 
important in facilitating cell type-specific SRF-dependent transcription [62-65].   
 To date, multiple SRF-binding partners have been identified, suggesting a model in 
which SRF-dependent transcription is regulated by interaction with other transcription 
factors and co-factors.  Elk-1, SAP-1, and SAP-2/NET/ERP, the so-called ternary complex 
factors (TCFs), were the first identified cofactors that linked serum and growth factor 
stimulation to SRF-mediated activation of the c-fos SRE [66].  SRF also interacts directly 
with the transcription factors GATA-4 and Nkx2.5 to modulate cardiomyocyte 
 11
differentiation, while interaction with MyoD and myogenin promotes skeletal muscle-
specific gene transcription [64, 67-69].  Finally, the cysteine-rich LIM-only proteins CRP1 
and CRP2 are also capable of regulating SRF-dependent transcription, likely by organizing 
SRF in complex with other transcription factors or chromatin remodeling factors [70, 71].         
 
Myocardin Family of Transcription Factors 
The identification of the SRF cofactor myocardin greatly advanced our understanding 
of the molecular mechanisms governing SMC-specific gene transcription.  Myocardin was 
originally identified in a bioinformatic screen for novel cardiac-restricted genes, but was 
later found to be highly expressed in adult and developing smooth muscle [72].  Several 
reports have utilized dominant negative myocardin variants or siRNA to demonstrate that 
myocardin is a potent stimulator of SMC-specific transcription [73-76].  The in vivo 
importance of myocardin is illustrated by the finding that germline deletion of myocardin is 
embryonic lethal and results in a complete lack of vascular SMCs [77].  Interestingly, cardiac 
development occurred normally, with no observable defects in heart looping or chamber 
formation.   
While it is clear that myocardin is important to SMC differentiation, an accumulating 
amount of data question whether it is essential for SMC lineage determination in all SMC 
subtypes.  For example, SM22 and SM α-actin are detected in SMC tissue as early as E9.5, 
even though myocardin expression is not observed until E12.5 [75, 78].  Furthermore, forced 
expression of myocardin in embryonic stem cells stimulates expression of many, but not all, 
SMC-specific genes [79].  Finally, myocardin -/- stem cells can still give rise to vascular 
SMCs in vivo [79, 80].  These data clearly indicate that factors other than myocardin can 
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regulate SMC differentiation during vascular development.  Indeed, a bioinformatic screen 
for myocardin homologs led to the identification of the myocardin-related transcription 
factors A and B (MRTF-A, MRTF-B) [81].   
The overall amino acid conservation between myocardin, MRTF-A, and MRTF-B is 
only 35%, but the N-terminal basic, glutamine (Q)-rich, and SAP domains share more than 
60% amino acid identity (figure 1.2C).  A critical seven-residue sequence called the B1 
domain is located between the basic and Q-rich domains and is required for SRF binding 
[82].  The conserved SAP domain has not been well characterized in vivo, but other SAP 
domains have been shown to regulate nuclear organization and chromosomal dynamics [83].  
The most distal N-terminal domains shared among the myocardin family members are a 
series of RPEL motifs that mediate actin monomer binding.  C-terminally located are the 
leucine zipper (LZ) motif and transactivation domain (TAD), which mediate dimerization 
and transcriptional activation, respectively [84].  Unlike myocardin expression, which is 
cardiomyocyte- and SMC-specific, MRTF-A and MRTF-B are more widely expressed, but 
are particularly abundant in cultured aortic SMCs and SMC-rich tissues [33, 81, 85, 86].     
We and others demonstrated that MRTF-A can potently stimulate transcription of 
SMC-specific genes (figure 1.2d) [33, 85-87].  Furthermore, a dominant negative of MRTF-
A inhibits transcription of SM α-actin, SM22 and SM-MHC in primary aortic SMCs [86, 
88].  Germline deletion of MRTF-A in mice results in reduced SRF-dependent gene 
transcription in mammary myoepithelial cells, providing additional evidence for an in vivo 
role for MRTF-A in regulating SMC-specific gene transcription [89, 90].  Given the 
widespread expression pattern of MRTF-A and the potency with which it activates SMC 
gene transcription, the restricted phenotype of these animals is rather surprising.  However, 
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the close functional homology and similar expression pattern of MRTF-B suggests that 
compensation may mask additional in vivo roles of MRTF-A.   
MRTF-B is the least studied of the myocardin family members. Along with the 
human homolog MKL-2, MRTF-B enhances promoter activity of several SM marker genes, 
but less potently than myocardin and MRTF-A (figure 1.2d) [86, 91].  Mice containing a 
loss-of-function mutation within the MRTF-B gene die at mid-gestation due to multiple 
cardiovascular abnormalities, including failed differentiation of neural crest-derived SMCs 
within the branchial arch [92, 93].  These data suggest that MRTF-B is important in the 
differentiation of at least some SMC subsets.  Unfortunately, the redundancy observed 
amongst the myocardin family members, as well as the early lethality associated with the 
myocardin and MRTF-B knockouts, hampers dissection of lineage-specific roles for each 
protein.  Nonetheless, further characterization of the molecular mechanisms that regulate the 
myocardin family members will be essential to better understanding their role in regulating 
SMC phenotype.   
 
The Rho Family of GTPases 
 As discussed earlier, it is clear that a variety of extracellular cues are capable of 
stimulating SMC differentiation, and identifying the signaling pathways that sense and 
integrate these signals has been a major focus of our laboratory.  Indeed, we and others have 
identified the small GTPase RhoA as an important regulator of SMC-specific gene 
expression.  RhoA belongs to the family of Rho GTPases, which also includes Rac1 and 
Cdc42.  These proteins act as molecular switches that activate downstream effector proteins 
to regulate cellular processes such as cytoskeletal remodeling, membrane trafficking and cell 
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adhesion (see [94, 95] for reviews).  Activation of RhoA, Rac and Cdc42 induces the 
formation of dynamic actin structures, including stress fibers, lamellipodia or filopodia, 
respectively. While the Rho GTPases have traditionally been studied in the context of 
migration and adhesion, it has become clear they are also critical regulators of gene 
transcription [96-98].  
Rho GTPases cycle between a GDP- and GTP-bound state, but can only interact with 
downstream effectors when bound to GTP (see [98] for a comprehensive review).  Although 
they have some intrinsic GTP hydrolase activity, it is tightly controlled by guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs).  GEFs activate 
GTPases by promoting exchange of GDP for GTP binding, while GAPs inactivate by 
enhancing GTP hydrolysis.  GTP binding induces a conformational change in the conserved 
switch I and II regions, subsequently exposing the effector loop domain that interacts with 
downstream target proteins.  Sequence variation in the effector loop determines the specific 
effectors bound by different GTPases.  Rho proteins are further regulated by GDP-
dissociation inhibitors (GDIs), which inhibit GTPase activity by preventing nucleotide 
exchange [99].  
Our specific interest in RhoA as a determinant of SMC differentiation arose from 
studies by the Treisman laboratory linking RhoA signaling to SRF-dependent transcription.  
These studies demonstrated that activation of RhoA by serum, lysophosphatidic acid (LPA), 
or G-protein coupled receptor agonists induced transcription of a modified c-fos promoter 
lacking the TCF binding Ets domain [100-102].  Interestingly, increases in promoter activity 
were dependent on SRF and RhoA-mediated actin polymerization, but were independent of 
the TCF family of transcription factors.  Since these studies were conducted with artificial c-
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fos promoters in immortalized cells, the physiological importance of this signaling cascade in 
regulating SRF-dependent transcription remained unclear.   
Our laboratory subsequently demonstrated that RhoA signaling is an important 
modulator of SMC-specific gene expression [103].  Inhibition of RhoA activity by dominant 
negative RhoA (N19) or RhoA-specific toxin C3 transferase significantly decreased 
transcription of numerous SM marker genes in primary rat aortic SMCs.  Furthermore, a 
constitutively active variant of RhoA (L63) potently increased SMC-specific gene 
transcription, but only modestly activated the c-fos promoter.  This increase in promoter 
activity was inhibited by the actin depolymerizing agent, latrunculin B (LB), further 
supporting a role for actin polymerization in SRF-dependent transcription. RhoA signaling 
has now been implicated in the regulation of SMC-specific transcription induced by various 
extracellular stimuli, including TGF-β, thrombin, Ca2+ currents, and mechanical force [104-
108].  In addition, in vivo studies demonstrated that RhoA activity is required for 
differentiation of isolated proepicardial cells into SMCs [109].  Since activation or inhibition 
of RhoA has little effect on early growth gene expression, activation of RhoA-dependent 
signaling pathways may regulate expression of SMC-specific genes without effecting 
transcription of other SRF-dependent genes.   
 
Actin Dynamics Regulate Cellular Localization of the MRTFs 
We have shown that stimulation of SRF-dependent SMC gene transcription by RhoA 
requires actin polymerization, in excellent agreement with other studies [62, 103, 110].  
However, a RhoA target that interacted with SRF had not been described, making it difficult 
to determine the precise mechanisms by which RhoA modulates SMC-specific transcription.  
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Recently, an elegant study by Miralles et al. shed light on this question [88].  The authors 
found MRTF-A to be predominantly cytoplasmic in serum-starved NIH3T3 cells.  Upon 
serum treatment, however, MRTF-A rapidly localized to the nucleus, accumulated in an 
SRF-DNA complex, and potently stimulated transcription of a modified c-fos promoter.  
Nuclear localization was blocked using C3 transferase or latrunculin B, implicating RhoA 
and actin polymerization in the nuclear accumulation of MRTF-A.  MRTF-A was 
subsequently shown to be required for RhoA signaling to SRF, as inhibition of MRTF-A by 
a dominant negative or RNAi blocked RhoA- and serum-mediated activation of SRF-
dependent transcription [87].  To determine the importance of this pathway in regulating 
SMC phenotype, we conducted similar studies in SMCs and found that RhoA-mediated 
activation of SMC-specific gene transcription also required MRTF-A [33, 86].  Taken 
together, these data suggest that MRTF-A links RhoA-actin signaling to SRF.   
While this evidence clearly indicated that nuclear accumulation of MRTF-A is 
enhanced by actin polymerization, the molecular mechanisms regulating this process 
remained elusive. These were elucidated by the finding that destruction of MRTF-A’s RPEL 
motifs results in nuclear sequestration of MRTF-A under serum starved conditions [88]. The 
RPEL motifs were subsequently identified as globular (G)-actin binding interfaces, and 
RhoA-dependent increases in actin polymerization reduces the actin-MRTF complex, 
leading to nuclear accumulation of MRTF-A (figure 1.3).  These and other studies suggest 
that under serum-starved conditions, when cellular G-actin levels are high, binding of actin 
to the RPEL motifs prevents nuclear localization of MRTF-A by masking a nuclear 
localization signal [88, 111].  However, a functional nuclear localization sequence for 
MRTF-A has yet to be identified, suggesting an alternative mechanism may determine 
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MRTF-A distribution.  Sequence divergence within the RPEL motifs is likely responsible for 
the differing localization patterns of the myocardin family members [112].  For example, G-
actin has a lower affinity for the RPEL motifs of myocardin than for those of MRTF-A, 
accounting for the constitutively nuclear localization of myocardin.  In addition, we have 
shown that cytoplasmic retention of MRTF-B is greater than MRTF-A in the presence and 
absence of serum, suggesting that MRTF-B may possess the highest G-actin binding affinity 
of the three myocardin family members [113].  Taken together, the current model of SMC 
differentiation suggests that activation of RhoA by a variety of extracellular cues leads to 
actin polymerization and subsequent reductions in cytoplasmic G-actin pools.  This event 
promotes localization of MRTF-A/B to the nucleus resulting in SRF binding and activation 
of SMC-specific gene transcription (figure 1.3) 
 
Signaling Downstream of RhoA 
 While considerable evidence has demonstrated RhoA to be an important regulator of 
SMC differentiation, the elucidation of downstream signaling pathways that modulate this 
process has received little attention.  In the GTP-bound state, RhoA interacts with a wide 
variety of effectors, including Rho kinase (ROCK), diaphanous proteins 1 and 2 (Dia1 and 
Dia2), protein kinase N (PKN), citron kinase, rhophilin, and rhotekin. Since the effect of 
RhoA on SMC-specific gene transcription is at least partially dependent on actin remodeling, 
studies of Rho-mediated differentiation have focused primarily on ROCK, given its ability to 
stimulate actin polymerization, stress fiber formation, and cell contractility (especially in 
SMCs) [114, 115].  ROCK promotes actin polymerization by activating LIM-kinase, which 
subsequently inhibits cofilin-mediated F-actin disassembly [116].  Interestingly, we and  
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Figure 1.3.  Schematic of signaling cascades that regulate SMC-specific gene transcription.  In 
an unstimulated (serum starved) cell, elevated cytoplasmic G-actin levels sequester MRTF in the 
cytoplasm.  The lack of MRTF nuclear localization results in low levels of SMC-specific gene 
transcription.  Activation of RhoA by a variety of extracellular stimuli (blue lighting bolts), stimulates 
actin polymerization and subsequent reductions in cellular G-actin pools.  This leads to nuclear 
localization of MRTF, where it binds SRF and enhances transcription of SM-marker genes.  
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others have demonstrated that the ROCK inhibitor Y-27632 only partially inhibits SM-
specific gene expression, suggesting that additional RhoA effectors are involved in SMC 
differentiation [33, 117].    
 Two other RhoA effectors known to stimulate actin polymerization are Dia1 and 
Dia2 [118-120].  These proteins belong to the subfamily of diaphanous-related formins 
(DRFs), which also includes Dia3 and the Formin Homology Domain Protein (FHOD1) (see 
[121-123] for reviews). The DRFs are identified by two highly conserved formin homology 
(FH) domains, a GTPase binding domain (GBD) that interacts with Rho family GTPases, 
and a diaphanous autoregulatory domain (DAD) (figure 1.4A).  The dimerization domain 
(DD) and coiled-coil region both mediate dimerization of the N-terminal region of the DRFs, 
although the physiological importance of this dimerization is still unclear.  The molecular 
mechanisms that control DRF activity have been fairly well described.  In the inactive state, 
the DRFs are inhibited by an intramolecular interaction between the C-terminal DAD and the 
N-terminal diaphanous inhibitory domain (DID) (figure 1.4B) [124, 125].  High affinity 
binding of GTP-RhoA to the GBD disrupts the DAD-DID interaction, thereby exposing the 
catalytically active FH1/FH2 region to stimulate actin polymerization.  Interestingly, several 
studies have identified Dia1 and Dia2 as binding partners for multiple GTPases.  For 
example, Cdc42 and Rif bind Dia2 to induce filopodia formation, while RhoB-Dia2 
signaling governs endosomal trafficking [126-128].  The association of DRFs with multiple 
GTPases likely explains their ability to regulate a diverse group of actin-dependent 
phenomena, including membrane ruffling, cell migration, cytokinesis, mitochondrial 
distribution, cell polarity, stress fiber formation, and cell adhesion.  A more in depth  
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Figure 1.4.  Regulation of actin dynamics by the diaphanous-related formins (DRF), mDia1 and 
mDia2  A) Domain structure of the DRFs.  GBD, GTPase Binding Domain; DID, Diaphanous 
Inhibitory Domain; FH, Formin Homology; DAD, Diaphanous Autoregulatory Domain.  B) mDia1/2 
are autoinhibited by an interaction between the DID and DAD, which sterically hinders the catalytic 
function of the FH2.  Binding of RhoA (or other GTPases) alleviates autoinhibition resulting in 
stimulation of actin polymerization by the FH2 domain. The binding of profilin to the FH1 domain 
enhances actin filament formation.  C) Current schematic models suggest that the FH2 dimerizes to 
form a flexible “donut”, which binds actin monomers and allows the formin to “stair step” along the 
growing filament.   
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discussion on the role of the DRFs in these processes is beyond the scope of this dissertation, 
but the reader is directed to [123] for an excellent review.    
Further characterization of the DRFs will require identifying the molecular 
mechanisms by which formins nucleate actin.  Early in vivo studies of the formin Bni1 
determined that the ~400 residue FH2 domain was indispensable for actin cable assembly in 
yeast [129, 130].  Subsequent studies found that the FH2 directly nucleated actin, and that 
polymerization occurred at the barbed ends [131].  Furthermore, an interaction between the 
proline-rich FH1 domain and the actin-binding protein profilin accelerated actin filament 
elongation [132].  Unlike other actin nucleators, formins remain continually associated with 
the filaments during elongation, a property that is characteristic of all formins described to 
date [133-135].  Current schematic models suggest that the FH2 dimerizes to form a flexible 
“donut”, which binds actin monomers and allows the formin to “stair step” along the 
growing filament (figure 1.4C) [136].  Indeed, mutation of conserved tryptophan residues 
within the FH2 required for dimerization inhibits formin-mediated actin polymerization 
[137].  The processive nature of formins facilitates rapid actin polymerization.  As a formin 
adds actin monomers to the barbed end of the filament, it simultaneously inhibits the binding 
of capping proteins that would otherwise block filament extension.  Although less 
extensively studied, formins also regulate microtubule-dependent processes.  Several studies 
indicate that Dia1 and Dia2 associate with stable microtubules and these associations may 
play critical roles in cytokinesis and cell migration [127, 138-140].  
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Regulation of MRTFs by Nuclear Actin   
Evidence linking nuclear actin to the regulation of gene transcription was first 
reported in 1984 by two separate groups [141, 142].  However, these studies were initially 
rebuffed on suspicion of experimental contamination by abundant cytoplasmic actin.   
Skepticism grew when reagents used to visualize actin filaments in the cytoplasm, such as 
phalloidin, did not identify similar structures within the nucleus.  More than 20 years later, it 
is now widely accepted that actin exists in the nucleus and is involved in regulating gene 
transcription by interacting with ATP-dependent chromosomal remodeling factors, 
heterogeneous nuclear particles of Ribouclear protein (RNP), and all three RNA polymerases 
(see [143] for a review). Whether actin is monomeric or polymeric in these complexes 
remains unknown, primarily because tools to identify polymerized nuclear actin are lacking. 
However, nuclear actin filaments were identified in the nuclear pore complexes of amphibian 
oocytes, and immunochemical studies have had some success in identifying other nuclear 
actin structures [144, 145].  Interestingly, a recent study by McDonald et al. identified a 
dynamic pool of polymeric GFP-β-actin within the nucleus by using fluorescence recovery 
after photobleaching (FRAP) [146].  
 The cytoplasmic binding of G-actin was originally believed to sequester MRTF-A in 
the cytoplasm, but recent observations suggest that nuclear translocation of the MRTFs is 
mechanistically more complicated than originally thought.  For example, a mutant G-actin 
has been described that can stimulate MRTF-A nuclear translocation independently of its 
effects on actin treadmilling, indicating that G-actin may be more directly involved in 
MRTF-A transport [147].  Indeed, Vartiainen et al. recently demonstrated that G-actin 
binding is required for nuclear export of MRTF-A and that export, and not import, is the 
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major limiting step in regulating MRTF-A nuclear accumulation [148].  Although an 
interaction with actin did not prevent the association of MRTF-A with SRF-target genes, its 
activity was inhibited.  These data suggest that nuclear actin dynamics may be an important 
determinant in regulating MRTF-A subcellular localization.  Taken together, these lines of 
evidence indicate that MRTF-A nuclear localization and SRF-dependent transcription are 
controlled by communication between nuclear and cytoplasmic actin pools.  Knowledge of 
RhoA-dependent signaling pathways that regulate nuclear actin dynamics is currently 
lacking, and will likely be a prosperous area for future research.     
 
Objective of this dissertation research 
 Further elucidation of the signaling pathways that govern SMC-specific gene 
transcription will be essential to our understanding of SMC differentiation and its 
contribution to diseases such as atherosclerosis, and restenosis.  Although it is clear that 
RhoA plays a critical role in regulating SM-marker gene expression, the downstream 
signaling cascades that mediate this regulation remain poorly understood.  The objectives of 
this dissertation were to (1) determine whether the RhoA effectors Dia1 and Dia2 are 
important determinants of SMC phenotype, (2) identify the mechanism(s) that control the 
activity or activation of Dia1/2, and (3) characterize a potential role of Dia1/2 in regulating 
subcellular localization of the MRTFs by controlling nuclear actin dynamics.   
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ABSTRACT 
 
We have previously shown that smooth muscle cell (SMC) differentiation marker 
gene expression is regulated by the small GTPase, RhoA. The objective of the present study 
was to determine the contributions of the RhoA effectors, mouse diaphanous 1 and 2 (mDia1 
and mDia2), to this regulatory mechanism. mDia1 and mDia2 are expressed highly in aortic 
SMC and in a number of SMC-containing organs including bladder, lung, and esophagus. 
Activation of mDia1/2 signaling by RhoA strongly stimulated SMC-specific promoter 
activity in multiple cell-types including primary aortic SMC, and stimulated endogenous SM 
α-actin expression in 10T1/2 cells. Expression of a dominant negative mDia1 variant that 
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inhibits both mDia1 and mDia2 significantly decreased SMC-specific transcription in SMC.  
The effects of mDia1 and mDia2 required the presence of SRF and the activity of the 
myocardin transcription factors and were dependent upon changes in actin polymerization. 
Importantly, stimulation of mDia1/2 signaling synergistically enhanced the activities of the 
myocardin-related transcription factors, MRTF-A and MRTF-B, and this effect was due to 
increased nuclear localization of these factors. These results indicate that RhoA-dependent 
signaling through mDia1/2 and the MRTFs is important for SMC-specific gene expression in 
SMC. 
 
INTRODUCTION 
A large number of environmental cues including growth factors, contractile agonists, 
matrix components, and cell-cell interactions have been shown to regulate smooth muscle 
cell (SMC) differentiation (see [46] for review).  However, the signaling mechanisms by 
which these factors regulate SMC-specific transcription are poorly understood. Expression of 
most SMC differentiation markers, including SM α-actin, SM myosin heavy chain (SM 
MHC), SM22, calponin, and telokin requires serum response factor (SRF) binding to one or 
more conserved CArG (CC(A/T6)GG) cis elements present within their promoters [49, 149-
153].  However, because SRF is a ubiquitously expressed transcription factor that also 
regulates the early response growth genes, c-fos and egr-1 (see [154] for review), it is clear 
that additional factors are required to differentially regulate these gene programs. 
The identification of the myocardin family of SRF co-factors by Wang et al. was an 
important advance in our understanding of the transcription mechanisms that regulate SMC-
specific transcription (see [155] and [84] for reviews). The founding member of this family, 
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myocardin, strongly enhances SMC differentiation marker gene expression through direct 
interactions with SRF. Myocardin is expressed specifically in heart and SMC and its genetic 
deletion leads to embryonic lethality due to failure of SMC differentiation/investment of the 
developing aorta. The Myocardin-Related Transcription Factors, MRTF-A/MKL-1 and 
MRTF-B/MKL-2, are also expressed in some SMC sub-types including the aorta, and like 
myocardin, can strongly activate SMC differentiation marker gene expression [33, 81, 85, 
87, 91].  Because the MRTFs are thought to be expressed more widely, their involvement in 
regulating cell-type-specific gene expression is less clear.  
 We have previously shown that the small GTPase, RhoA, regulates SM 
differentiation marker gene expression, and we hypothesize that RhoA acts as an integrator 
of many of the environmental cues that regulate this process [103].  For example, SMC-
specific transcription in primary SMC cultures was stimulated by expression of 
constitutively active of RhoA (L63), and completely abolished by the RhoA inhibitor, C3 
transferase. Neither of these interventions had dramatic effects on c-fos expression, 
suggesting that this pathway may be important for differentially regulating SRF-dependent 
growth and differentiation. A number of laboratories including our own have demonstrated 
that RhoA’s downstream effects on the actin cytoskeleton were critical for activation of 
SRF-dependent transcription [33, 62, 103, 110, 156].  The RhoA effector, Rho-kinase 
(ROCK), has been the most thoroughly studied in this regard because it has major effects on 
actin polymerization, stress fiber formation, and contractility (see [94] for review). 
Interestingly, the ROK inhibitor, Y-27632, only partially inhibits SMC differentiation 
marker gene expression, strongly suggesting that other RhoA effectors are important [103, 
104].   
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Two other RhoA effectors that have been shown to stimulate actin polymerization are 
the diaphanous formins 1 and 2 (mDia1 and mDia2) [118-120].  These proteins belong to the 
subfamily of diaphanous-related formins (DRFs) that also includes mDia3 and FHOD1. 
Previous studies have demonstrated that the DRFs act as potent actin and microtubule 
polymerizing factors that regulate a number of processes including cell migration and 
division (see [121]and [122] for reviews). The DRFs are identified by three highly conserved 
formin homology (FH) domains, a conserved GTPase binding domain (GBD) that interacts 
with Rho family GTPases, and a Diaphanous Auto-regulatory Domain (DAD).  The 
molecular mechanisms that control DRF/Dia activity have been fairly well described.  In the 
inactive state, the DRFs are inhibited by an interaction between the DAD and the N-terminal 
Diaphanous Inhibitory Domain (DID) (See figure 2.1a).  High affinity binding of activated 
RhoA (or another GTPase) to the GBD disrupts the DAD-DID interaction to expose the 
catalytically active FH1/FH2 region.  The precise mechanisms by which mDia1/2 stimulate 
actin polymerization are not completely understood. However, mDia1/2 seem to promote 
polymerization from actin filament barbed ends in cooperation with the actin binding 
protein, profilin [133, 157, 158]. 
The goal of these studies was to determine the contributions of mDia1 and mDia2 to 
the regulation of SMC-specific transcription.  Our results demonstrate that both of these 
RhoA effectors are highly expressed in SMC, that they strongly activate SMC-specific 
transcription, and that their effects are mediated by the myocardin family of SRF co-factors.  
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METHODS 
Plasmids and Reagents 
mDia1 and mDia2 cDNAs were generous gifts from Shuh Narumiya (Kyoto University, 
Japan). All mDia cDNAs were subcloned into flag pcDNA3.1 and/or pEGFP-C3 (Clontech) 
and include, full length mDia1, full length mDia2, ∆GBDmDia1 (AA 238-1255), 
∆GBDmDia2 (AA 257-1171), mDia2DAD (AA1030-1171), mDia1FH1FH2∆1 (AA567-
1182 minus the 20AA from 750-770), EGFP-∆GBDmDia1, and EGFP-∆GBDmDia2. 
Myocardin, MRTF-A, and MRTF-B cDNAs were generous gifts of Da-Zhi Wang 
(University of North Carolina, Chapel Hill, NC). All myocardin cDNAs were subcloned into 
flag pcDNA3.1 and pEGFP-C3. The dominant negative MRTF-A was generated by PCR and 
consists of AA 1-630. 
Cell Culture, Transfections, and Reporter Assays 
SMCs from rat thoracic aorta were isolated and cultured as previously described [33]. 
10T1/2 and A7r5 SMC were obtained from ATCC. SRF -/- embryonic stem cells were a 
generous gift from Alfred Nordheim (Tubingen University, Germany) and have been 
previously described [159].  For transfections, cells were cultured in 24 or 48 well plates, 
maintained in 10% serum, and transfected 24 h after plating at 70-80% confluency using the 
transfection reagent, TransIT-LT1 (Mirus, Madison, WI), as per protocol.  The SM22, SM α-
actin, and c-fos promoter luciferase reporter constructs have been previously described [33]. 
The SM α-actin promoter constructs containing CArG mutations were a generous gift of 
Gary Owens (University of Virginia) and have been previously described [74]. When 
transfecting expression constructs (mDia1/2, MRTFs, etc.) the total amount of expression 
vector in each well was equalized by addition of empty vector. For experiments involving 
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pharmacological inhibitors, cells were serum starved for 6 h and then treated with Y-27632 
(10µM) (Calbiochem, San Diego, CA) or Latrunculin B (0.5µM) (Calbiochem, San Diego, 
CA) for 24 h before luciferase measurements.   
RT-PCR and Western Blots 
Tissues were obtained from adult C57/Bl6 mice and confluent dishes of primary rat aortic 
SMC, A7r5 SMC, and 10T1/2 cells. For Western blots, tissue and cells were lysed in radio 
immunoprecipitation assay (RIPA) buffer plus protease inhibitors. Protein concentrations 
were determined using the BCA assay (Pierce). Protein lysates (40ug) from each tissue and 
cell type were run on an 10% SDS polyacrylamide gel, transferred to nitrocellulose, and 
probed with anti-mDia1, anti-mDia2 (generous gifts of Henry Higgs, Dartmouth Medical 
School, Hanover, NH), anti-SM α-actin (Sigma), anti-tubulin (Sigma), or anti-flag (Sigma) 
antibodies. In some experiments cells were serum starved for 24 h and then treated with 
TGF-β (1ng/ml) for 24 h before lysate preparation. 
Immunohistochemistry 
For immunohistochemical visualization of mDia1/2, the MRTFs, or SM α-actin, cells fixed 
in 3.7% paraformaldehyde were permeabilized in 0.5% Triton X-100 for 3 min, blocked in 
20% goat serum/3% BSA for 2 h, then exposed to antibody for 2 h at a dilution of 1:500. 
Texas Red or FITC-conjugated secondary antibodies were used for visualization at 1:1000.  
In some studies Texas Red-conjugated phalloidin (1:400; Molecular Probes) was used to 
detect actin stress fibers, and DAPI (1:10,000) was used to detect nuclei. 
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RESULTS 
 
mDia 1/2 signaling regulates SMC-specific transcription - To test whether the RhoA 
effectors, mDia1 and mDia2, contribute to the regulation of SMC-specific transcription we 
co-transfected mDia1 and mDia2 along with SM22 or SM α-actin promoter/luciferase 
constructs into multi-potential 10T1/2 mouse cells. We and others have shown that these 
cells up-regulate the expression of many SMC-specific genes upon treatment with TGF-β or 
sphingosine 1-phosphate (S1P) making them very useful for studying the regulation of SMC-
specific transcription [32, 33].  Figure 2.1b demonstrates that expression of full length 
mDia1 or mDia2 induced a modest (2-3 fold) increase in SM22 and SM α-actin promoter 
activity. However, co-expression of constitutively active L63RhoA with mDia1 or mDia2 
strongly an synergistically activated SM22 and SM α-actin promoter activity to 
approximately 25 fold, suggesting that basal RhoA activity is a limiting factor for mDia 
activation.  Previous studies have shown that N-terminal truncations that remove the 
GBD/DID inhibitory domain of mDia1 and mDia2 (∆GBD) resulted in constitutive 
activation of these proteins. Remarkably, ∆GBDmDia1 and ∆GBDmDia2 activated SM22 
and SM actin by 30-40 fold, indicating that these signaling molecules are powerful activators 
of SMC-specific transcription.  The increased efficacy of mDia1 versus mDia2 was most 
likely due to increased expression of the mDia1 constructs (data not shown). ∆GBDmDia1 or 
∆GBDmDia2 had comparatively little effect on c-fos promoter activity. Both ∆GBDmDia1 
or ∆GBDmDia2 also activated the endogenous expression of SM α-actin as shown by the 
Western blot or immunohistochemistry (figure 2.1c). Given that transfection efficiency in the  
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Figure 2.1. RhoA-dependent activation of mDia1 or mDia2 increased SMC-specific promoter 
activity. A, Schematic of mDia activation by RhoA. The inhibitory DID–DAD interaction is relieved 
by binding of activated RhoA. FH indicates formin homology domain; GBD, GTPase binding 
domain; DID, diaphanous inhibitory domain; DAD, diaphanous autoregulatory domain. B, 10T1/2 
cells were cotransfected with SM22, SM -actin, or c-fos luciferase reporter constructs along with Wt 
mDia1, constitutively active L63RhoA, Wt mDia1 plus L63RhoA, or GBDmDia1. The total 
amount of expression vector in each well was equalized by addition of empty vector (EV). Luciferase 
activity was measured 48 hours after transfection. C, The same experiments were performed with 
mDia2. D, Endogenous SM -actin expression was detected by Western blot and 
immunohistochemistry in cells transfected with GBDmDia2. SM -actin expression in TGF-ß–
treated cells is shown as a control. 
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10T1/2 cell line was typically around 25%, this increase was as strong as or stronger than 
that seen upon treatment of cells with TGF-β.  
 
Dia1 and Dia2 are highly expressed in SMC - To further investigate the role of mDia1 and 
mDia2, we analyzed their expression in tissues and cell lines. The Western blot shown in 
Figure 2.2a demonstrates that mDia1 and mDia2 are very highly expressed in primary rat 
aortic SMC, A7r5 rat SMC, and 10T1/2 cells as well as in numerous mouse tissues that 
contain a high SMC component, such as aorta, bladder, and lung. Given that mDia1 and 
mDia2 could strongly activate SMC-specific transcription and that these proteins were 
highly expressed in SMC it is likely that they play important roles in regulating SMC 
differentiation. 
 
Endogenous mDia1/2 signaling regulates SMC-specific transcription in SMC - We next 
tested whether mDia signaling was important for regulating SMC-specific promoter activity 
in SMC. Expression of ∆GBDmDia1 or ∆GBDmDia2 in SMC significantly up-regulated 
SM22 and SM α-actin promoter activity (figure 2.2b). However, these effects were much 
less dramatic than those observed in 10T1/2 cells most likely due to the relatively high levels 
of SMC-specific transcriptional activity already exhibited by primary SMC. To determine 
whether endogenous mDia1/2 signaling was required for SMC-specific promoter activity we 
utilized a dominant negative form of mDia1 (FH1FH2∆1) originally described by Copeland 
et al. that has been shown to inhibit the function of both of these proteins [160].  This 
strategy also allowed us to avoid known redundancy between mDia1 and mDia2 signaling.  
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Results 
Figure 2.2. Endgenous mDia1 and mDia2 signaling was important for SMC-specific transcription. A, 
Expression of mDia1 and mDia2 in mouse tissues and cell lines was measured by Western blot. B, 
Rat aortic SMCs were cotransfected with SM22, SM -actin, or c-fos luciferase reporter constructs 
along with GBDmDia1 or GBDmDia2. *P<0.05 vs empty vector. C, SMC, A7r5 SMC, and 
10T1/2 cells were transfected with SM -actin luciferase and increasing concentrations of DN 
mDia1. D, SMC, A7r5 SMC, and 10T1/2 cells were transfected with SM22 reporter and increasing 
concentrations of an mDia2 DAD peptide (AA 1030-1171). *P<0.05 vs empty vector. 
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shown in figure 2.2c demonstrate that FH1FH2∆1mDia1 almost completely inhibited the 
effects of ∆GBDmDia1 or ∆GBDmDia2 on SM22 promoter activity supporting its effects as 
a dominant negative. Importantly, FH1FH2∆1mDia1 strongly inhibited SMC-specific 
promoter activity in a dose-dependent manner in primary rat aortic SMC, the A7r5 rat SMC 
line, and in 10T1/2 cells (figure 2.2c, right panel).  Results from previous studies have shown 
that expression of DAD peptides can activate endogenous Dia signaling by interfering with 
the intra-molecular repression that is mediated by the DID-DAD interaction [125].  
Expression of a Dia2 DAD peptide (AA 1030-1171) in all three cell types resulted in a dose-
dependent increase in SM22 promoter activity (figures 2.2d). Taken together, these results 
suggest that endogeous mDia signaling is very important for regulating SMC-specific 
promoter activity in SMC and other SMC-like cell lines. 
 
The effects of mDia1/2 require SRF binding to CArG elements - It is clear that RhoA-
dependent regulation of SMC-specific transcription involves activation of SRF. To test 
whether the effects of mDia1 and mDia2 were also dependent upon SRF, we performed 
similar experiments in an SRF knockout embryonic stem cell line.  ∆GBDmDia2 did not 
significantly increase SM α-actin promoter activity in SRF -/- ES cells (figure 2.3a). Re-
expression of SRF strongly activated the SM α-actin promoter (~50 fold) and rescued the 
effects of ∆GBDmDia2 on SM α-actin promoter activity strongly supporting the 
involvement of SRF in this response. We have previously shown that three CArG elements 
were required for SM α-actin promoter activity in vivo [49], and it has been suggested that 
the presence of multiple CArG elements may at least partially explain myocardin’s gene-
specific effects [161].  Thus, we used a series of SM α-actin promoter constructs that  
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Figure 2.3. The effects of ∆GBDmDia2 required SRF and specific CArG elements.   A) SRF -/- 
embryonic stem cells were transfected with ∆GBDmDia2 in the presence or absence of flag-SRF.  B)  
10T1/2 cells were co-transfected with ∆GBDmDia2 and SM α-actin reporters containing single or 
combinatorial CArG mutations (a, b, and i). Inset: SM α-actin promoter showing the three CArG 
elements that are required for its expression in vivo 
 36
contained CArG mutations to determine whether the effects of mDia were also dependent 
upon this mechanism. Mutation of all three CArG elements, two within the proximal  
promoter (a & b) and one within the first intron (i) (see figure 2.3b), completely inhibited the 
effects of ∆GBDmDia2 on SM α-actin promoter while single mutations to any one CArG 
reduced ∆GBDmDia2-induced activity by about 50%.  Interestingly, the intronic CArG, by 
itself, could mediate a significant portion of the effects  of ∆GBDmDia2, and any 
combination of mutations that included the intronic CArG resulted in complete loss of 
promoter activity. 
 
The myocardin family of transcription factors are important for the effects of mDia1/2  
- To test whether the myocardin transcription factors were critical for the effects of mDia1 
and mDia2, we used a dominant negative form of MRTF-A lacking the C-terminal 
transactivation domain that inhibits all three myocardin family members. As shown in figure 
2.4a, this dominant negative dose-dependently inhibited the effects of ∆GBDmDia1 and 
∆GBDmDia2 on SM22 promoter activity. In addition, ∆GBDmDia1 (data not shown) and 
∆GBDmDia2 (figure 2.4b) enhanced the abilities of the myocardin factors to transactivate 
the SM22 promoter activity.  Interestingly, diaphanous signaling had a relatively greater 
effect on the activities of the MRTFs than on myocardin. For example, even though all three 
myocardin transcription factors were expressed at similar levels, myocardin, MRTF-A, and 
MRTF-B activated SM22 promoter activity by 110, 60, and 30 fold, respectively, a result in 
relatively good agreement with previous studies [81].  However, in the presence of 
∆GBDmDia2 all three myocardin factors stimulated SMC-specific promoter activity to a 
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Figure 2.4.  Dia1 and Dia2 signal through the myocardin family.  A) 10T1/2 cells were co-
transfected with ∆GBDmDia1 or ∆GBDmDia2 and increasing concentrations of DN MRTF-A. B) 
Cells were co-transfected with submaximal concentrations of myocardin, MRTF-A, or MRTF-B in 
the presence or absence of ∆GBDmDia2. Inset – myocardin (MyoC), MRTF-A, and MRTF-B 
expression levels as measured by Western Blot.   
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similar extent.  Taken together, these data strongly suggest that mDia1 and mDia2 signal 
through the myocardin transcription factors to activate SMC-specific transcription. 
 
The effects of Dia1/2 are mediated by actin polymerization – Since we had previously 
shown that RhoA-mediated stimulation of actin polymerization was important for SMC-
specific transcription [103], we wanted to test whether the effects of ∆GBDmDia1 and 
∆GBDmDia2 were also mediated by changes in actin dynamics. Thus, we examined F-actin 
in over 200 ∆GBDmDia2 expressing cells using Texas Red-conjugated phalloidin. The 
representative micrographs shown in figure 2.5a demonstrate that ∆GBDmDia2 significantly 
enhanced actin polymerization in 10T1/2 (top panels). This effect was not as easily observed 
in SMC due to high basal levels of actin polymerization in primary SMC cultures even under 
serum-starved conditions. However, expression of dominant negative FH1FH2∆1mDia1 in 
SMC significantly inhibited actin polymerization, indicating that mDia signaling was 
important for maintaining actin polymerization in this cell-type (figure 2.5a, bottom panels). 
As shown in figure 2.5b, treatment of SMC and 10T1/2 cells with the actin depolymerizing 
drug latrunculin B (LB) or co-expression of G-actin nearly completely inhibited the effects 
of ∆GBDmDia2 on SM22 reporter activity, suggesting that changes in G-actin pools were 
important. Treatment of cells with the ROK inhibitor, Y-27632, did not affect ∆GBDmDia2-
induced promoter activity. Identical results were obtained with ∆GBDmDia1 (data not 
shown).  
 
mDia1/2 signaling induces MRTF nuclear localization - The data presented so far indicate 
that mDia1 and mDia2 strongly up-regulate SMC-specific transcription by stimulating actin  
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Figure 2.5. The effects of mDia1 and mDia2 were mediated by actin dynamics. A, 10T1/2 cells were 
transfected with EGFP- GBDmDia2 (top panels) or Flag-DN mDia1 (bottom panels) and serum 
starved for 24 hours. F-actin was visualized using Texas Red phalloidin. B, 10T1/2 cells and SMCs 
were transfected with GBDmDia2 and then treated with 0.5 µmol/L latrunculin B (LB) or 10 
µmol/L Y-27632 for 24 hours before measuring luciferase activity. In separate experiments, cells 
were cotransfected with GBDmDia2 and YFP-G-actin. Values are expressed relative to untreated 
cells transfected with GBDmDia2 alone. *P<0.05 vs untreated/empty vector. 
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polymerization and myocardin family transcription factor activity. Recent studies by 
Miralles et al indicated that the effects of RhoA on SRF-dependent transcription were 
mediated by changes in MRTF-A localization [88].  These authors demonstrated that MRTF-
A was excluded from the nucleus in serum starved cells, through an interaction that involved 
G-actin binding to conserved RPEL domains present in MRTF-A’s N-terminus. Previous 
results from our lab suggested that stimulation of MRTF-A localization by the strong RhoA 
activator, sphingosine 1-phosphate (S1P), was important for S1P-induced up-regulation of 
SMC differentiation marker gene expression [33].  We also demonstrated that MRTF-A and 
especially MRTF-B localized to the cytoplasm in a large percentage of serum starved SMC 
and 10T1/2 cells [86]. To test whether the effects of ∆GBDmDia1 and ∆GBDmDia2 were 
mediated by changes in MRTF nuclear localization, we co-transfected flag tagged-versions 
of MRTF-A and MRTF-B along with GFP-∆GBDmDia2 into primary SMC and 10T1/2 
cells. Results shown in figure 2.6 demonstrate that MRTF-B was localized almost 
exclusively to the cytoplasm in serum-starved SMC and 10T1/2 (left panel), and co-
expression of ∆GBDmDia2 in either cell type resulted in MRTF-B nuclear localization in 
nearly all cells (right panel). Expression of ∆GBDmDia2 also increased the percentage of 
cells containing MRTF-A in the nucleus to nearly 100% (data not shown). When coupled 
with our previous results, these data strongly indicate that RhoA-dependent activation of 
mDia1 and mDia2 stimulates SMC differentiation marker gene expression by promoting 
nuclear localization of MRTF-A and MRTF-B. 
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Figure 2.6. mDia activation promoted nuclear localization of MRTF-A and MRTF-B. A, 10T1/2 
cells and SMCs were transfected with Flag-MRTF-B±EGFP- GBDmDia2. Cells were serum starved 
for 24 hours, fixed, and visualized. Note that MRTF-B localized almost exclusively to the cytoplasm 
in control cells (left panels) and to the nucleus in cells expressing constitutively active mDia2 (right 
panels). 
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DISCUSSION 
The molecular signaling mechanisms that regulate SMC differentiation are poorly 
understood.  We have previously shown that RhoA regulates SMC-specific transcription by 
stimulating actin polymerization [33, 103], but the RhoA effectors involved have not been 
completely described.  Results from the present study indicate that mDia1 and mDia2 are 
important regulators of SMC differentiation marker gene expression. First, both of these 
RhoA effectors were highly expressed in SMC. Second, RhoA-mediated activation of Dia1/2 
strongly stimulated SMC-specific transcription in SMC and SMC-like cell lines. Third, a 
dominant negative version of mDia1 that inhibits endogenous mDia1 and mDia2 signaling 
strongly inhibited SMC-specific promoter activity in SMC and SMC-like cell lines. Finally, 
the effects of mDia1/2 were dependent upon SRF and were likely due to nuclear 
translocation of the SRF cofactors, MRTF-A and MRTF-B. 
Our analysis of mDia expression is in relatively good agreement with a previous 
study of mDia1 expression by Northern blotting [162].  While neither mDia1 nor mDia2 is 
expressed specifically in SMC, relatively strong expression in isolated SMC and many SMC-
containing tissues suggests that these RhoA effectors play an important role in regulating 
SMC function. Given their abilities to stimulate SMC differentiation marker gene 
expression, it will be crucial to further characterize mDia1 and mDia2 expression (and 
perhaps activity) during all stages of development, using methods that provide better cell-
type-specific resolution. It is also important to emphasize that lack of SMC-specificity of 
mDia1 or mDia2 does not necessarily preclude their involvement in regulating SMC 
differentiation. Cell-type-specific signaling can also result from differences in proteins 
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downstream of the more general signaling pathways and we believe that the myocardin 
transcription factors may serve this function in SMC (see below).  
It is clear that actin polymerization mediated by the catalytically active FH1/FH2 
domain is inhibited by an intra-molecular interaction between the DAD auto-regulatory 
domain and the DID inhibitory domain. Extensive structure-function analyses, including two 
recent X-ray crystallography studies, indicate that the GBD and DID domains overlap 
slightly and that GTP-RhoA binding to the GBD displaces DAD from the DID binding 
pocket to activate the mDia proteins [124, 125, 127, 163, 164].  In the present studies, we 
used several different strategies to activate mDia signaling, including co-expression of 
constitutively active RhoA, deletion of the mDia GBD/DID domain, and expression of a 
competing DAD peptide. All three of these interventions significantly up-regulated SMC-
specific transcription in 10T1/2 cells and rat aortic SMC. In 10T1/2 cells, expression of 
∆GBDmDia1 or ∆GBDmDia2 transactivated the SM22 promoter by 45 and 30 fold, 
respectively, levels of transactivation usually only seen upon over-expression of the 
myocardin transcription factors. Expression of ∆GBDmDia1, ∆GBDmDia2 or DAD peptide 
in SMC also led to significant increases in SMC-specific transcription, but these effects were 
more modest. A similar difference in relative activities is observed upon over expression of 
the myocardin factors in SMC and is most likely due to the relatively high levels of SMC-
specific transcriptional activity already exhibited by primary SMC. Our data would suggest 
that strong mDia expression (and activity) probably contributes to this high basal activity. 
Nevertheless, when taken together with the inhibitory effects of DN mDia1 in SMC and the 
high level of mDia1 and mDia2 expression in SMC, these data provide strong support for the 
involvement of RhoA-dependent mDia signaling in SMC differentiation.  
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Our results also demonstrated that mDia1 and mDia2 had very little effect on the 
activity of the c-fos promoter, further supporting the idea that RhoA signaling differentially 
regulates SRF-dependent SMC differentiation vs SRF-dependent SMC growth.  The 
selectivity and/or promiscuity of individual DRFs for various Rho family GTPases may also 
be interesting in regard to gene-specific regulation by SRF. For example, mDia1 and mDia2 
have been shown to interact with RhoA, RhoB, and RhoC, but not with Rac1 [118, 162], 
while FHOD1 interacts with Rac1, but not RhoA [165, 166].  Interestingly, mDia2 has also 
been shown to bind Cdc42 and a newly described GTPase, Rif, and these interactions are 
thought to play a role in filopodial extension [126, 127].  Expression of constitutively active 
Cdc42 did increase mDia2-dependent activation of the SMC-specific promoters, but these 
effects were not as great as those observed with L63RhoA (Staus and Mack, unpublished 
observation). Since the small GTPases are regulated by different signaling inputs, reside in 
different cellular compartments, and regulate the formation of slightly different actin 
structures, it is interesting to speculate that the DRFs may relay specific information to the 
nucleus that could lead to different levels of SRF-dependent gene expression or to 
differential expression of subsets of SRF-dependent genes.  
The inhibitory effects of latrunculin B and over-expression of G-actin clearly 
implicate actin dynamics in mDia-induced regulation of SMC-specific transcription. RhoA 
also stimulates actin polymerization through ROK/LIMK/cofilin and it is thought that these 
pathways interact functionally to regulate SRF activity [62, 119].  In the present study, Y-
27632 did not affect transactivation by ∆GBDmDia1, suggesting that ROK activity was not 
required for this response. When coupled with the strong effects of constitutively active 
mDia1 and mDia2 on SMC-specific promoter activity, these data suggest that RhoA 
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signaling to mDia1 and mDia2 may be more important for regulating SMC differentiation 
than RhoA signaling to ROK. Another RhoA effector, PKN, has recently been shown to be 
important for the induction of SMC-specific promoter activity by TGF-β, but whether 
changes in actin dynamics were involved was not addressed [167].  The present studies also 
demonstrated that mDia2 expression was up-regulated upon TGF-β treatment, suggesting 
additional cross-talk between these two pathways. 
A growing body of evidence indicates that the effects of actin dynamics on SRF-
dependent transcription are mediated by nuclear localization of the MRTFs. G-actin binding 
to the N-terminal RPEL domains found in MRTF-A and MRTF-B has been shown to be 
important for sequestering the MRTFs in the cytoplasm, and reduction of G-actin pools by 
RhoA-dependent signaling is important for relieving this inhibitory signal [33, 88, 147].  
Results from the present study provide further support for this model. Importantly, 
expression of constitutively active mDia1 or mDia2 stimulated the nuclear localization of 
both MRTF-A and MRTF-B and synergistically activated MRTF-A- and MRTF-B-
dependent SMC-specific transcription. Interestingly, in the presence of constitutively active 
mDia1 or mDia2, the activities of MRTF-A and MRTF-B were equal to that of myocardin, 
suggesting that mDia1/2 activity may be a limiting factor for their activities. Somewhat 
surprisingly, constitutively active mDia1 and mDia2 also increased myocardin-dependent 
transactivation even though myocardin was constitutively nuclear. This most likely reflects 
cooperative effects with endogenously expressed MRTFs, but it is possible that mDia 
signaling activates myocardin by a separate mechanism. Kuwahara et al. have recently 
identified another protein called STARS (STriated muscle Activator of Rho Signaling) that 
stimulates SRF-dependent transcription by regulating MRTF nuclear localization [168, 169].  
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Whether mDia1/2 activity is important for differentiation of other muscle cell types is an 
interesting question for future studies. 
It is clear that MRTF-A and MRTF-B, like myocardin, can upregulate a number of 
CArG-containing muscle-specific genes. While the MRTFs are expressed in some SMC 
subsets including the aorta, these SRF co-factors are thought to be expressed more widely, 
which complicates their contribution to cell-type-specific gene expression [33, 81, 85, 93].  
Several recent studies, however, indicate that the MRTFs are important for regulating SMC 
differentiation. Two separate groups have shown that genetic disruption of MRTF-B leads to 
a lethal embryonic defect in pharyngeal arch remodeling and that this phenotype is 
accompanied by a failure of SMC differentiation in the cardiac neural crest cells that 
populate the cardiac outflow tract [92, 93].  In addition, Pipes et al. used a chimeric mouse 
model to demonstrate that myocardin -/- cells could populate the developing aorta suggesting 
that the MRTFs probably regulate SMC differentiation under certain circumstances [80].  
Interestingly, several groups have reported somewhat contrasting results on the 
regulation of MRTF-A localization by signaling pathways, suggesting that this mechanism 
may be more complicated than originally described and that cell-type-specific differences or 
local environmental cues may be important parameters for regulating this process [85, 91]. 
Given the observation that MRTF expression does not necessarily correlate with MRTF 
transcriptional activity, it is possible that differential RhoA/mDia signaling could play an 
important role in the control of cell-type-specific gene expression by the MRTFs. Since SMC 
never terminally differentiate, this mechanism could be particularly important for modulating 
SMC phenotype in response to environmental signals. 
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In summary, our results indicate that mDia1 and mDia2 are very important regulators 
of SMC-specific gene expression. These RhoA effectors strongly activate the MRTFs by 
increasing actin polymerization, which induces their nuclear localization.  The precise roles 
that mDia1 and mDia2 play in the regulation of SMC differentiation during vascular 
development or in the regulation of SMC phenotype during the progression of cardiovascular 
disease will be an important area for future studies. 
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ABSTRACT 
The RhoA effector, mDia2, regulates SRF-dependent smooth muscle cell (SMC)-specific 
transcription by stimulating actin polymerization and myocardin-related transcription factor 
(MRTF) nuclear localization. While it is clear that RhoA activates mDia2 by disrupting the 
interaction between the diaphanous autoregulatory domain (DAD) and the diaphanous 
inhibitory domain (DID), it is currently unknown whether additional signaling pathways 
regulate mDia2 activity. In the present study we demonstrate that mDia2 is phosphorylated 
by Rho-kinase at two conserved residues (T1061 and S1070) just C-terminal to the DAD 
basic region that stabilizes the DID-DAD interaction. Phosphomimetic mutations (S/T to E) 
resulted in enhanced mDia2 activity in 10T1/2 cells as measured by SRF-dependent 
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transcription, actin polymerization, and MRTF nuclear localization and activity. Although 
the T1061E/S1070E double mutation was not sufficient to fully activate mDia2, it resulted in 
stronger association with and activation by L63RhoA. An mDia2 DAD peptide containing 
the double E mutation showed dramatically decreased binding to the DID, and when 
overexpressed in 10T1/2 cells, failed to activate endogenous mDia as well as a wild-type 
peptide. Based upon structural and sequence information, we also identified an acidic region 
in the mDia2 DID that when disrupted resulted in significant mDia2 activation   Taken 
together our results indicate that phosphorylation of the mDia2 DAD by Rho-kinase 
enhances mDia2 function by destabilizing the DID-DAD interaction and sensitizing mDia2 
to activation by RhoA. These results will have important implications for a number of cell 
functions that involve actin polymerization as well as for the control of SMC phenotype and 
contractility.   
 
INTRODUCTION 
Extensive studies indicate that RhoA signaling regulates gene expression by 
activating the MADS box transcription factor, known as serum response factor (SRF) (see 
[170] for review). We and others have shown that this pathway is important for the 
expression of many muscle differentiation marker genes that contain SRF binding CArG 
elements within their promoters [58, 103, 171]. Additional studies have shown that the 
effects of RhoA on SRF-dependent gene expression are secondary to its effects on actin 
polymerization and are mediated by nuclear translocation of the SRF co-factors Myocardin-
Related Transcription Factor-A (MRTF-A) and MRTF-B [33, 88, 113, 169]. Given the 
importance of the MRTFs in regulating SMC differentiation marker gene expression in vivo 
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[89, 90, 92, 93], it is likely that this pathway is an important mechanism by which 
extracellular signals regulate SMC phenotype. 
When activated by GTP binding, RhoA interacts with several effector molecules that 
regulate actin polymerization.  Rho-kinase has been the most thoroughly studied in this 
regard and inhibits the disassembly of actin polymers through LIM-kinase-dependent 
inhibition of cofilin [116]. Rho-kinase also inhibits myosin phosphatase to stimulate actin-
myosin-based contraction, which in turn, promotes actin fiber bundling and stress fiber 
formation [114, 115].   The RhoA effectors, mDia1 and mDia2, also strongly stimulate actin 
polymerization and SRF-dependent transcription [162, 164], and recent studies from our lab 
demonstrate that these formin proteins are highly expressed in SMC and are powerful 
activators of SMC-specific transcription [172]. 
mDia1 and mDia2, along with mDia3 and FHOD1, are members of a subfamily of 
diaphanous-related formins (DRFs) that act as potent actin polymerizing factors (see [121] 
and [122] for reviews). The DRFs are identified by three highly conserved formin homology 
(FH) domains, an N-terminal GTPase binding domain (GBD), an adjacent Diaphanous 
Inhibitory Domain (DID), and a C-terminal Diaphanous Auto-regulatory Domain (DAD) 
(see figure 3.1a).  The molecular mechanisms that control DRF activity have been fairly well 
described.  In the inactive state, the catalytic FH1/FH2 domain is inhibited by a DRF 
conformation that is maintained by an interaction between the N-terminal DID and C-
terminal DAD domains [124, 160].  Crystal structure analysis of this interaction in mDia1 
revealed that the core DAD sequence forms an amphipathic helix that binds to a highly 
conserved hydrophobic pocket formed by the DID [173].  Recent studies on mDia2 by 
Waller et al. and on FHOD1 by Schonichen et al. suggest that a conserved basic region C-
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terminal to the core DAD domain may also be important for DID-DAD binding [125, 174].  
Since the GBD and DID binding pockets slightly overlap, high affinity binding of an 
activated GTPase to the GBD disrupts the DAD-DID interaction to expose the catalytically 
active FH1/FH2 region [173, 175]. 
While there is some promiscuity in the activation of the DRFs by the small GTPases, 
mDia1 and mDia2 are activated most strongly by RhoA while mDia3 and FHOD1 are 
activated by Cdc42 and Rac1, respectively (see [176] for review). Interestingly, mDia2 has 
also been shown to bind Cdc42 and the Rho GTPase, Rif, which may target mDia2 and actin 
polymerization to the tips of filopodia. [165, 166, 177]. mDia1 and mDia2 promote actin 
polymerization from actin filament barbed ends in physical cooperation with the actin 
binding protein profilin [133, 157, 158], but the precise mechanisms involved are not 
completely understood. 
Given that mDia1 and mDia2 have such a dramatic effect on SMC-specific 
transcription, we have become interested in the molecular mechanisms that regulate their 
activities. Since most studies have focused on DRF activation by the small GTPases, it is 
unclear whether post-translational modification plays a significant role. Wang et al. 
demonstrated that the FHOD1 DAD was phosphorylated by PKG at S1131, but the 
functional consequences of this modification were not examined [178]. The mDia2 DAD 
contains a very similar site at T1061, and based upon its proximity to the basic domain, we 
hypothesized that T1061 phosphorylation would stimulate mDia2 activity by disrupting the 
contributions of the basic region to the DID-DAD interaction. 
 
 MATERIALS AND METHODS 
 52
Plasmids and Reagents – Full length mDia2 was a generous gift of Shuh Narumiya (Kyoto 
University, Japan). Constitutively active Rho-kinase (pcMV-Myc-ROCK∆3) and GST-L63 
RhoA were kind gifts from Keith Burridge (University of North Carolina). Wild-type ROCK 
(pCAG-Myc-ROCK) and cDNA for MRTF-B were gifts from Channing Der and Da-Zhi 
Wang (University of North Carolina), respectively. GST fusion proteins and flag-tagged 
expression plasmids for mDia2 were generated by subcloning into the pcDNA3.1 (Clontech), 
pGEX-4T1 (Amersham Biosciences), or pEGFP (Clontech) vectors.  The mDia2 DID and 
DAD fragments were generated by PCR and comprise amino acids 1-533 and 1030-1171, 
respectively. The S1070 and T1061 mutations to alanine (A) or glutamic acid (E) were made 
by the Quikchange Site-Directed Mutagenesis Kit (Stratagene).   
Transient Transfections and Reporter Gene Assays – The maintenance and transfection of 
multipotential 10T1/2 cells were performed as previously described [172]. In brief, cells 
were maintained in 48 well plates in 10% serum and were transfected 24 h after plating at 
70-80% confluency using the transfection reagent TransIT-LT1 (Mirus, Madison, WI), as per 
protocol.  Cells were harvested 24 h after transfection for luciferase assay, which used the 
luciferase assay kit from Promega (Madison, WI). The SM22 (from –450 to +88) and SM α-
actin promoters (from -2560 to +2784) used in this study have been previously described 
[103, 149]. 
GST-fusion Protein Expression – The expression of the DID, DAD and L63 RhoA GST 
fusion proteins were induced in BL-21 bacteria by 18 h incubation at room temperature with 
100 µM isopropyl-D-thiogalactopyranoside. Following bacterial lysis, GST-fusion proteins 
were purified using glutathione-Sepharose beads (Sigma). 
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In Vitro and In Vivo Kinase Assays – In vitro Rho-kinase assays were performed as 
previously described [179].  In brief, constitutively active Rho-kinase (ROCK∆3) was 
immunoprecipitated from Cos-7 cells and then incubated for 20 min at 30 °C in 25 µl of 
kinase buffer containing 200 µM ATP, 10 µCi of [γ-32P]ATP and 2 µg GST-fusion protein. 
The Rho-kinase inhibitor Y-27632 (30µM) (Calbiochem) was added to some reactions. For 
in vivo [32P] phosphate labeling, Cos-7 cells were transfected with either Wt or 
phosphorylation mutants of flag-tagged mDia2 in the presence or absence of Myc-ROCK∆3.  
Cells were pre-incubated with phosphate-free medium 3 h and then labeled with 1 mCi/ml 
32P orthophosphate for 4 h. mDia2 was then immunoprecipitated using M2 Flag antibody 
conjugated to agarose beads (Sigma) and analyzed by SDS-PAGE and autoradiography. 
Western Blotting - 10T1/2 cells were grown to confluency, lysed in RIPA buffer, and cleared 
by centrifugation (4oC for 30 min at 14,000 rpm) and protein concentrations were determined 
by BCA assay (Pierce). Fifty µg of total protein was run on a 10% SDS polyacrylamide gel, 
transferred to nitrocellulose and detected with M2 anti-flag antibody (Sigma). 
GST Pull-Downs – Cos-7 cells were transfected and scraped into 1% NP40 Buffer (0.15 M 
NaCl, 10 mM NaPO4 (pH 7.2), 1% NP40, and 0.5% (DAD and L63 pull-downs) or 2% (DID 
pull-downs) Triton X-100) 24 h post-transfection. After lysis, 250 µg of total protein was 
incubated with 10 µg of GST-DID or 20 µg of GST-L63 RhoA / GST-mDia2 DAD fusion 
beads at 4°C for 3 h. Complexes were pelleted by centrifugation and washed 2X in lysis 
buffer and 1X in cold Tris-buffered saline. Samples were subsequently boiled in SDS-PAGE 
buffer, electrophoresed by SDS-PAGE, and probed with M2 anti-flag antibody. 
Immunoflourescence -10T1/2 cells were plated and transfected in 8-well chamber slides, 
maintained in 10% serum overnight. Cells transfected with Myc-ROCK or GFP-MRTF-B 
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were serum-starved for 16 h or 8 h, respectively.  Cells were fixed in 3.7% 
paraformaldehyde/PBS for 20 min and permeabilized in 0.5% Triton X-100/PBS for 3-4 
min. Cells were then incubated with M2 anti-flag (1:500) (Sigma) or anti-Myc (1:500) (Cell 
Signaling) in 20% goat serum / 3% BSA in PBS for 2 h.    Texas Red, FITC (Jackson 
ImmunoResearch), or Cy5 (Molecular Probes) conjugated secondary antibodies were used at 
1:1000 while Texas Red Phalloidin (Molecular Probes) and DAPI (Molecular Probes) were 
used at 1:500 and 90nM, respectively. 
 
RESULTS 
 
The mDia2 DAD domain is phosphorylated by Rho-kinase 
Based upon the previous demonstration that the FHOD1 DAD was phosphorylated 
by PKG [178], we originally tested whether two highly conserved amino acids, T1061 and 
S1070, just C-terminal to the mDia2 DAD basic region were phosphorylated by this enzyme 
(see figure 3.1a). However, we failed to detect a significant increase in mDia2 
phosphorylation upon activation of PKG in Cos-7 cells even though the PKG substrate, 
VASP, was strongly phosphorylated in these experiments (data not shown). T1061 and 
S1070 also conform to the consensus Rho-kinase phosphorylation site (R/KXS/T). When 
coupled with the fact that Rho-kinase phosphorylates LIM-kinase at a threonine residue just 
C-terminal to a highly conserved basic domain [179], we tested whether the mDia2 DAD 
was phosphorylated by Rho-kinase. We first performed in vitro kinase assays with 
constitutively active Rho-kinase immunoprecipitated from Cos-7 cells. As shown in figure 
3.1b, Rho-kinase strongly phosphorylated GST-DAD (but not GST alone) and mutation of 
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Figure 3.1. Phosphorylation of mDia2 by Rho-kinase.  A) Schematic of mDia2 activation by RhoA 
and sequence conservation in the DAD domain.  B) Rho-kinase (ROCK) in vitro kinase assay. mDia2 
DAD GST fusion proteins (Wt and the indicated phosphorylation mutations) were 32P labeled for 15 
minutes by constitutively active ROCK that was immunoprecipitated from Cos lysates. Samples were 
separated on an SDS PAGE gel, transferred to nitrocellulose, and exposed to film. The Ponceau-
stained blot in the lower panel demonstrates equal GST-fusion protein loading. C) Cos-7 cells were 
transfected with Wt or phophorylation deficient variants of full-length (top panel) or DAD (bottom 
panel) mDia2 along with constitutively active Rho-kinase (ROCK∆3). Following 32P orthophosphate 
labeling for 4 h, mDia2 was then immunoprecipitated and analyzed by autoradiography. 
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 S1070 to alanine or addition of the Rho-kinase inhibitor, Y-27632, completely eliminated 
this phosphorylation. The upper band visible in these blots represents Rho-kinase auto-
phosphorylation and serves as an excellent positive internal control in these experiments.  To 
test for mDia2 phosphorylation in vivo, we co-transfected Wt and phosphorylation deficient 
variants of full-length mDia2 along with constitutively active Rho-kinase into Cos-7 cells. 
Phosphorylation of full-length mDia2 was significantly increased by the presence of Rho-
kinase (figure 3.1c, top panel), and importantly, this increase was attenuated by T1061A and 
S1070A mutations. Although in vivo phosphorylation of mDia2 DAD peptides by Rho-
kinase was not as strong (figure 3.1c, bottom panel), the T1061A and S1070A mutations 
nearly completely inhibited phosphorylation of the DAD peptide. These results suggest that 
Rho-kinase's ability to phosphorylate T1061 and S1070 may be facilitated by structural 
features of the full-length molecule. It is also possible that the DAD peptide exhibits higher 
baseline phosphorylation or that T1061 and S1070 are targeted by additional kinases in this 
context. During the course of our studies, Takeya et al. demonstrated that FHOD1 was 
phosphorylated by Rho-kinase at several conserved DAD residues including S1131, S1137, 
and T1141 [180], further supporting a role for Rho-kinase in DRF regulation. 
 
Phosphorylation of T1061/S1070 enhances mDia2 activity 
To examine the consequences of T1061/S1070 phosphorylation on mDia2 function, 
we tested a series of phosphomimetic (S/T to E) and inhibitory (S/T to A) mDia2 mutations 
on SRF-dependent, SMC-specific promoter activity in multi-potential 10T1/2 cells, a model 
in which SMC marker gene expression can be up-regulated by a variety of extrinsic cues. As 
shown in figure 3.2a, expression of Wt mDia2 increased SM22 promoter activity by 6 fold 
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Figure 3.2. DAD phosphorylation by Rho-kinase enhances mDia2 activity. Full length mDia2 
and the indicated mDia2 phosphorylation variants were transfected into 10T1/2 cells along with a 
luciferase reporter construct driven by the SM22 (A) or SM -actin (B) promoters. Luciferase 
activity was measured in cell lysates 24 h post-transfection. Inset in A shows expression levels of the 
different mDia2 variants. * p<0.05 vs Wt; ** p<0.05 versus T1061E C) HeLa cells, used for their 
low basal levels of stress fibers, were transfected with flag-mDia2 Wt or 2E and actin polymerization 
visualized via phalloidin staining. D) 10T1/2 cells were co-transfected with SM22-luciferase and 
either the Wt or 2E mDia2 variant. 18 h post-transfection, cells were treated for 6 h with 10 M Y-
27632 and then luciferase assays were performed. Data are expressed relative to luciferase activity in 
untreated cells set to 1. * p<0.05 vs untreated. E) 10T1/2 cells were transfected with GFP, GFP-
mDia2, or GFP-mDia2 2A plus or minus constitutively active myc-tagged Rho-kinase. 
Paraformaldehyde fixed cells were imaged for myc and GFP expression and for actin polymerization 
with phalloidin 
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and this effect was significantly increased by the T1061E mutation. Interestingly, while the 
S1070E mutation had no effect on its own, the mDia2 variant containing the 
T1061E/S1070E double mutation (2E) enhanced SM22 activity more strongly perhaps 
suggesting some cooperativity between the two sites. Although the S1070A mutation slightly 
but significantly decreased mDia2 activity, in general, the inhibitory alanine mutations had 
little effect suggesting that basal levels of T1061/S1070 phosphorylation in 10T1/2 cells are 
relatively low. The phosphomimetic mutations had nearly identical effects on the SRF-
dependent, SM α-actin promoter (figure 3.2b).  
We next tested the effects of DAD phosphorylation on mDia2’s ability to stimulate 
actin polymerization. As shown in figure 3.2c, expression of full-length flag mDia2 in HeLa 
cells did not alter phalloidin staining.  This is in excellent agreement with previous studies 
[125] and most likely results from the auto-inhibited nature of the full length molecule. In 
contrast, expression of the mDia2 2E variant led to a modest increase in phalloidin staining 
indicative of mDia2 activation. To further explore the relationship between Rho-kinase and 
mDia2, we treated mDia2 and mDia2-2E expressing cells with the Rho-kinase inhibitor Y-
27632. As shown in figure 3.2d, Y-27632 reduced SM22 promoter activation by Wt mDia2, 
but had no effect on the 2E variant. Taken together these results indicate that 
phosphorylation of T1061 and S1070 by Rho-kinase enhances the effects of mDia2 on actin 
polymerization and SRF-dependent transcription. 
To more closely examine the role of Rho-kinase in this process, we expressed the Wt 
and 2A mDia2 variants with constitutively active Rho-kinase.  As shown in Figure 3.2e, 
expression of constitutively active Rho-kinase on its own modestly increased phalloidin 
staining (small arrow head) in 10T1/2 cells.  Co-expression of Wt mDia2 significantly 
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enhanced this signal indicating that these molecules synergize to regulate actin 
polymerization (large arrows). Importantly, co-expression of Rho-kinase with the mDia2-2A 
variant did not result in increased phalloidin staining over that observed with Rho-kinase 
alone suggesting that phosphorylation of these residues is required for this synergy (bottom 
panel).  
Based upon previous data from our lab and others, we hypothesized that the effects of 
the mDia2-2E variant on SMC-specific promoter activity were mediated by the effects of 
increased actin polymerization on MRTF nuclear localization. To test this more directly, we 
treated mDia2-2E-expressing cells with the actin polymerization inhibitor latrunculin B. As 
shown in Figure 3.3a, the presence of latrunculin B significantly inhibited the effects of 
mDia2-2E on SMC-specific promoter activity as previously observed with ∆GBDmDia2 (see 
chapter 2). In addition, expression of the mDia2-2E variant increased the activity and nuclear 
localization of MRTF-B (figs 3.3b and 3.3c). Since MRTF activity is directly regulated by 
changes in G-actin pools, these results provide further evidence that phosphorylation of the 
mDia2 DAD enhances actin polymerization. 
It has been suggested that GTPase binding to the GBD is not sufficient to fully 
activate DRF-dependent actin polymerization and that an additional, as yet undescribed 
signal, may also be required [163]. The effects of mDia2 phosphorylation could be explained 
by increased catalytic activity or by increased sensitization of the phosphorylated form to 
activation by RhoA. To distinguish between these possibilities, we made similar mutations in 
the context of the constitutively active form of mDia2 that lacks the GBD domain. Neither 
mutation increased ∆GDBmDia2's ability to stimulate SM22 promoter activity suggesting 
that the positive effect of the 2E mutation was not due to increased catalytic activity (data not 
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Figure 3.3.  DAD phosphorylation enhances MRTF-B activation and nuclear localization.  A) 
SM22-luciferase activity was measured in mDia2-2E expressing 10T1/2 cells in the presence or 
absence of the actin polymerization inhibitor, latrunculin B (LB). * p<0.05 vs untreated B) 10T1/2 
cells were transfected with equal amounts of GFP-MRTF-B and flag-mDia2-2E and localization 
visualized after 18 h serum starvation (0.5% FBS).  C) 10T1/2 cells were cotransfected with SM22 
luciferase, MRTF-B, and the indicated mDia2 phosphorylation variant. Luciferase activity was 
measured at 24 h. * p<0.05 vs Wt  
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Figure 3.4. DAD phosphorylation sensitizes mDia2 to activation by RhoA.  A) The 2E and GBD 
variants of mDia2 were transfected into 10T1/2 cells plus or minus dominant negative N19RhoA and 
SM22 luciferase activity was measured at 24 h. Data are expressed relative to luciferase activity 
measured in the absence of N19RhoA set to 1. * p<0.05 vs. minus N19RhoA  B) The indicated 
mDia2 variant was transfected into 10T1/2 cells plus or minus constitutively active L63RhoA. * 
p<0.05 vs Wt  C) A GST-L63RhoA fusion protein was used to pull-down flag-tagged Wt and 2E 
mDia2 DAD variants (AA 1030-1171) from Cos7 cell lysates.  
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shown). We also found that the transcriptional activity of the 2E variant, unlike that of 
∆GBDmDia2, was inhibited by dominant negative N19RhoA (Fig 3.4a), suggesting that 
DAD phosphorylation does not render mDia2 constitutively active. Results shown in figure 
3.4b demonstrate that the 2E variant was synergistically activated by L63RhoA, and 
importantly, this increase in RhoA-dependent activation was accompanied by a concomitant 
increase in mDia2 binding to RhoA as measured by GST pull down assays (Fig 3.4c). Taken 
together these data suggest that DAD phosphorylation regulates mDia2 activity by enhancing 
or sustaining mDia2 activation by RhoA. 
T1061/S1070 phosphorylation inhibits DAD binding to the DID 
 
 We originally hypothesized that addition of negatively charged phosphate groups at 
T1061 and S1070 would activate mDia2 by interfering with the basic region’s role in 
stabilizing the mDia2 DID-DAD interaction. To test this more directly we generated a GST-
DID (AA 1-533) fusion protein and used it to pull down Wt, 2A, and 2E DAD (AA 1030-
1162) variants from Cos-7 lysates. As shown in figure 3.5a, the Wt and 2A variants were 
efficiently precipitated in this assay, while the 2E variant was not. Another method used to 
study DID-DAD interactions is based upon the activation model shown in figure 3.1a and 
involves the stimulation of endogenous mDia activity by competitive inhibition of the DID-
DAD interaction by exogenously expressed DAD peptides [125, 172]. In this assay the 
ability of a specific DAD peptide to stimulate endogenous mDia activity can be used as a 
rough measure of its ability to bind the DID. As expected, expression of Wt DAD in 10T1/2 
cells activated endogenous mDia2 as measured by increased SM22 promoter activity (figure 
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Figure 3.5. DAD phosphorylation weakens the DID-DAD interaction.  A) A GST-mDia2 fusion 
protein (AA 1-533) containing the entire DID was used to pull-down the indicated flag-tagged mDia2 
DAD variant from Cos7 cell lysates.  B) 10T1/2 cells were transfected with the indicated flag-tagged 
mDia2 DAD variants peptides along with the SM22-luciferase. * p<0.05 vs. Wt 
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 3.5b). Importantly, the T1061E and 2E variants had significantly less effect providing 
additional evidence that DAD phosphorylation decreases DID-DAD binding. 
 
A conserved acidic region within the DID is important for the DID-DAD interaction. 
 Our results strongly support a role for the basic region in modifying mDia2 
activation. However, the mechanisms by which this region alters DID-DAD binding is 
currently unclear because nothing is known about DID residues with which the DAD 
interacts with the DID. The DID binding pocket consists of 5 armadillo repeats with all five 
B helices making contact with the hydrophobic face of the DAD helix [173].  Although the 
basic domain did not show sufficient order to be placed into the DID-DAD crystal structure, 
it likely extends C-terminally from the core DAD sequence toward the α5B helix of the DID.  
Based upon sequence conservation (between species and other DRF family members, see 
figure 3.6a) and positioning within the α5B helix, we hypothesized that two acidic residues 
(E377 and D378) were important for the DID-DAD interaction. To test this directly, we 
generated a E377K/D378K double mutation within the context of an N-terminal mDia2 
construct (AA 1-533) that contained the entire DID sequence. As shown in Figure 3.6b, this 
mutation dramatically inhibited the DID-DAD interaction as measured in pull down assays 
with a GST-DAD fusion protein. Importantly, in the context of full-length molecule, the 
E377K/D378K double mutation very strongly activated SM22 promoter activity providing 
additional evidence that this acidic region was important for maintaining mDia2 in the 
inactive state (figure 3.6c). To further test this hypothesis we used an assay recently 
described by Copeland et al. that measures the ability of the N-terminal half of mDia2 to 
inhibit the C-terminal half of mDia2 that contains the catalytically active FH1/FH2 domain 
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Figure 3.6. Identification of acidic DID residues that may interact with the DAD basic domain.  
A) Conservation of an acidic region in the DID α5B helix.  B) A GST-DAD fusion protein was used 
to pull-down flag-tagged mDia2 N-terminal fragments (AA 1-533) containing Wt or E377K/D378K 
sequence from Cos7 cells. C) Full-length Wt or E377K/D378K mDia2 were transfected into 10T1/2 
cells along with SM22 luciferase. L63RhoA was included in a second group of transfections. 
Luciferase activity was measured at 24 h. * p<0.05 vs Wt D) The catalytically active C-terminal half 
of mDia2 (flag-FH1FH2 + DAD) was transfected into cells in the presence or absence of the 
indicated flag tagged mDia2 N-terminal fragment. * p<0.05 vs Wt. 
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 and DAD [181]. As expected, expression of the Wt N-terminal fragment attenuated the 
activation of the SM22 promoter by the C-terminal fragment while the N-terminal fragment 
containing the E377K/D378K double mutation was less effective (figure 3.6d). 
 
DISCUSSION 
It is clear that mDia2 activity is inhibited by the DID-DAD interaction and that RhoA 
binding displaces DAD from the DID binding pocket to expose the catalytic activity of the 
FH1/FH2 domain. Virtually nothing is known about additional signaling mechanisms that 
regulate mDia2 activity, and the goal of the current study was to examine the effects of DAD 
phosphorylation on this process.  Our results demonstrate that mDia2 is phosphorylated at 
T1061 and S1070 by Rho-kinase. These modifications weaken the DID-DAD interaction 
sensitizing the phosphorylated form to activation by RhoA. To our knowledge this is the first 
demonstration of direct cross-talk between two RhoA effectors and our findings should have 
important implications for RhoA-dependent regulation of actin polymerization. 
The core DAD sequence, MDSLLEAL, is critically important for the DID-DAD 
interaction, and recent crystal structure analyses of mDia1 have demonstrated that this region 
forms an amphipathic helix that binds tightly to a hydrophobic pocket on the DID surface 
[173]. Mutation analyses by Wallar et al. have recently implicated the basic region (RRKR) 
N-terminal to the core domain in mDia2 regulation.  These authors demonstrated that single 
glutamate substitutions at any one of these residues resulted in a significant reduction in 
DAD affinity for DID and that DAD peptides containing these mutations were incapable of 
activating endogenous mDia. Our demonstration that the T1061E/S1070E phosphomimetics 
enhanced mDia2 activity fits well with these results and supports a model in which the DID-
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DAD interaction is regulated by phosphorylation. Importantly, during the completion of the 
current studies, Takeya et al. demonstrated that phosphorylation of the FHOD1 DAD 
inhibited its interaction with the putative N-terminal FHOD1 DID, providing further 
evidence for this model [180]. Moreover, our identification of acidic residues in the DID that 
potentially interact with the basic domain extends our understanding of the molecular 
interactions that regulate DID-DAD binding and mDia2 activity. It will certainly be 
important to further characterize this interaction by additional structural studies. 
Interestingly, basic sequences are found in many other DRFs (mDia1, mDia3, dDia, FHOD1, 
Bni1), but only mDia2 and FHOD1 have conserved consensus Rho-kinase phosphorylation 
sites near this domain, suggesting differential regulation of the DRFs by this mechanism. 
Although difficult to determine at present, the timing of DAD phosphorylation during 
the mDia2 activation cycle could have important implications on the regulation of mDia2 
activity. For example, since mDia2 activation is essentially determined by competitive 
binding of RhoA and DAD to the GBD/DID domain, a phosphorylation-mediated weakening 
of the DID-DAD interaction would favor RhoA binding and initial activation. Alternatively, 
DAD phosphorylation that occurred subsequent to RhoA binding could prevent the re-
association of the DID-DAD complex leading to prolonged mDia2 activity. Qualitatively, 
full length mDia2 was more strongly phosphorylated by Rho-kinase than the DAD peptide, 
perhaps supporting the former mechanism. In addition, T1061 and T1070 could be targets 
for other kinases especially in the open conformation. It will be important to identify all of 
the kinases that can phosphorylate these residues and to determine whether activation state 
affects mDia2 phosphorylation by Rho-kinase. Likewise, the identification of phosphatases 
that could dephosphorylate these residues will also be important. 
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The precise physiologic significance of mDia2 activation by Rho-kinase is not 
completely clear. However, given that this mechanism occurs downstream of RhoA, we 
hypothesize that it allows for more dynamic temporal or spatial control of actin 
polymerization. This could be particularly relevant at the very leading edge of migrating 
cells where precise actin polymerization is required for cell extension. In addition, since 
mDia2 activity has been shown to be targeted to filopodia by Cdc42 and Rif [165, 166, 177], 
it will be important to test the effects of phosphorylation on mDia2 activation by these small 
GTPases.  We also demonstrated that DAD phosphorylation increased mDia2 association 
with RhoA, which could have implications for the specificity of mDia2 activation by the 
different small GTPases with which it interacts. Finally, since both Rho-kinase and mDia2 
activity are important for SMC-specific gene expression [172], this mechanism may play a 
role in the regulation of SMC phenotype. Rho-kinase is also a major regulator of SMC 
contractility and this mechanism could help ensure that levels of actin contractile fibers are 
sufficient to maintain correct SMC tone. 
In summary, the results from the present study indicate that Rho-kinase regulates 
mDia2 activity by phosphorylating the DAD at conserved residues near the basic region. 
This phosphorylation weakens the intramolecular DID-DAD interaction and facilitates the 
activation of mDia2 by RhoA resulting in increased actin polymerization and SRF-dependent 
transcription. Given the importance of mDia2 in the regulation of a number of cellular 
processes (especially in SMC) and the fact that this mechanism may link two important 
RhoA effectors, it will be critical to further characterize this signaling mechanism and its 
physiologic consequences.  
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ABSTRACT 
RhoA-mediated changes in the actin cytoskeleton can stimulate transcription of 
smooth muscle (SM)-specific genes by regulating the subcellular localization of the 
myocardin-related transcription factors (MRTFs) A and B.  Herein, we show that silencing 
of the RhoA effectors mDia2 and mDia1, either in isolation or concurrently, significantly 
reduces expression of SM marker genes in primary mouse aortic smooth muscle cells 
(SMCs) and in multi-potential 10T1/2 cells treated with sphingosine-1-phosphate (S1P).  
While we originally attributed these results to an increase in cytoplasmic globular actin (G-
actin), recent evidence linking nuclear G-actin to MRTF nuclear export led us to investigate 
a possible role for the diaphanous-related formins (DRF) in the nucleus. We found that 
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mDia2, but not mDia1 or FHOD1, accumulated in the nucleus following treatment with 
leptomycin, an inhibitor of Crm-1 dependent nuclear export. Deletion mapping and mutation 
analyses identified a nuclear localization sequence (NLS) in the core formin homology 2 
(FH2) domain, and nuclear accumulation mediated by this NLS is likely inhibited by the 
autoinhibitory state of mDia2.  Furthermore, an additional NLS and a leucine-rich nuclear 
export sequence (NES) were identified in the extreme N- and C-termini of mDia2, 
respectively.  In comparison to wild-type mDia2, mutants of mDia2 excluded from the 
nucleus were significantly impaired in their ability to stimulate MRTF-B nuclear 
accumulation and SMC-specific gene transcription. Taken together, these data imply a novel 
role for nuclear mDia2 in the functional regulation and subcellular localization of the 
MRTFs.  
 
INTRODUCTION 
Serum response factor (SRF) regulates the expression of a number of muscle-
specific, cytoskeletal, and early response growth genes by binding to conserved CArG 
(CC(A/T)6GG) cis elements found within their promoters (see [170] for review). SRF's cell 
type- and gene-specific effects are mediated by direct interactions with additional cofactors, 
and extensive evidence indicates that the myocardin factors (myocardin and the Myocardin-
Related Transcription Factors, MRTF-A/MKL-1 and MRTF-B/MKL-2) regulate SMC-
specific transcription [72, 81, 182]. Indeed, genetic deletion of myocardin or MRTF-B in the 
mouse resulted in embryonic lethality due to defects in SMC differentiation in the dorsal 
aorta and brachial arches, respectively. Moreover, mice lacking MRTF-A fail to up-regulate 
SMC differentiation marker gene expression in myoepithelial cells during lactation [89, 90]. 
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The precise contributions of each myocardin factor to SMC differentiation is certainly 
complicated by the high functional homology and overlapping expression patterns of the 
myocardin factors, the well-known plasticity of SMC, and the existence of multiple SMC 
lineages. However, it is clear that the identification of the molecular mechanisms that 
regulate the myocardin factors will be critical for our understanding of the control of SMC 
phenotype. 
The Treisman lab was the first to demonstrate that MRTF-A activity was regulated 
by the small GTPase, RhoA. This group demonstrated that MRTF-A nuclear localization was 
inhibited by G-actin binding to the RPEL domains within the MRTF-A N-terminus and that 
this inhibitory mechanism was relieved by a RhoA-induced reduction in G-actin pools. 
Recent observations suggest that this mechanism is slightly more complicated.  For example, 
a mutant G-actin has been described that can stimulate MRTF-A nuclear translocation 
independent of its effects on actin treadmilling, indicating that G-actin may be more directly 
involved in MRTF-A transport [147].  In addition, Vartiainen et al. recently demonstrated 
that the major factor regulating MRTF-A nuclear accumulation was Crm-1-dependent 
nuclear export and that binding of MRTF-A to G-actin present in the nucleus somehow 
facilitated this export mechanism. Furthermore, the association between MRTF-A and G-
actin in the nucleus inhibited MRTF-A transcriptional activity without preventing its 
association with SRF-target genes.  Taken together, these data suggest that nuclear G-actin is 
a critical determinant of MRTF-A nuclear accumulation and activity. Although actin's 
presence within the nucleus is now well-accepted, almost nothing is known about the 
regulation of nuclear actin levels or polymerization within this compartment. 
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We have previously shown that the RhoA effectors, mDia1 and mDia2, are highly 
expressed in SMCs and strongly activate SMC marker gene expression by promoting nuclear 
localization of the MRTFs [172]. mDia1 and mDia2 (along with mDia3 and FHOD1)  
belong to the subfamily of diaphanous-related formins (DRFs) that act as potent actin 
polymerizing factors (see [176] and [123] for reviews).  The DRFs are identified by two 
highly conserved formin homology (FH) domains, a GTPase binding domain (GBD) that 
interacts with Rho family GTPases, and a Diaphanous Auto-regulatory Domain (DAD). The 
dimerization domain (DD) and coiled-coil region mediate N-terminal dimerization of the 
DRFs, although the physiological importance of this dimerization is still unclear.  The 
molecular mechanisms that control DRF/mDia activity have been fairly well described.  In 
their inactive state, the DRFs are inhibited by an intramolecular interaction between the C-
terminal DAD and the N-terminal Diaphanous Inhibitory Domain (DID) [124, 125]. High 
affinity binding of activated RhoA to the GBD disrupts the DAD-DID interaction, thus 
exposing the catalytically active FH1FH2 region and stimulating actin polymerization 
In the present study we demonstrate that mDia2 shuttles between the cytoplasm and 
nucleus by a CRM-1-dependent mechanism. We identify several mDia2 sequences that 
regulate its nuclear import and export and use mDia2 variants to show that the presence of 
mDia2 in the nucleus is important for its effects on MRTF activity and SMC-specific gene 
expression. 
 
MATERIALS AND METHODS 
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Cell Culture -- SMCs were isolated from thoracic aortas of 8-week FAKflox/flox mice by 
enzymatic digestion as described previously [183].  10T1/2 cells (ATCC) or low passage 
SMCs were maintained in normal Dulbecco’s modified Eagle’s medium or F12 plus 10% 
fetal bovine serum and 0.5% penicillin-streptomycin. 
Plasmids – mDia2 constructs were generated by standard procedures and expressed in either 
N-terminal flag-tagged pcDNA3.1 or pEGFP (Clontech).  The mDia2 K35A/R36A and 
L1064A/L1065A variants were generated using the Quikchange Site-Directed Mutagenesis 
Kit (Stratagene).  MRTF-A/B were obtained and cloned as described previously [184]. Flag-
RhoA (L63) was received from Gary Owens (University of Virginia). GFP-FHOD1 and 
GFP-mDia1 were generous gifts from Michael Mendelsohn (Tufts University School of 
Medicine) and Shuh Narumiya (Kyoto University, Japan), respectively.  
siRNA Knockdown  - The following short interfering (si)RNAs were obtained from 
Invitrogen; control (GFP) 5'-GGUGCGCUCCUGGACGUAGCC-3' , mDia2 5'-
GCAUGACAAGUUUGUGAUATT-3' and mDia1 5’-GGACCUCUAUUGCCCUCAATT-
3’.10T1/2 or SMCs were harvested 48 or 96 h after siRNA transfection (Dharmafect; 
Dharmacon) for protein expression analysis. For S1P treatment, 10T1/2 were serum starved 
in 0.5% FBS for 12 h and then treated with S1P (10 µm) (Mateya) for 24 h.  For luciferase-
reporter assays, promoters were transfected 24 h prior to siRNA treatment and harvested 48 h 
thereafter.      
Immunofluorescence – 10T1/2 cells were plated in 8- or  4-well chamber slides, maintained 
in 10% serum for 48 hours, fixed in 3.7% paraformaldehyde and permeabilized in 0.5% 
Triton X-100.  Slides were incubated for 2-3 hours in M2 anti-flag antibody (1:500; Sigma) 
or anti-mDia2 (1:500; kind gift of Henry Higgs, Dartmouth).  Texas Red- or FITC-
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conjugated anti-mouse IgG (1:1000; Jackson ImmunoResearch) and DAPI (90 nM) were 
added for 1 h.  Leptomycin B treatments (5 ng/mL; Sigma) were administered for 3 h.   
Cell Fractionation – Cell fractionation was conducted as previously described [185].  In 
short, 10T1/2 cells were gently scraped into cytoplasmic lysis buffer, lysed on ice for 15 
minutes and nuclei pelleted by centrifugation.  Supernatant was saved as the cytoplasmic 
fraction. The nuclear pellet was washed three times and resuspended in cytoplasmic lysis 
buffer containing 0.5 M NaCl. 5% of the nuclear fraction volume and 2.5% of the 
cytoplasmic fraction volume were analyzed by SDS-PAGE.  Antibodies to mDia1, mDia2 
and FHOD1 were generous gifts of Henry Higgs (Dartmouth) and Michael Mendelsohn 
(Tufts University School of Medicine). 
Transient Transfections and Reporter Gene Assays – 10T1/2 cells were seeded on 48-well 
plates and transfected with expression vectors at 70-80% confluency using TransIT-LT1 
(Mirus), according to the manufacturer’s protocol.  Luciferase assays were conducted 24 
hours after transfection using the Steady-Glo system (Promega). The SM22, SM α-actin, c-
fos and TK promoters have been described elsewhere [33].  
GST Fusion Pull-downs / Western Blots - GST pull-down assays were performed as 
previously described [186] . Cos7 or 10T1/2 cells expressing flag-tagged mDia2 variants 
were scraped in RIPA containing protease inhibitors. GST-fusion proteins (15 µg) were 
incubated with Cos7 lysates (500 µg total protein) for 3 hrs and interacting complexes were 
pelleted by centrifugation. Western blots were probed using anti-flag M2 antibody (1:1000; 
Sigma), Histone H3 (1:1000; Abcam), Vinculin (1:2000; Sigma) or Tubulin (1:5000; Sigma). 
 
RESULTS 
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Knockdown of mDia1 and mDia2 inhibits SMC differentiation marker gene expression 
We have previously implicated mDia-signaling in the regulation of SMC 
differentiation by overexpression of constitutively active or dominant variants of mDia1 and 
mDia2 [184].  To confirm and extend these studies, we examined the individual and 
combinatorial roles of mDia1 and mDia2 in regulating SMC differentiation marker gene 
expression in mouse aortic smooth muscle cells using siRNA. We consistently observed a 
60% knock-down of mDia1 protein levels and even this relatively modest reduction inhibited 
SM22 and SM a-actin expression (figure 4.1a). The knockdown of mDia2 had less of an 
effect, but a compensatory function of mDia1 in mDia2 knockdown cells may have blunted 
this response. In support of this idea, the combinatorial knockdown of mDia1 and mDia2 
inhibited SMC marker gene expression to a much greater extent, suggesting some 
redundancy in this pathway. We also demonstrated that the double knockdown strongly 
inhibited the SM22 and SM α-actin promoters but had little effect on the CArG-dependent c-
fos promoter or a CArG-independent minimal thymidine kinase promoter (figure 4.1b).  
We also tested whether mDia signaling was required for activation of SMC 
differentiation marker gene expression in multi-potential 10T1/2 cells treated with the RhoA-
dependent agonist, sphingosine-1-phosphate (S1P).  As shown in figure 4.1c, S1P strongly 
enhanced expression of SM α-actin, but knockdown of mDia1 and mDia2 significantly 
attenuated this response. Interestingly, we found that mDia1 and mDia2 protein levels were 
strongly increased following S1P treatment in this model, suggesting that both expression 
levels and activation state of mDia may be relevant to the regulation of SMC phenotype.  
The S1P-induced activation of SM22-luciferase reporter in 10T1/2 cells was significantly 
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Figure 4.1.  Knockdown of mDia1 and mDia2 inhibits SM marker gene expression. A) Primary 
mouse aortic SMCs were transfected with GFP, mDia1 and (Dbl) /or mDia2 siRNA and allowed to 
grow in serum containing 10% FBS for 96 h. Equal amounts of protein were separated by SDS-PAGE 
and probed with antibodies as indicated. GAPDH was used as loading control. B)  SMCs were 
transfected with siRNA (as indicated) 24 h post transfection with 500ng of PGL3-SM22, SM α-actin, 
c-fos or TK. Luciferase activity measured 48 h later. C) 10T1/2 cells were transfected with the 
indicated siRNA.  24 h post transfection the cells were serum starved in 0.5% FBS for 18 h and 
stimulated with 10 µM S1P for 24 h. Protein expression determined as described in A.  D) 10T1/2 
cells were transfected with 500 ng of the PGL3-SM22 luciferase reporter and manipulated as 
discussed in C. Duration of S1P treatment was decreased to 8 h and the cells were subsequently 
measured for luciferase activity. (*P 0.05).   
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 attenuated by mDia1 knockdown, and as observed in SMC, this effect was enhanced by the 
combinatorial knockdown of mDia2 (figure 4.1d).    Taken together, these data indicate that 
both mDia1 and mDia2 are critical for maintaining the differentiated SMC phenotype and for 
the differentiation of multi-potential 10T1/2 cells into SM (or SM-like) cells.    
 
mDia2 shuttles through the nucleus 
The effects of mDia1 and mDia2 on MRTF-dependent gene expression were 
originally attributed to a decrease in cytoplasmic G-actin levels that promoted MRTF-A 
nuclear translocation. It is clear that mDia1 and mDia2 can regulate actin polymerization in 
this compartment as well as at a variety of specific cytoplasmic structures (i.e. the leading 
edge, filopodia, and endosomes, etc). However, a recent report indicates that the rate limiting 
step in MRTF-A nuclear accumulation is nuclear export, and that the binding of MRTF-A to 
nuclear G-actin facilitates this process [148]. Based upon this important finding and several 
studies demonstrating that ROCK, profilin, and VASP can localize to the nucleus, we 
hypothesized that the regulation of nuclear actin dynamics could govern MRTF localization. 
Given the vital role of mDia signaling in this process, we further hypothesized that nuclear 
localization of one or more of these proteins was involved in this mechanism.  
To begin to address the role of mDia1 and mDia2 in the nucleus, we visualized GFP-tagged 
fusions of mDia1, mDia2, and FHOD1 in multi-potential 10T1/2 cells.  As shown in figure 
4.2a, all three full-length DRFs were predominantly cytoplasmic, although a small amount of 
nuclear mDia2 was detected in some cells. Surprisingly, inhibition of Crm-1-dependent 
nuclear export with leptomycin B (LMB) induced nuclear accumulation of mDia2, but not 
mDia1 or FHOD1. These data indicate that mDia2 shuttles through the nucleus and that its 
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Figure 4.2: mDia2 shuttles between the nucleus and cytoplasm.  A) 10T1/2 cells were transfected 
with GFP or GFP-tagged FHOD1, mDia1, or mDia2. After 48h in 10% serum, cells were treated with 
leptomycin B for 3 hours, fixed, and visualized.  B) Leptomycin B (LMB)-treated 10T1/2 cells were 
fixed and stained with anti-mDia2. C) Nuclear and cytoplasmic fractions were prepared from 10T1/2 
cells grown in 10%serum and probed with antibodies specific for mDia1, mDia2 and FHOD1.  Anti-
vinculin and anti-histone 3 were used as controls for cross contamination of the cytoplasmic and 
nuclear fractions, respectively 
 79
 cytoplasmic localization is maintained, at least in part, by Crm-1-dependent nuclear export. 
It is important to note that we observed very little difference between Flag- and GFP-tagged 
proteins, suggesting that the presence of the GFP moiety had little effect on DRF 
localization.  To examine localization of the endogenous proteins, we performed cell 
fractionation experiments and probed cytoplasmic and nuclear fractions with antibodies 
specific to mDia1, mDia2, and FHOD1. Even in the absence of leptomycin, a considerable 
amount of mDia2, but not mDia1 or FHOD1, was detected in the nuclear fraction (figure 
4.2c). Further immunoflourescence analysis revealed that endogenous mDia2 localized 
almost exclusively to the nucleus in the presence of leptomycin (figure 4.2b). Although we 
did not detect mDia1 or FHOD1 in the nucleus following leptomycin treatment, it remains 
possible that cytoplasmic localization of these DRFs is maintained by a CRM-1-independent 
nuclear export mechanism. In fact, an mDia1 N-terminal deletion mutant was recently shown 
to be predominantly nuclear in NIH 3T3 cells [181], as was a similar caspase-3 cleavage 
fragment of FHOD1 in HeLa cells [187]. Thus, there is some evidence to suggest that these 
DRFs may enter the nucleus under some conditions. In addition, mDia1 has been shown to 
associate in a complex with exportin6, a recently identified nuclear envelope protein not 
inhibited by leptomycin that exports G-actin from the nucleus [188].  
 
Identification of nuclear import and export sequences of mDia2  
In order to test whether nuclear mDia2 played an important role in regulating MRTF activity, 
we needed to identify the import and export signals that regulate its localization. We first 
generated a series of GFP-mDia2 deletion constructs (see figure 4.3a) and expressed them in 
10T1/2 cells.  The FH2 domain of mDia2 localized predominantly to the nucleus, and 
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Figure 4.3: mDia2 contains two nuclear import signals.  A) Schematic of mDia2 truncations used 
to identify nuclear import signals. B-D) 10T1/2 cells were transfected with GFP-tagged mDia2 
variants (as indicated), maintained in 10% FBS for 48 hours, fixed and visualized.  LMB (5ng/mL) 
treatments lasted 3 h.   Note conservation of FH2 (B) and N-terminal (D) NLS sequences. 
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from residues 673-692 (figure 4.3b).  Deletion of these amino acids (FH2∆NLS) completely 
inhibited nuclear localization of the FH2.  Furthermore, this putative NLS enhanced nuclear 
accumulation of GFP (figure 4.3c, upper panels), providing evidence that this region is 
sufficient to drive nuclear localization. Interestingly, deletion of this NLS from the full-
length mDia2 molecule (∆NLS) did not block nuclear accumulation in the presence of LMB 
(figure 4.3c), suggesting the presence of additional sequences outside the FH2 domain 
capable of stimulating nuclear import.     
Additional mapping studies revealed that an N-terminal 256 amino acids of mDia2 
containing the GBD (GFP-GBD) localized to the nucleus (figure 4.3d). Further deletion 
analysis identified the presence of a NLS within the first 58 AA (GBD∆58) and deletion of 
this region from full length mDia2 (∆58) completely blocked nuclear accumulation in the 
presence of leptomycin (figure 4.3d, bottom left panel). To further define this N-terminal 
NLS, we made double alanine mutations to two conserved basic regions within this region in 
the context of full length mDia2. While a R18A/R19A mutation had no effect on mDia2 
localization (data not shown), a K35A/R36A mutation completely blocked nuclear 
accumulation in the presence of leptomycin, clearly indicating that the nuclear import of full-
length mDia2 is primarily controlled by this sequence. The contribution of the FH2 NLS to 
mDia2 localization will require further investigation, and at present, we cannot completely 
rule out a potential role for this sequence under other different circumstances.  
The accumulation of mDia2 in the nucleus in the presence of leptomycin B strongly 
suggests that mDia2 contains a leucine-rich Crm-1-dependent nuclear export sequence 
(NES). To identify this sequence we analyzed the localization of another series of GFP-
mDia2 deletions (figure 4.4a). Fusion of the DAD to either GFP alone (fig 4.4b) or GFP- 
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Figure 4.4: Identification of mDia2 nuclear export sequences.  A)   Schematic depicting the mDia2 
deletions and mutations localized in these studies. B-D) GFP-tagged mDia2 variants (as indicated) 
were transfected into 10T1/2 cells and maintained in 10% FBS for 48 h. Cells were either treated with 
LMB for 3 hours or left untreated, fixed and then visualized.  Note conservation of C-terminal NES 
(D). * denotes specific amino acids that were mutated.  
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FH1FH2 (fig 4.4c) blocked nuclear localization of these constructs, and this effect  was 
rescued by leptomycin B treatment, strongly suggesting that this region functions as a NES.  
We identified a leucine-rich region at the extreme C-terminus (AA 1064 to 1071), and 
deletion of this region (∆NES) in the context of GFP-DAD or GFP-FH1FH2 resulted in 
nuclear localization in the absence of leptomycin B (Fig 4.4b and c, far right panels). 
Furthermore, both the ∆NES deletion and a double alanine mutation (L1044A/L1045A) 
promoted significant nuclear accumulation of full-length mDia2 (figure 4.4d). Taken 
together, these data suggest that mDia2 nuclear export is regulated, at least in part, by a Crm-
1 dependent NES located within the extreme C-terminus.   
 
Determining the molecular mechanisms that govern mDia2 nuclear shuttling 
The identification of multiple NLS’s in mDia2 suggests that its nuclear import may 
be more complex than originally thought.  We and others have shown that the intramolecular 
interaction between the DAD and DID prevents actin polymerization by sterically inhibiting 
the FH2 domain.  Since the FH2 NLS cannot drive full-length mDia2 nuclear accumulation 
following LMB treatment, perhaps the mDia2 auto-inhibited state blocks the function or 
availability of this NLS.  To further test this possibility, we monitored flag-FH1FH2-DAD 
localization in 10T1/2 cells after LMB treatment in the presence of mDia2 N-terminal 
variants fused to GFP (see figure 4.5b for domain schematic).  We found that FH1FH2-DAD 
nuclear accumulation following LMB treatment was inhibited in the presence of GFP-
NTer∆58, but not wild type NTer (figure 4.5a). This indicates that when bound to the N-
terminus, FH1FH2-DAD nuclear import is mediated through the N-terminal NLS rather than 
the FH2 NLS.  We also found that an A272D mutation to NTer∆58 reversed its inhibitory 
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Figure 4.5: Autoinhibited state of mDia2 inhibits function of the FH2 NLS: A) 10T1/2 cells were 
co-transfected with flag-mDia2 FH1FH2-DAD and GFP-mDia2 NTer variants.  All cells were treated 
with LMB for 3 h and nuclei were stained using DAPI (90 µM).  B) Summary schematic of mDia2 
truncations. C) Amino acids 256-533 were fused to GFP-mDia2 FH1FH2 (256-1030) and localization 
monitored before and after LMB treatment (3 h).  
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effect on FH1FH2-DAD nuclear localization. The A272D mutation, modeled after a similar 
mutation described in mDia1 [189], inhibits the DID-DAD interaction without affecting 
RhoA binding in mDia2 (data not shown). These data suggest that inhibition of FH1FH2-
DAD nuclear accumulation by NTer∆58 is dependent on the DID-DAD interaction. Taken 
together, these findings extend our data implicating a role for mDia2 autoinhibition in the 
regulation of the FH2 NLS.  We also found that nuclear accumulation of FH1FH2 was 
completely abolished when directly fused to the FH3/DID domains (amino acids 256-533) 
and that this change in localization was not sensitive to LMB treatment (figure 4.5c).  It is 
likely that this region inhibits FH1FH2 nuclear accumulation by regulating the function of 
the FH2 NLS and/or promoting cytoplasmic sequestration.  However, it is also possible that 
this region may enhance nuclear export via a Crm-1 independent mechanism (see 
discussion).  Additional studies are required to test these hypotheses. 
 
Regulation of SMC-specific transcription by mDia2 nuclear localization  
 Our data so far indicates that mDia2 shuttles through the nucleus and is an important 
regulator of SMC phenotype. To determine if activation of SMC-specific gene transcription 
by mDia2 requires its nuclear localization, we compared the ability of wild type, ∆58 and 
K35A/R36A mDia2 to stimulate activity of the SM22 promoter in 10T1/2 cells.  In the 
absence (figure 4.6a) or presence of constitutively active RhoA (figure 4.6b), the ∆58 and 
K35A/R36A mutants of mDia2 activated the SM22 promoter only half as robustly as wild 
type mDia2.  Notably, these mutants were unimpaired in their ability to bind active RhoA, as 
shown by GST pull-down assays (figure 4.6c).  These data support previous reports that the 
first 75 amino acids of mDia1 are dispensable for high affinity RhoA binding [163, 175] .  
 86
  
 
Figure 4.6: Deletion or mutation of N-terminal NLS inhibits mDia2-mediated regulation of 
SMC-specific gene transcription.  10T1/2 cells were transfected with 125 ng of individual flag-
mDia2 variants and PGL3-SM22 in the absence (A) or presence (B) of flag-L63 RhoA (12.5ng) and 
luciferase activity measured 24 h later. C) GST-L63 RhoA pull-downs of flag-mDia2 variants 
expressed in Cos7 cells. D) 10T1/2 cells were transfected with equal amounts of GFP-MRTF-B and 
either Wt or ∆58 flag-mDia2. Cells were maintained in 10% FBS for 36 h, placed in 0.5% FBS for 18 
h, and then fixed and visualized. E) Quantification of GFP-MRTF-B localization from at least 100 
cells from three independent experiments. Nuc: Nucleus.  Cyto: Cytoplasm F) 10T1/2 cells were 
transfected with PGL3-SM22 (125ng), flag-mDia2 variant (125ng) and flag-MRTFB (12.5ng) and 
luciferase activity recorded 24 h post-transfection (*P 0.05).    
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 Given recent evidence that nuclear export of the MRTFs is regulated by nuclear actin 
dynamics, we investigated whether inhibition of mDia2 nuclear import would affect 
localization or activity of MRTF-B.  Indeed, mDia2 ∆58 was significantly less capable of 
stimulating nuclear accumulation of MRTF-B in comparison to wild type mDia2 (figure 
4.6d-e).  This variant and the K35A/R36A mutant were similarly deficient in stimulating 
transactivation of the SM22 promoter by MRTF-B (figure 4.6f). These findings suggest that 
mDia2 function in the nucleus is important in regulating SMC-specific gene transcription 
and subcellular localization of MRTF-B.    
We also found that mDia2 FH1FH2 was predominantly nuclear and potently 
enhanced SM22 promoter activity and nuclear accumulation of MRTF-B (figure 4.7a, b), 
further supporting a nuclear role for mDia2.  We were unable to measure the effects of 
FH1FH2∆NLS on SM22 promoter activity and MRTF subcellular localization since 
mutation of the FH2 NLS had deleterious effects on the ability of FH1FH2 to stimulate actin 
polymerization (figure 4.7c).  Therefore, we targeted the dominant negative mDia variant 
F1F2∆1 to the nucleus (Nuc-F1F2∆1) to determine the contribution of nuclear FH1FH2 
signaling to SM marker gene transcription. For a description of how these dominant negative 
variants may function please see Chapter 2.  We found that Nuc-F1F2∆1 dose dependently 
inhibited FH1FH2-mediated stimulation of SM22 promoter activity to a comparable level to 
Wt F1F2∆1 (figure 4.7d).  Importantly, this inhibitory effect seems to be specific to the 
nucleus since we did not observe decreases in cytoplasmic actin polymerization from cell 
expressing Nuc-F1F2∆1 (figure 4.7e).   Taken together, these findings indicate that 
inhibiting the nuclear function of mDia2 attenuates MRTF-B nuclear accumulation and SM 
marker gene transcription. 
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Figure 4.7: A nuclear targeted mDia dominant negative inhibited activation of the SM22 
promoter by FH1FH2. A) 10T1/2 cells were transfected with PGL3-SM22 (125 ng) and FH1FH2 
(112.5 ng) in the presence or absence of flag-MRTFB (12.5ng).  Luciferase activity measured 24 h 
post transfection. B) GFP-MRTFB and flag-mDia2 FH1FH2 were transfected into 10T1/2 cells, 
maintained in 10% FBS for 36 h, serum starved in 0.5% FBS for 18 h, fixed, and visualized by 
fluorescence microscopy. C) GFP-mDia2 FH1FH2 Wt or ∆NLS were transfected into HeLa cells 
(chosen for their low basal levels of stress fibers), starved in 0.5% FBS for 12 h, fixed, and actin 
polymerization visualized with phalloidin (1:100).  D) 10T1/2 cells were transfected with flag-mDia2 
FH1FH2 (30 ng), PGL3-SM22 (125 ng) and increasing amounts of flag-mDia1 F1F2∆1 or pCMV-
Myc-Nuc-F1F2∆1 (100-500ng).  Luciferase measured 24 h later (*P 0.05) E) HeLa cells were 
transfected with flag-F1F2∆1 or Nuc-F1F2∆1 and stained with flag or myc antibodies 48 h later, 
respectively.  Changes in actin polymerization determined via phalloidin staining.  
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DISCUSSION 
 Herein we extend our previous studies implicating the DRFs in regulating SMC-
specific gene transcription and MRTF subcellular localization.  Double knockdown of 
mDia1 and mDia2 significantly inhibited expression of the SM marker genes SM22 and SM 
α-actin but had negligible effects on transcription of the c-fos and TK genes.  mDia2, but not 
mDia1 or FHOD1, accumulated in the nucleus following LMB treatment and this nuclear 
shuttling is facilitated by an NLS and NES found in the distal N- and C-termini of mDia2, 
respectively. An additional NLS was found in the FH2 domain, but its function is likely 
blocked by the autoinhibitory state of mDia2.  mDia2 variants that could not localize to the 
nucleus were significantly impaired in their ability to stimulate SM22 promoter activity and 
MRTF-B nuclear accumulation.  Finally, activation of SM22 promoter activity by the 
FH1FH2 domain, which is predominantly nuclear, was dose dependently inhibited by a 
nuclear targeted mDia dominant negative. These data support a model in which mDia2-
signaling in the nucleus reduces nuclear G-actin levels, prevents MRTF nuclear export, and 
subsequently stimulates SMC-specific gene transcription.     
 
The DRFs mDia1 and mDia2 are important determinants of SMC phenotype 
 The diaphanous-related formins have been shown to regulate a diverse set of actin-
dependent cellular events, including membrane ruffling, cell migration, cytokinesis, cell 
polarity, stress fiber formation, and cell adhesion (see [123] for review).  Here we expand the 
role for DRFs to include regulation of SMC-specific gene transcription.  Knockdown of 
mDia1 and mDia2 inhibited the expression of multiple SM marker genes in primary mouse 
aortic SMCs and 10T1/2 cells after treatment with S1P.  Importantly, neither knockdown 
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impacted the activity of the c-fos or TK promoters, suggesting that mDia1 and mDia2 
specifically regulate SMC gene transcription.  We also found that the protein levels of 
mDia1 and mDia2 were elevated following S1P treatment, suggesting that their expression in 
addition to their activity may be an important determinant of SMC phenotype.  It is 
intriguing to suggest that the expression of mDia1 and mDia2 may be at least in part 
regulated by SRF, but we cannot rule out changes in protein stability and additional studies 
will be need to decipher between these possibilities.   
Germline deletion of mDia1in mice induced myeloproliferative defects and 
lymphopenia due to defective lymphocyte migration, but no gross vascular abnormalities 
were reported [190, 191]. A lack of a vascular phenotype may be attributed to a 
compensatory function of mDia2 in mDia1 knockout mice.  In support of this, we find that 
knockdown of mDia1 enhances expression of endogenous mDia2 in both SMCs (figure 4.1a) 
and 10T1/2 cells (data not shown), which is in good agreement with other studies [127].  
Closer examination of mDia1 knockout mice for defects in SMC phenotype, as well as 
generation of mDia2 and mDia1/2 knockout mice, may further elucidate our understating of 
formin function in SMC differentiation.   
The human homologs of mDia1 and mDia2 are associated with the development of 
two different rare forms of non-syndromic genetic deafness, DFNA1 and DFN2, respectively 
[192, 193].  Genetic mapping and sequence analysis discovered that DFNAI patients contain 
a single nucleotide substitution in a splice donor of Dia1, which induces a frameshift 
mutation and C-terminal truncation [193].  The functional consequence of this mutation on 
Dia1 activity is still unclear, but similar truncations induced aberrant actin polymerization in 
Cos7 cells [162].  Electrophysiological data suggest deafness in DFNA1 patients may be due 
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in part to dysfunctional control of inner ear fluid homeostasis.  These defects are commonly 
associated with functional abnormalities in the stria vascularis, which contains the majority 
of vasculature of the inner ear.  Indeed, mice null for the S1P2 receptor are deaf by one 
month of age due to altered homeostasis of the inner ear fluids, which is the result of defects 
in the vascular bed of the stria vascularis [194, 195].  Taken together, these findings suggest 
that vascular defects stemming from dysfunctional Dia signaling could contribute to deafness 
observed in DFNA1 and DFN2 patients.   
 
Molecular mechanisms governing mDia2 Nuclear shuttling 
 The nucleoplasmic shuttling of macromolecules proceeds through nuclear pore 
complexes by either passive diffusion or facilitated transport.  Passive diffusion is restricted 
to molecules smaller than 40 kDa; thus, nuclear transport of large proteins such as the DRFs 
are typically controlled by nuclear transport receptors of the importin β-superfamily.  We 
demonstrated that shuttling of full-length mDia2 requires an N-terminal basic NLS and a C-
terminal leucine-rich Crm-1 dependent NES.  Indeed, during the final preparation of this 
manuscript, Miki et al. [196] also identified these regions as major regulatory elements of 
mDia2 nuclear localization in HeLa cells.    
We identified an additional NLS within the FH2 domain but its role in regulating 
mDia2 nuclear import is still unclear.  Given that the autoinhibited state of mDia2 can block 
FH2-mediated actin assembly, we hypothesized that this conformation may also mask the 
function of the FH2 NLS.  Indeed, full-length constructs containing only this NLS failed to 
accumulate in the nucleus after LMB treatment.  We found that although nuclear import of 
FH1FH2-DAD following LMB treatment was facilitated by the FH2 NLS, this localization 
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was completely inhibited by co-expression of N-terminal mDia2 fragments.  Since these 
inhibitory effects required the DID-DAD interaction, these findings further support a role of 
mDia2 autoinhibition in regulating the FH2 NLS function.   A cryptic NLS in the FH2 
domain suggests that the activation state of mDia2 may differentially regulate its subcellular 
localization and may be a novel mechanism by which active mDia2 is imported into the 
nucleus.  Additionally, since splice variants and cleavage products have recently been 
identified in other diaphanous family members, it is intriguing to consider that the FH2 NLS 
may be important in analogous variants of mDia2 [187, 197]. 
Nuclear accumulation of FH1FH2 was also completely blocked when fused to the N-
terminal amino acids 256-533, but the mechanism underlying this inhibition is currently 
being investigated.  We predict three possible mechanisms that could explain this inhibitory 
effect.  (1) Residues 256-533 could inhibit nuclear import by directly binding and masking 
the region containing the FH2 NLS.  Indeed, structure-function studies have proposed an 
interaction between the N-terminus and FH2 domain that is independent of the DID-DAD 
interaction [163]. (2) The N-terminal region could also alter FH1FH2 nuclear import by 
facilitating dimerization.   Several conserved coiled-coil regions have been predicted in this 
region and similar residues in mDia1 was shown to be dimeric through the use of gel 
filtration chromatography [163].  Inhibition of nuclear import by dimerization has been 
reported for several other factors [198, 199]. (3)  It is also possible that amino acids 256-533 
inhibit nuclear accumulation of FH1FH2 through a Crm-1 independent export mechanism.  
Interestingly, mDia1 was identified as a substrate for exportin6 [188] and a variant of mDia1 
consisting of the FH1,FH2 and DAD domains is predominantly nuclear [160], but we found 
that addition of the N-terminal 257-567 amino acids inhibited this localization (data not 
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shown).  Since fusion of amino acids 256-533 to GFP or mDia2 GBD did not induce 
cytoplasmic localization (unpublished observation), nuclear export may require sequences 
within the FH1FH2 domain.  Recent studies found that actin is required for nuclear export of 
MRTF [148]. Similarly, perhaps binding of nuclear actin to the FH2 is required for residues 
256-533 to facilitate nuclear export of mDia2. 
We have also identified a leucine-rich Crm-1 dependent export sequence within the 
C-terminus of mDia2. However, mutation or deletion of this NES induced nuclear 
accumulation to a lesser degree than LMB treatment, suggesting the presence of an 
additional NES. We and others have found LMB treatment induces nuclear accumulation of 
N-terminal fragments of mDia2, but no functional Crm-1 dependent export sequence has yet 
to be identified within this region [196].  It is possible that the DID within these N-terminal 
fragments binds to endogenous mDia2 and is subsequently carried to the nucleus upon 
inhibition of Crm-1. Recently, Alberts demonstrated that a DAD peptide containing just the 
core region, which contains several conserved leucines but lacks the NES discussed above, 
may also regulate mDia2 nuclear export [200]. These experiments showed that nuclear 
accumulation of GFP was blocked when fused to the DAD core, and that an L1044A 
mutation to the DAD restored nuclear localization. Since our NES mutations only partially 
inhibited nuclear export of mDia2, it is possible that an additional NES within the DAD core 
is sufficient to affect some nuclear export.  Given that the DAD regulates both activation and 
nuclear export of mDia2, further studies will need to clarify if nuclear shuttling of mDia2 is 
influenced by its activation state.  
 
Regulation of SMC-specific gene transcription by nuclear mDia2 
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 Regulation of gene transcription by nuclear actin was first reported in the 1980s, but 
these studies were largely dismissed on the basis of possible experimental contamination 
from abundant cytoplasmic actin pools.  More than 25 years later, it is well established that 
actin exists in the nucleus and regulates a plethora of nuclear proteins, including chromatin 
remodeling factors, RNP particles and all three RNA polymerases (reviewed in [201]).  
Interestingly, a recent study by Vartiainen et al. has implicated nuclear actin dynamics in the 
control of MRTF-A subcellular localization [148].  These authors demonstrate that nuclear 
G-actin stimulates Crm1-dependent nuclear export of MRTF-A and inhibits SRF-dependent 
gene transcription. Further, MRTF-A bound G-actin in both the cytoplasm and nucleus, but 
this interaction varied dramatically with changes in RhoA-mediated actin treadmilling. 
However, it is currently unknown whether RhoA directly regulates nuclear actin pools or if a 
change in nuclear actin dynamics simply reflects changes in cytoplasmic actin treadmilling.  
Herein, we show that the RhoA effector mDia2 shuttles to the nucleus and that inhibition of 
this localization reduces nuclear accumulation of MRTF-B and transcription of SMC-
specific genes. To our knowledge, this is the first evidence identifying a nuclear role for a 
RhoA effector in the regulation of MRTF localization and SRF-dependent transcription.  
While we attribute these effects to changes in nuclear actin dynamics mediated by mDia2, 
we have been unable to confirm this premise due to the lack of a reliable label for nuclear 
actin.  Only recently was McDonald et al. able to distinguish highly dynamic nuclear actin 
polymers, distinct from cytoplasmic actin filaments, by using fluorescence recovery after 
photobleaching (FRAP) of GFP-β-actin in HeLa cells [146]. These findings are in agreement 
with other immunofluorescence studies describing distinct immunological signatures of 
nuclear actin as detected by monoclonal antibodies [145, 202].  This may indicate that at 
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least a fraction of the nuclear actin pool has a unique conformation whose polymeric state 
may be unrecognizable by conventional actin stains such as phalloidin. Others have shown 
that latrunculin, which sequesters actin monomers, inhibited nuclear processes, such as 
export and transcription, providing functional data to support the presence of polymeric actin 
in the nucleus [146, 203].  Given abundant evidence that MRTF-A is a good sensor of actin 
monomer pools and that DRFs are dynamic regulators of actin polymerization, we highly 
favor a model in which mDia2 activity in the nucleus depletes nuclear G-actin, inhibits 
MRTF nuclear export, and activates SMC-specific gene transcription (figure 4.8).  Based on 
our results, we cannot decipher whether activation of mDia2 by RhoA occurs prior or 
subsequent to nuclear import.  In addition to its small size (~24 kDa), RhoA possesses  a 
conserved canonical NLS in its C-terminus, and might thus utilize facilitated and/or passive 
diffusion to enter the nucleus [204].  The presence of Rho guanine nucleotide exchange 
factors in the nucleus further supports a nuclear function of RhoA-signaling [205-207].  
Previously, interactions between Cdc42, RhoB, and mDia2 have been successfully detected 
using fluorescence resonance energy transfer (FRET) [127, 128]  Similar experiments using 
probes for RhoA and mDia2 will be critical to determine whether these factors interact in the 
nucleus.   
 
Conclusions 
 In this study, our findings suggest that nuclear shuttling of mDia2 plays an important 
role in the regulation of MRTF subcellular localization and SMC-specific gene transcription.  
We did not detect mDia1 or FHOD1 in the nucleus following leptomycin treatment and other 
studies suggest that cytoplasmic localization of these DRFs may be maintained by a CRM-1- 
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Figure 4.8: Current model of SMC differentiation by the DRFs.  In unstimulated cells, a direct 
interaction with G-actin reduces MRTF nuclear accumulation by inhibiting nuclear import while 
simultaneously enhancing nuclear export, subsequently reducing transcription of SMC-specific genes. 
Herein we also demonstrate that although mDia2 is predominantly cytoplasmic, it shuttles from the 
cytoplasm to the nucleus and is exported in a Crm-1 dependent manner.  A similar export mechanism 
has been identified for G-actin and MRTF, although the small size of actin likely allows it to also 
enter the nuclues by passive diffusion.  Additional studies are required to determine if mDia1 and 
RhoA are present in the nucleus and whether they utilize similar or different export mechanisms. 
Following stimulation by a variety of extracellular stimuli, activation of RhoA leads to an increase in 
cytoplasmic actin treadmilling and nuclear import of MRTF, which is at least in part accomplished by 
activation of mDia1 and mDia2.  Similarly, a reduction in nuclear G-actin pools (partially regulated 
by activation of mDia2) inhibits MRTF nuclear export, leading to an increase in MRTF nuclear 
accumulation and SMC marker gene expression.    
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independent nuclear export mechanism.   We suspect that the DRFs at least in part regulate 
SM marker gene expression by regulating nuclear actin dynamics. In support of this, other 
bona fide actin nucleators, such as the Arp2/3 complex, localize to the nucleus and have been 
suggested to regulate nuclear actin polymerization [185, 208].  Since actin associates with 
nuclear lamins and can control the nuclear export of molecules, such as MRTF-A and HIV-1 
mRNA, this suggests the regulation of nuclear actin dynamics by the DRFs (or other 
formins) may also modulate nuclear architecture and trafficking.  With an abundance of new 
evidence implicating actin in a variety of nuclear processes, future studies to identify the 
roles of formins regulating the actin nucleoskeleton will be important 
CONCLUSIONS, PERSPECTIVES, AND FUTURE DIRECTIONS
 
It is clear that the dynamic regulation of SMC phenotype plays an important role in 
vascular development and disease.  A plethora of studies from our laboratory and others have 
made significant progress in identifying the signaling mechanisms that govern SMC-specific 
gene transcription.  Given the inherent complexity of these signaling cascades, it is critical to 
incorporate the findings described within this dissertation into our current understanding of 
SMC differentiation.   
 
Regulation of SMC-specific gene transcription: The role of SRF, MRTF and RhoA   
Nearly all SMC-specific genes contain conserved promoter elements called CArG 
boxes that bind to the transcription factor SRF [46, 52]. Mutagenesis of SMC gene CArG 
elements or germline deletion of SRF in mice significantly inhibits SM marker gene 
expression in vivo, demonstrating the importance of these factors in SMC differentiation [49, 
50, 59, 60]. Since SRF is ubiquitously expressed and controls the transcription of growth 
genes as well as skeletal muscle- and cardiomyocyte-specific genes, it is clear that additional 
factors are required to promote SMC-specific gene transcription [61-64].  Indeed, myocardin 
and the myocardin-related transcription factors (MRTF-A and MRTF–B) were identified as 
SRF cofactors that specifically enhanced transcription of SMC marker genes, and genetic 
disruption of any myocardin family member resulted in abnormal SMC differentiation [74, 
77, 89, 92, 184].    
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The upstream signaling mechanisms that regulate SRF and the myocardin family 
were first elucidated by the Treisman laboratory, which showed that activation of the small 
GTPase RhoA could potently stimulate SRF-dependent transcription [100].  Interestingly, 
these effects were inhibited by latruculin, an actin monomer-sequestering drug, strongly 
implicating actin polymerization in the regulation of SMC-specific gene transcription.  A 
pivotal study by Miralles et al. subsequently showed that subcellular localization of MRTF-
A was similarly regulated by actin dynamics [88].  MRTF-A was predominantly cytoplasmic 
when G-actin levels were elevated by serum starvation, but translocated to the nucleus upon 
stimulation of actin polymerization.  These authors further demonstrated that G-actin directly 
bound the N-terminus of MRTF-A, and that this interaction likely inhibited nuclear import.  
Taken together, these data supported a model in which activation of RhoA promotes actin 
polymerization, resulting in nuclear localization of MRTF-A and transcription of SMC-
specific genes (see figure 1.3).   
 
Adding the DRFs to the puzzle 
Investigation of RhoA effectors that regulate SMC differentiation has mainly focused 
on Rho Kinase (ROCK), since it enhances actin polymerization, stress fiber formation, and 
contractility in SMCs [114, 115].  However, we and others have shown that treatment with 
Y-27632, a potent inhibitor of ROCK, only partially attenuates SMC-specific gene 
transcription [33, 117], suggesting that additional RhoA effectors are involved in this 
process.  Chapter 1 of this dissertation demonstrated that the RhoA effectors mDia1 and 
mDia2 are highly expressed in SMCs, and potently stimulate SMC marker gene expression.  
Neither Diaphanous-Related Formin (DRF) activated transcription of the SRF-dependent 
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growth gene cfos, suggesting the transcriptional effect induced by mDia1/2 is unique to SMC 
genes. Activation of mDia2 was sufficient to induce MRTF-A/B nuclear accumulation, and 
this event was required for mDia2-mediated SMC-specific gene transcription.  Furthermore, 
overexpression of a dominant negative variant that blocks mDia-mediated actin 
polymerization attenuated SM marker gene transcription in a dose-dependent fashion.  These 
results are supported by the experiments described in chapter 3, which showed that silencing 
of mDia1/2 with siRNA significantly inhibits SM marker gene expression in primary aortic 
SMCs. When compiled, these data indicate that activation of mDia1 and mDia2 by RhoA 
can increase transcription of SMC-specific genes by stimulating nuclear accumulation of the 
MRTFs.   
Initial studies, including our own, proposed that MRTF localization was primarily 
regulated via G-actin binding.  According to this model, when the MRTFs were bound to G-
actin, they were sequestered in the cytoplasm; when dissociated from G-actin, they were 
imported to the nucleus.  However, a recent report by Vartiainen et al. argues against this 
paradigm, providing elegant evidence that nuclear export, and not import, is the major 
determinant of MRTF localization.  Interestingly, direct binding of actin to MRTF-A within 
the nucleus stimulated Crm-1-mediated nuclear export of MRTF-A and inhibited SRF-
dependent transcription. Given our evidence that mDia1 and mDia2 potently stimulate 
nuclear accumulation of MRTF-A, we chose to investigate a potential function of these 
DRFs in the nucleus.  We found that mDia2, but not mDia1 or FHOD1, accumulated in the 
nucleus after leptomycin treatment, suggesting that mDia2 shuttles through the nucleus via a 
Crm-1 dependent export mechanism.  Deletion mapping and mutation analysis revealed two 
nuclear localization signals (NLS) within mDia2: one in the FH2 domain, and a second in the 
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distal N-terminus. Furthermore, nuclear export of mDia2 was mediated by a leucine-rich 
region adjacent to the DAD.  In comparison to wild-type mDia2, variants that were excluded 
from the nucleus were weak stimulators of SMC-specific gene transcription and MRTF-B 
nuclear accumulation.  We also found that the nuclear-localized FH1FH2 domain of mDia2 
strongly stimulated SM22 promoter activity, an effect that was dose-dependently inhibited 
by a nuclear-targeted dominant negative of mDia2.  Taken together, these data support a 
model in which mDia2 activity in the nucleus and cytoplasm depletes cellular G-actin pools 
resulting in MRTF nuclear accumulation and activation of SMC-specific gene transcription 
(see figure 4.8 for schematic of current SMC differentiation model).   
 
RhoA signaling in the nucleus 
 Although our data indicate that nuclear localization of mDia2 is important to its role 
in SMC-specific gene transcription, whether mDia2 is activated prior to or following nuclear 
import remains unknown. It is entirely plausible that RhoA could enter the nucleus passively 
or actively, since it possesses not only a low molecular weight (~24kDa), but also a 
canonical C-terminal NLS [204].  While most reports have described RhoA localization as 
predominantly cytoplasmic, cell fractionation studies have in fact identified a small nuclear 
RhoA pool [209].  Additionally, the Rho GEFs ECT2 and NET1 have also been detected in 
the nucleus, further supporting a nuclear function of RhoA [206, 207].  While we have 
focused on the role of RhoA in regulating nuclear mDia2 signaling, it is certainly possible 
that other factors may regulate nuclear mDia2 activity.  RhoB has been reported to bind 
mDia2 [128] and to localize to the nucleus [210, 211], but additional studies are required to 
determine if RhoB (or RhoC) might play a role in mDia2-mediated transcription.  In chapter 
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2, we demonstrate that ROCK activates mDia2 by phosphorylating the DAD.  Given that 
ROCK has also been detected in the nucleus, one might hypothesize that ROCK regulates 
nuclear mDia2 activity [212].  Since it is clear that RhoA can regulate a plethora of cellular 
processes, a closer examination of nuclear RhoA signaling will be critical to better 
understand its myriad functions. 
 
A role for the DRFs in nuclear actin dynamics 
 There is now overwhelming evidence implicating the DRFs in the regulation of actin 
polymerization (see [123] for review).  Since we and others have shown that the DRFs, or 
variants of them, localize to the nucleus, it is intriguing to consider these factors as 
potentially important regulators of nuclear actin dynamics.  In support of this, other bona fide 
actin nucleators, such as the Arp2/3 complex, localize to the nucleus and have been 
suggested to regulate nuclear actin polymerization [185, 208].  Additionally, the actin-
binding protein profilin, which is required for robust DRF-mediated actin polymerization, 
has also been detected in the nucleus [188, 213].   Since traditional actin labeling tools such 
as phalloidin are unable to detect nuclear actin structures, methodological limitations 
currently pose an impediment to the study of nucleoskeletal remodeling.  While non-
physiological approaches (e.g., latrunculin treatments and in vitro polymerization assays) 
have been used with some success, it is clear that the development of new tools to visualize 
and quantitatively measure nuclear actin polymerization in situ will be critical to the 
advancement of this field.  Two groups have recently developed monoclonal antibodies that 
may be specific for nuclear actin [145, 202]. One antibody recognizes actin in its dimeric 
form, while the other binds to its nucleotide-binding cleft.  However, these promising tools 
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are still in their infancy, and have only been tested in a limited number of cell types.  We are 
currently evaluating the ability of these antibodies to recognize nuclear actin structures in 
SMCs and 10T1/2 cells.  
The most convincing evidence of nuclear F-actin comes from a recent study by 
McDonald et al. [146].  By measuring fluorescence recovery after photobleaching (FRAP), 
the authors demonstrated that the recovery rate of GFP-β-actin in the nucleus depends on the 
equilibrium between nuclear G- and F-actin.  Latrunculin B treatment, which inhibits actin 
polymerization, increased the GFP-actin recovery rate, while jasplakinolide, which promotes 
polymerization, decreased the recovery rate.  These data suggest that monomeric actin 
diffuses into the photobleached nucleus at a faster rate than polymeric actin.  Using this 
FRAP-based approach, we hope to directly assess the role of the DRFs in nuclear actin 
dynamics.  Given its nuclear localization, we predict that the catalytically active FH1FH2 
fragment will attenuate GFP-β-actin recovery by enhancing nuclear actin polymerization and 
impeding G-actin diffusion.  Similar experiments will be conducted in cells transfected with 
various DRF-targeted siRNAs.  FRET has also been used to quantitate the equilibrium of F- 
and G-actin in live cells [214].  In brief, when CFP- and YFP-actin are co-expressed in cells, 
polymerization of the labeled monomers facilitates energy transfer between the CFP and 
YFP fluorophors, resulting in a FRET signal.  As yet, this technique has not been used to 
monitor nuclear actin, but could prove a useful tool for spatiotemporal analysis of 
nucleoskeletal remodeling in the context of overexpressed mDia2 variants.    
 
Mechanisms regulating mDia2 autoinhibition 
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Given the important roles of mDia2 in SMC-specific gene transcription, we sought to 
further characterize the molecular mechanisms that govern its activity.  The autohibitory 
state of mDia2 is mainly controlled by the binding of the core DAD motif (MDXLLXL) to 
residues within the DID.  Binding of active RhoA to the GTPase binding domain (GBD) 
results in the dissociation of the DID from the DAD and exposure of the catalytically active 
FH1FH2 domain.  Additional studies identified a basic region adjacent to the DAD core 
motif which is conserved throughout the DRFs, and mutation of these residues partially 
disrupts the DID-DAD interaction [125].  We found that this basic region bound to 
corresponding acidic residues within the DID, and mutation of these acidic residues partially 
activated mDia2 by weakening DID-DAD binding. Indeed, a similar acidic region was 
recently identified in mDia1 [215].  Interestingly, we identified two conserved ROCK 
consensus phosphorylation sites near the basic region, and hypothesized that addition of 
negatively charged phosphate groups could disrupt DID-DAD binding, thereby enhancing 
mDia2 activity. We found that ROCK phosphorylated the mDia2 DAD at T1061 and S1070 
in vitro and in vivo.  Phospho-mimetic mutation (mDia2-2E) of both residues decreased the 
DID-DAD interaction, thereby stimulating actin polymerization, MRTF activation, and 
SMC-specific gene transcription.   
Detailed analysis of mDia activation has revealed that RhoA binding only partially 
alleviates the DID-DAD interaction, suggesting that additional signaling events are required 
for full activation [163].  In good agreement with this claim, we found that overexpression of 
constitutively active (L63) RhoA activated SMC-specific gene transcription to a lesser extent 
than constitutively active mDia2 (∆GBD) [184]. Thus, we hypothesized that while RhoA 
binding may alleviate the core DAD-DID interaction, additional disruption of the basic 
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region via phosphorylation might be required to completely activate mDia2.  In support of 
this, we found that L63 RhoA activated mDia2-2E much more robustly than wild-type 
mDia2. Taken together, these data suggest that phosphorylation of the DAD by ROCK may 
partially activate mDia2 by disrupting the electrostatic attraction between the basic and 
acidic motifs in the DAD and DID regions, respectively.  In sum, our data supports a model 
in which full activation of mDia2 requires both RhoA binding and phosphorylation of the 
DAD.   
The ability of mDia2 to regulate numerous cellular processes is likely achieved by its 
promiscuous binding of various GTPases, including Cdc42, Rif, and RhoA-C [118, 126, 
127].  Although the presence of a unique threonine-serine-histidine (TSH) motif in the 
mDia2 DID has been shown to mediate binding of these GTPases [215], very little is known 
of how conformational changes in mDia2 can alter these interactions.  For example, could 
phosphorylation-induced changes in the DID-DAD interaction trigger a conformational shift 
in the GBD that determines the binding affinity of specific GTPases?  We found that RhoA 
bound more strongly to mDia2-2E than to wild-type mDia2, and it will be interesting to see 
if a similar increase in binding occurs with other GTPases.  Currently, our model assumes 
that phosphorylation occurs when mDia2 is in the “closed” conformation, and activates the 
molecule by relieving DID-DAD binding. However, it remains possible that phosphorylation 
may occur when mDia2 is active.  According to this model, phosphorylation of the DAD 
could prevent reassociation of the DID and the DAD, thus trapping the molecule in its 
“open” conformation and prolonging its activity.  A closer examination of DAD 
phosphorylation in active and inactive mDia2 variants will be needed to evaluate the 
accuracy of these two models.   
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In addition to regulating SMC differentiation, RhoA also modulates vascular tone.  
Vascular SMC contraction is closely associated with myosin light chain (MLC) 
phosphorylation, which is regulated by RhoA-dependent activation of ROCK and subsequent 
inhibition of MLC phosphatase [216].  Protein kinase G (PKG) is one of the most well 
known physiological inducers of SMC relaxation, which is in part accomplished by 
inhibition of RhoA-mediated contractility [217, 218]. Interestingly, numerous studies have 
indicated that PKG positively regulates SMC differentiation, despite its inhibitory effect on 
RhoA-mediated cell contractility (see [217] review).  This paradoxical evidence could be 
explained by direct phosphorylation of mDia2 by PKG.  In this model, activation of PKG 
would inhibit the RhoA-ROCK-MLC pathway of contractility, but could simultaneously 
activate mDia2 to maintain the differentiated state of the SMC.  Although we found that 
PKG can phosphorylate the mDia2 DAD in vitro (data not shown), additional in vivo studies 
will be essential to determine the biological consequence of this phosphorylation event.  
During the course of our studies, two separate reports identified FHOD1 as a substrate for 
both PKG and ROCK [178, 180].  Although the functional consequence of PKG 
phosphorylation was not investigated, phosphorylation by ROCK occurred in the DAD 
domain and significantly enhanced the activity of FHOD1.  Taken together, our studies and 
others suggest that the activation state of the DRFs is regulated not only by GTPase binding, 
but also by multiple phosphorylation events.   
 
Developmental and pathological roles of the DRFs in vivo 
 Although the DRFs have been fairly well described as dynamic regulators of the 
actin cytoskeleton, their in vivo function is poorly understood.  The human homologs of 
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mDia1 and mDia2 (Dia1 and Dia3) are associated with the development of two different rare 
forms of non-syndromic genetic deafness, DFNA1 and DFN2 [192, 193].  Genetic mapping 
and sequence analysis discovered that a single nucleotide substitution in a splice donor 
induced a frameshift and C-terminal truncation of Dia1 in the DFNA1 patients [193]. A 
similar truncation in mDia1 has been shown to disrupt DID-DAD binding and induce 
aberrant stress fiber formation in Cos-7 cells [118]. This cytoskeletal perturbation has been 
proposed to be responsible for dysregulated function of stereocilia within the ear, but 
additional studies are needed to support this claim [219].   
Alternatively, Dia might be important for the proper formation and function of the 
inner ear vasculature.  Studies that have further characterized DFNA1 have identified that 
hydrops, or fluid imbalances of the ear, could be the etiology of deafness in these patients 
[220].  The presence of hydrops can be indicative of functional abnormalities in the stria 
vascularis, which encompasses the majority of the inner ear vessels and is important in 
maintaining fluid homeostasis [221].  Indeed, two separate studies have reported that mice 
lacking the S1P2 receptor have defects in the vascular bed of the stria vascularis and are deaf 
by one month of age due to dysfunctional control of inner ear fluid homeostasis [194, 195].  
Given our data strongly implicating the diaphanous proteins in SMC differentiation, it is 
intriguing to hypothesize that dysregulated Dia signaling could result in failed SMC 
maturation, leading to abnormal structure and function of the stria vascularis, and ultimately 
deafness.   In chapter 3, we found that S1P-mediated stimulation of SMC gene expression 
was dependent on the presence of mDia1 and mDia2, suggesting that the S1P-RhoA-mDia 
signaling axis may be required for maintenance of inner ear fluid homeostasis by the stria 
vascularis.  Further structural and functional analysis of the stria vascularis in the absence or 
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disruption of mDia signaling could prove valuable to the development of therapeutic 
approaches for DFNA1 and DFN2.   
The absence of other vascular phenotypes associated with mDia1 or mDia2 may be 
due to inadequate in vivo animal models.  There has been no indication of vascular 
abnormalities in mDia1-null mice, but such a phenotype may be masked by compensatory 
upregulation of mDia2 [190, 191].  In support of this, we and others have found that cells in 
which mDia1 has been deleted or silenced exhibit increased expression of mDia2 [127].  The 
generation of mDia2 and mDia1/2 double-knockout mice is required to better understand the 
role of these DRFs in vascular development.  To our knowledge, the only study investigating 
the in vivo role of mDia2 during development has been conducted in zebrafish through the 
use of antisense morpholino oligonucleotides (MOs), which ablate mDia2 expression by 
blocking translation [222].  MOs targeted to mDia2 induced gastrulation defects which were 
attributed to abnormal actin filament assembly and cell movement at the leading edge of the 
blastoderm.   These findings are in agreement with a plethora of studies indicating that 
mDia2 regulates cell motility by controlling the formation of actin stress fibers, filopodia, 
and lamellipodia [223-226].  These early developmental defects have unfortunately made it 
difficult to access the role of mDia2 in SMC differentiation in zebrafish.  It is reasonable that 
a similar phenotype in mice may occur following deletion of mDia2, and for these reasons it 
will be imperative to specifically target mDia2 in SMCs using the Cre/LoxP recombination 
system.   
There are several extant mouse models that express Cre recombinase under the 
control of an SMC-specific promoter, including SM22 and SM-MHC. However, their use in 
SMC-specific knockout studies has been limited because of low excision efficiencies, lack of 
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SMC specificity during development, and embryonic lethality (see [227] for commentary).  
To overcome these obstacles, our lab has obtained mice containing a fusion protein of Cre 
recombinase and the modified estrogen receptor domain under the control of the SM-MHC 
promoter (SM-MHC-Cre-ER) [228].  Treatment of these adult mice with tamoxifen resulted 
in robust recombination in SMCs but not in other cell types, including skeletal and cardiac 
muscle cells [228]. It will also be interesting to identify the role of mDia1 or mDia2 in the 
differentiation of variant SMC lineages.  For example, using the Wnt1-Cre-ER mouse, we 
could selectively ablate mDia2 expression in neural crest cells, and assess the impact of this 
deletion on SMC differentiation from this particular embryonic origin [229].            
Although they lack vascular abnormalities, mDia1-null mice do develop an age-
dependent myeloproliferative phenotype that resembles human myeloproliferative and 
myelodysplastic syndromes (MPS, MDS) [191].  While these data suggest that mDia1 
inhibits proliferation of myeloid cells, a separate study found that increased levels of mDia1 
stimulated cell proliferation in melanocytes [230].  Thus, the role of mDia1 in cell 
proliferation may be cell-type specific, a possibility that warrants further investigation. 
Given their importance in regulating cell migration, proliferation and differentiation, it is 
worthwhile to investigate how the DRFs might contribute to the initiation and progression of 
specific cancers.  A recent study discovered that depletion of SRF or MRTF in MDA-MB-
231 breast carcinoma and B16F2 melanoma cells results in reduced cell adhesion, spreading, 
invasion and motility in culture [231].  Furthermore, tumor cells lacking SRF or MRTF were 
unable to colonize the lung from the bloodstream.  These data suggest that modulation of 
gene expression by the RhoA-actin-MRTF-SRF signaling pathway is an important 
component of cytoskeletal remodeling and metastasis. Since we have shown that DRFs can 
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regulate the SRF-MRTF signaling pathway, it will be interesting to address whether deletion 
of mDia1 or mDia2 can similarly impede cancer cell motility.  Interestingly, several formins 
have already been implicated in tumor progression and metastasis in colorectal carcinomas, 
leiomyosarcomas, and osteosarcomas [232-235]. Smooth muscle neoplasms occur in almost 
25% of women in the United States, and are the cause of approximately one-third of 
hysterectomies performed each year [236].   Altered SRF binding to the promoters of certain 
SMC-specific genes have been closely linked to the progression of these neoplasms [236], 
suggesting that upstream RhoA or mDia signaling may also contribute to their pathogenesis. 
Given their unique ability to control cell migration by regulating the actin cytoskeleton and 
gene expression, developing therapeutic strategies to target the DRFs in cancer may prove to 
be beneficial.  
 
Conclusion  
 The studies detailed in this dissertation identify the DRFs as dynamic regulators of 
SMC differentiation.  However, additional studies are required to further characterize the 
molecular mechanisms that govern DRF activity and to determine the role of these factors in 
nucleoskeletal dynamics.  Since existing reports have primarily utilized biochemical and 
cellular techniques to study the DRFs, the development of small animal models to study 
these proteins in vivo remains an outstanding need in the field.   Such models may well 
identify new roles for the DRFs in the pathogenesis of diseases such as atherosclerosis, 
restenosis, deafness, and cancer. Given a better understanding of how the DRFs contribute to 
these pathologies, development of small molecular compounds that can alter GTPase binding 
or intramolecular interactions could prove a valuable therapeutic approach.   
111 
REFERENCES:
 
1. Adachi, M., M. Fukuda, and E. Nishida. 1999. Two co-existing mechanisms for 
nuclear import of MAP kinase: passive diffusion of a monomer and active transport 
of a dimer. Embo J 18:5347-58. 
2. Adam, P. J., C. P. Regan, M. B. Hautmann, and G. K. Owens. 2000. Positive- and 
negative-acting Kruppel-like transcription factors bind a transforming growth factor 
beta control element required for expression of the smooth muscle cell differentiation 
marker SM22alpha in vivo. J Biol Chem 275:37798-806. 
3. Adini, I., I. Rabinovitz, J. F. Sun, G. C. Prendergast, and L. E. Benjamin. 2003. 
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during 
vascular development. Genes Dev 17:2721-32. 
4. Adnane, J., C. Muro-Cacho, L. Mathews, S. M. Sebti, and T. Munoz-Antonia. 
2002. Suppression of rho B expression in invasive carcinoma from head and neck 
cancer patients. Clin Cancer Res 8:2225-32. 
5. Alberts, A. S. 2001. Identification of a carboxyl-terminal diaphanous-related formin 
homology protein autoregulatory domain. J Biol Chem 276:2824-30. 
6. Alberts, A. S., O. Geneste, and R. Treisman. 1998. Activation of SRF-regulated 
chromosomal templates by Rho-family GTPases requires a signal that also induces 
H4 hyperacetylation. Cell 92:475-87. 
7. Ang, A. H., G. Tachas, J. H. Campbell, J. F. Bateman, and G. R. Campbell. 
1990. Collagen synthesis by cultured rabbit aortic smooth-muscle cells. Alteration 
with phenotype. Biochem J 265:461-9. 
8. Arai, A., J. A. Spencer, and E. N. Olson. 2002. STARS, a striated muscle activator 
of Rho signaling and serum response factor-dependent transcription. J Biol Chem 
277:24453-9. 
112 
9. Aravind, L., and E. V. Koonin. 2000. SAP - a putative DNA-binding motif involved 
in chromosomal organization. Trends Biochem Sci 25:112-4. 
10. Arsenian, S., B. Weinhold, M. Oelgeschlager, U. Ruther, and A. Nordheim. 1998. 
Serum response factor is essential for mesoderm formation during mouse 
embryogenesis. Embo J 17:6289-99. 
11. Balboa, M. A., and P. A. Insel. 1995. Nuclear phospholipase D in Madin-Darby 
canine kidney cells. Guanosine 5'-O-(thiotriphosphate)-stimulated activation is 
mediated by RhoA and is downstream of protein kinase C. J Biol Chem 270:29843-7. 
12. Beli, P., D. Mascheroni, D. Xu, and M. Innocenti. 2008. WAVE and Arp2/3 jointly 
inhibit filopodium formation by entering into a complex with mDia2. Nat Cell Biol 
10:849-57. 
13. Benitah, S. A., P. F. Valeron, L. van Aelst, C. J. Marshall, and J. C. Lacal. 2004. 
Rho GTPases in human cancer: an unresolved link to upstream and downstream 
transcriptional regulation. Biochim Biophys Acta 1705:121-32. 
14. Blank, R. S., and G. K. Owens. 1990. Platelet-derived growth factor regulates actin 
isoform expression and growth state in cultured rat aortic smooth muscle cells. J Cell 
Physiol 142:635-42. 
15. Browning, C. L., D. E. Culberson, I. V. Aragon, R. A. Fillmore, J. D. Croissant, 
R. J. Schwartz, and W. E. Zimmer. 1998. The developmentally regulated 
expression of serum response factor plays a key role in the control of smooth muscle-
specific genes. Dev Biol 194:18-37. 
16. Caplice, N. M., and B. Doyle. 2005. Vascular progenitor cells: origin and 
mechanisms of mobilization, differentiation, integration, and vasculogenesis. Stem 
Cells Dev 14:122-39. 
17. Carreira, S., J. Goodall, L. Denat, M. Rodriguez, P. Nuciforo, K. S. Hoek, A. 
Testori, L. Larue, and C. R. Goding. 2006. Mitf regulation of Dia1 controls 
melanoma proliferation and invasiveness. Genes Dev 20:3426-39. 
18. Cen, B., A. Selvaraj, R. C. Burgess, J. K. Hitzler, Z. Ma, S. W. Morris, and R. 
Prywes. 2003. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for 
serum response factor (SRF), is required for serum induction of SRF target genes. 
Mol Cell Biol 23:6597-608. 
113 
19. Chang, D. F., N. S. Belaguli, J. Chang, and R. J. Schwartz. 2007. LIM-only 
protein, CRP2, switched on smooth muscle gene activity in adult cardiac myocytes. 
Proc Natl Acad Sci U S A 104:157-62. 
20. Chang, D. F., N. S. Belaguli, D. Iyer, W. B. Roberts, S. P. Wu, X. R. Dong, J. G. 
Marx, M. S. Moore, M. C. Beckerle, M. W. Majesky, and R. J. Schwartz. 2003. 
Cysteine-rich LIM-only proteins CRP1 and CRP2 are potent smooth muscle 
differentiation cofactors. Dev Cell 4:107-18. 
21. Chen, C. Y., J. Croissant, M. Majesky, S. Topouzis, T. McQuinn, M. J. 
Frankovsky, and R. J. Schwartz. 1996. Activation of the cardiac alpha-actin 
promoter depends upon serum response factor, Tinman homologue, Nkx-2.5, and 
intact serum response elements. Dev Genet 19:119-30. 
22. Chen, C. Y., and R. J. Schwartz. 1996. Recruitment of the tinman homolog Nkx-2.5 
by serum response factor activates cardiac alpha-actin gene transcription. Mol Cell 
Biol 16:6372-84. 
23. Chen, J., C. M. Kitchen, J. W. Streb, and J. M. Miano. 2002. Myocardin: a 
component of a molecular switch for smooth muscle differentiation. J Mol Cell 
Cardiol 34:1345-56. 
24. Chen, S., M. Crawford, R. M. Day, V. R. Briones, J. E. Leader, P. A. Jose, and 
R. J. Lechleider. 2006. RhoA modulates Smad signaling during transforming growth 
factor-beta-induced smooth muscle differentiation. J Biol Chem 281:1765-70. 
25. Chrzanowska-Wodnicka, M., and K. Burridge. 1996. Rho-stimulated contractility 
drives the formation of stress fibers and focal adhesions. J Cell Biol 133:1403-15. 
26. Clowes, A. W., M. A. Reidy, and M. M. Clowes. 1983. Mechanisms of stenosis 
after arterial injury. Lab Invest 49:208-15. 
27. Copeland, J. W., S. J. Copeland, and R. Treisman. 2004. Homo-oligomerization is 
essential for F-actin assembly by the formin family FH2 domain. J Biol Chem 
279:50250-6. 
28. Copeland, J. W., and R. Treisman. 2002. The Diaphanous-related Formin mDia1 
Controls Serum Response Factor Activity through its Effects on Actin 
Polymerization. Mol Biol Cell 13:4088-99. 
114 
29. Copeland, S. J., B. J. Green, S. Burchat, G. A. Papalia, D. Banner, and J. W. 
Copeland. 2007. The diaphanous inhibitory domain/diaphanous autoregulatory 
domain interaction is able to mediate heterodimerization between mDia1 and mDia2. 
J Biol Chem 282:30120-30. 
30. Danielian, P. S., D. Muccino, D. H. Rowitch, S. K. Michael, and A. P. McMahon. 
1998. Modification of gene activity in mouse embryos in utero by a tamoxifen-
inducible form of Cre recombinase. Curr Biol 8:1323-6. 
31. Deaton, R. A., C. Su, T. G. Valencia, and S. R. Grant. 2005. Transforming growth 
factor-beta1-induced expression of smooth muscle marker genes involves activation 
of PKN and p38 MAPK. J Biol Chem 280:31172-81. 
32. Dickson, M. C., J. S. Martin, F. M. Cousins, A. B. Kulkarni, S. Karlsson, and R. 
J. Akhurst. 1995. Defective haematopoiesis and vasculogenesis in transforming 
growth factor-beta 1 knock out mice. Development 121:1845-54. 
33. Doran, A. C., N. Meller, and C. A. McNamara. 2008. Role of smooth muscle cells 
in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc 
Biol 28:812-9. 
34. Dovas, A., and J. R. Couchman. 2005. RhoGDI: multiple functions in the regulation 
of Rho family GTPase activities. Biochem J 390:1-9. 
35. Du, K. L., M. Chen, J. Li, J. J. Lepore, P. Mericko, and M. S. Parmacek. 2004. 
Megakaryoblastic leukemia factor-1 transduces cytoskeletal signals and induces 
smooth muscle cell differentiation from undifferentiated embryonic stem cells. J Biol 
Chem 279:17578-86. 
36. Du, K. L., H. S. Ip, J. Li, M. Chen, F. Dandre, W. Yu, M. M. Lu, G. K. Owens, 
and M. S. Parmacek. 2003. Myocardin is a critical serum response factor cofactor in 
the transcriptional program regulating smooth muscle cell differentiation. Mol Cell 
Biol 23:2425-37. 
37. Egly, J. M., N. G. Miyamoto, V. Moncollin, and P. Chambon. 1984. Is actin a 
transcription initiation factor for RNA polymerase B? Embo J 3:2363-71. 
38. Eichmann, A. B., K. Pardanaud, L. 2007. Tumor Angiogenesis. Basic Mechanisms 
and Cancer Therapy. Springer Berlin Heidelberg. 
115 
39. Eisenmann, K. M., R. A. West, D. Hildebrand, S. M. Kitchen, J. Peng, R. Sigler, 
J. Zhang, K. A. Siminovitch, and A. S. Alberts. 2007. T cell responses in 
mammalian diaphanous-related formin mDia1 knock-out mice. J Biol Chem 
282:25152-8. 
40. Etienne-Manneville, S., and A. Hall. 2002. Rho GTPases in cell biology. Nature 
420:629-35. 
41. Evangelista, M., D. Pruyne, D. C. Amberg, C. Boone, and A. Bretscher. 2002. 
Formins direct Arp2/3-independent actin filament assembly to polarize cell growth in 
yeast. Nat Cell Biol 4:260-9. 
42. Faix, J., and R. Grosse. 2006. Staying in shape with formins. Dev Cell 10:693-706. 
43. Ferguson, J. E., 3rd, R. W. Kelley, and C. Patterson. 2005. Mechanisms of 
endothelial differentiation in embryonic vasculogenesis. Arterioscler Thromb Vasc 
Biol 25:2246-54. 
44. Friederichs, J., R. Rosenberg, J. Mages, K. P. Janssen, C. Maeckl, H. Nekarda, 
B. Holzmann, and J. R. Siewert. 2005. Gene expression profiles of different clinical 
stages of colorectal carcinoma: toward a molecular genetic understanding of tumor 
progression. Int J Colorectal Dis 20:391-402. 
45. Fukuda, T., A. Kido, K. Kajino, M. Tsutsumi, Y. Miyauchi, T. Tsujiuchi, Y. 
Konishi, and O. Hino. 1999. Cloning of differentially expressed genes in highly and 
low metastatic rat osteosarcomas by a modified cDNA-AFLP method. Biochem 
Biophys Res Commun 261:35-40. 
46. Garcia-Mata, R., A. D. Dubash, L. Sharek, H. S. Carr, J. A. Frost, and K. 
Burridge. 2007. The nuclear RhoA exchange factor Net1 interacts with proteins of 
the Dlg family, affects their localization, and influences their tumor suppressor 
activity. Mol Cell Biol 27:8683-97. 
47. Gasman, S., Y. Kalaidzidis, and M. Zerial. 2003. RhoD regulates endosome 
dynamics through Diaphanous-related Formin and Src tyrosine kinase. Nat Cell Biol 
5:195-204. 
48. Gasteier, J. E., R. Madrid, E. Krautkramer, S. Schroder, W. Muranyi, S. 
Benichou, and O. T. Fackler. 2003. Activation of the Rac-binding partner FHOD1 
116 
induces actin stress fibers via a ROCK-dependent mechanism. J Biol Chem 
278:38902-12. 
49. Geneste, O., J. W. Copeland, and R. Treisman. 2002. LIM kinase and Diaphanous 
cooperate to regulate serum response factor and actin dynamics. J Cell Biol 157:831-
8. 
50. Gineitis, D., and R. Treisman. 2001. Differential usage of signal transduction 
pathways defines two types of serum response factor target gene. J Biol Chem 
276:24531-9. 
51. Girard, H. 1973. Arterial pressure in the chick embryo. Am J Physiol 224:454-60. 
52. Glukhova, M. A., A. E. Kabakov, M. G. Frid, O. I. Ornatsky, A. M. Belkin, D. N. 
Mukhin, A. N. Orekhov, V. E. Koteliansky, and V. N. Smirnov. 1988. Modulation 
of human aorta smooth muscle cell phenotype: a study of muscle-specific variants of 
vinculin, caldesmon, and actin expression. Proc Natl Acad Sci U S A 85:9542-6. 
53. Gonsior, S. M., S. Platz, S. Buchmeier, U. Scheer, B. M. Jockusch, and H. 
Hinssen. 1999. Conformational difference between nuclear and cytoplasmic actin as 
detected by a monoclonal antibody. J Cell Sci 112 (Pt 6):797-809. 
54. Goode, B. L., and M. J. Eck. 2007. Mechanism and function of formins in the 
control of actin assembly. Annu Rev Biochem 76:593-627. 
55. Grabocka, E., and P. B. Wedegaertner. 2007. Disruption of oligomerization 
induces nucleocytoplasmic shuttling of leukemia-associated rho Guanine-nucleotide 
exchange factor. Mol Pharmacol 72:993-1002. 
56. Groisman, R., H. Masutani, M. P. Leibovitch, P. Robin, I. Soudant, D. Trouche, 
and A. Harel-Bellan. 1996. Physical interaction between the mitogen-responsive 
serum response factor and myogenic basic-helix-loop-helix proteins. J Biol Chem 
271:5258-64. 
57. Guettler, S., M. K. Vartiainen, F. Miralles, B. Larijani, and R. Treisman. 2008. 
RPEL motifs link the serum response factor cofactor MAL but not myocardin to Rho 
signaling via actin binding. Mol Cell Biol 28:732-42. 
117 
58. Gupton, S. L., K. Eisenmann, A. S. Alberts, and C. M. Waterman-Storer. 2007. 
mDia2 regulates actin and focal adhesion dynamics and organization in the lamella 
for efficient epithelial cell migration. J Cell Sci 120:3475-87. 
59. Hall, A. 1999. Signal transduction pathways regulated by the Rho family of small 
GTPases. Br J Cancer 80 Suppl 1:25-7. 
60. Hautmann, M. B., C. S. Madsen, and G. K. Owens. 1997. A transforming growth 
factor beta (TGFbeta) control element drives TGFbeta-induced stimulation of smooth 
muscle alpha-actin gene expression in concert with two CArG elements. J Biol Chem 
272:10948-56. 
61. Hedin, U., B. A. Bottger, J. Luthman, S. Johansson, and J. Thyberg. 1989. A 
substrate of the cell-attachment sequence of fibronectin (Arg-Gly-Asp-Ser) is 
sufficient to promote transition of arterial smooth muscle cells from a contractile to a 
synthetic phenotype. Dev Biol 133:489-501. 
62. Hellstrom, M., M. Kal n, P. Lindahl, A. Abramsson, and C. Betsholtz. 1999. Role 
of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and 
pericytes during embryonic blood vessel formation in the mouse. Development 
126:3047-55. 
63. Herring, B. P., and A. F. Smith. 1997. Telokin expression in A10 smooth muscle 
cells requires serum response factor. Am J Physiol 272:C1394-404. 
64. Higashida, C., T. Miyoshi, A. Fujita, F. Oceguera-Yanez, J. Monypenny, Y. 
Andou, S. Narumiya, and N. Watanabe. 2004. Actin polymerization-driven 
molecular movement of mDia1 in living cells. Science 303:2007-10. 
65. Higgs, H. N. 2005. Formin proteins: a domain-based approach. Trends Biochem Sci 
30:342-53. 
66. Hill, C. S., and R. Treisman. 1995. Differential activation of c-fos promoter 
elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors. 
Embo J 14:5037-47. 
67. Hill, C. S., J. Wynne, and R. Treisman. 1995. The Rho family GTPases RhoA, 
Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 81:1159-70. 
118 
68. Hinson, J. S., M. D. Medlin, K. Lockman, J. M. Taylor, and C. P. Mack. 2007. 
Smooth muscle cell-specific transcription is regulated by nuclear localization of the 
myocardin-related transcription factors. Am J Physiol Heart Circ Physiol 292:H1170-
80. 
69. Hinson, J. S., Medlin, M.D, Lockman, K., Taylor, J.M., Mack, C.P. 2006. Smooth 
muscle cell-specific transcription is regulated by nuclear localization of the 
myocardin-related transcription factors. Am J. Physiol. 292. 
70. Hirschi, K. K., S. A. Rohovsky, and P. A. D'Amore. 1998. PDGF, TGF-beta, and 
heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 
10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141:805-14. 
71. Hofmann, W., B. Reichart, A. Ewald, E. Muller, I. Schmitt, R. H. Stauber, F. 
Lottspeich, B. M. Jockusch, U. Scheer, J. Hauber, and M. C. Dabauvalle. 2001. 
Cofactor requirements for nuclear export of Rev response element (RRE)- and 
constitutive transport element (CTE)-containing retroviral RNAs. An unexpected role 
for actin. J Cell Biol 152:895-910. 
72. Holycross, B. J., R. S. Blank, M. M. Thompson, M. J. Peach, and G. K. Owens. 
1992. Platelet-derived growth factor-BB-induced suppression of smooth muscle cell 
differentiation. Circ Res 71:1525-32. 
73. Homem, C. C., and M. Peifer. 2008. Diaphanous regulates myosin and adherens 
junctions to control cell contractility and protrusive behavior during morphogenesis. 
Development 135:1005-18. 
74. Insull, W., Jr. 2009. The pathology of atherosclerosis: plaque development and 
plaque responses to medical treatment. Am J Med 122:S3-S14. 
75. Ishizaki, T., Y. Morishima, M. Okamoto, T. Furuyashiki, T. Kato, and S. 
Narumiya. 2001. Coordination of microtubules and the actin cytoskeleton by the Rho 
effector mDia1. Nat Cell Biol 3:8-14. 
76. Jaffe, A. B., and A. Hall. 2005. Rho GTPases: biochemistry and biology. Annu Rev 
Cell Dev Biol 21:247-69. 
77. Kato, T., N. Watanabe, Y. Morishima, A. Fujita, T. Ishizaki, and S. Narumiya. 
2001. Localization of a mammalian homolog of diaphanous, mDia1, to the mitotic 
spindle in HeLa cells. J Cell Sci 114:775-84. 
119 
78. Kiseleva, E., S. P. Drummond, M. W. Goldberg, S. A. Rutherford, T. D. Allen, 
and K. L. Wilson. 2004. Actin- and protein-4.1-containing filaments link nuclear 
pore complexes to subnuclear organelles in Xenopus oocyte nuclei. J Cell Sci 
117:2481-90. 
79. Kocher, O., F. Gabbiani, G. Gabbiani, M. A. Reidy, M. S. Cokay, H. Peters, and 
I. Huttner. 1991. Phenotypic features of smooth muscle cells during the evolution of 
experimental carotid artery intimal thickening. Biochemical and morphologic studies. 
Lab Invest 65:459-70. 
80. Kocher, O., and G. Gabbiani. 1986. Cytoskeletal features of normal and 
atheromatous human arterial smooth muscle cells. Hum Pathol 17:875-80. 
81. Kono, M., I. A. Belyantseva, A. Skoura, G. I. Frolenkov, M. F. Starost, J. L. 
Dreier, D. Lidington, S. S. Bolz, T. B. Friedman, T. Hla, and R. L. Proia. 2007. 
Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem 
282:10690-6. 
82. Kovar, D. R. 2006. Molecular details of formin-mediated actin assembly. Curr Opin 
Cell Biol 18:11-7. 
83. Kovar, D. R., and T. D. Pollard. 2004. Insertional assembly of actin filament barbed 
ends in association with formins produces piconewton forces. Proc Natl Acad Sci U S 
A 101:14725-30. 
84. Kuwahara, K., T. Barrientos, G. C. Pipes, S. Li, and E. N. Olson. 2005. Muscle-
specific signaling mechanism that links actin dynamics to serum response factor. Mol 
Cell Biol 25:3173-81. 
85. Lai, S. L., T. H. Chan, M. J. Lin, W. P. Huang, S. W. Lou, and S. J. Lee. 2008. 
Diaphanous-related formin 2 and profilin I are required for gastrulation cell 
movements. PLoS ONE 3:e3439. 
86. Lalwani, A. K., R. K. Jackler, R. W. Sweetow, E. D. Lynch, H. Raventos, J. 
Morrow, M. C. King, and P. E. Leon. 1998. Further characterization of the DFNA1 
audiovestibular phenotype. Arch Otolaryngol Head Neck Surg 124:699-702. 
87. Lammers, M., S. Meyer, D. Kuhlmann, and A. Wittinghofer. 2008. Specificity of 
interactions between mDia isoforms and Rho proteins. J Biol Chem 283:35236-46. 
120 
88. Lammers, M., R. Rose, A. Scrima, and A. Wittinghofer. 2005. The regulation of 
mDia1 by autoinhibition and its release by Rho*GTP. Embo J 24:4176-87. 
89. Landerholm, T. E., X. R. Dong, J. Lu, N. S. Belaguli, R. J. Schwartz, and M. W. 
Majesky. 1999. A role for serum response factor in coronary smooth muscle 
differentiation from proepicardial cells. Development 126:2053-62. 
90. Li, F., and H. N. Higgs. 2005. Dissecting requirements for auto-inhibition of actin 
nucleation by the formin, mDia1. J Biol Chem 280:6986-92. 
91. Li, J., X. Zhu, M. Chen, L. Cheng, D. Zhou, M. M. Lu, K. Du, J. A. Epstein, and 
M. S. Parmacek. 2005. Myocardin-related transcription factor B is required in 
cardiac neural crest for smooth muscle differentiation and cardiovascular 
development. Proc Natl Acad Sci U S A 102:8916-21. 
92. Li, L., Z. Liu, B. Mercer, P. Overbeek, and E. N. Olson. 1997. Evidence for serum 
response factor-mediated regulatory networks governing SM22alpha transcription in 
smooth, skeletal, and cardiac muscle cells. Dev Biol 187:311-21. 
93. Li, L., J. M. Miano, P. Cserjesi, and E. N. Olson. 1996. SM22 alpha, a marker of 
adult smooth muscle, is expressed in multiple myogenic lineages during 
embryogenesis. Circ Res 78:188-95. 
94. Li, S., S. Chang, X. Qi, J. A. Richardson, and E. N. Olson. 2006. Requirement of a 
myocardin-related transcription factor for development of mammary myoepithelial 
cells. Mol Cell Biol 26:5797-808. 
95. Li, S., M. P. Czubryt, J. McAnally, R. Bassel-Duby, J. A. Richardson, F. F. 
Wiebel, A. Nordheim, and E. N. Olson. 2005. Requirement for serum response 
factor for skeletal muscle growth and maturation revealed by tissue-specific gene 
deletion in mice. Proc Natl Acad Sci U S A 102:1082-1087. 
96. Li, S., D. Z. Wang, Z. Wang, J. A. Richardson, and E. N. Olson. 2003. The serum 
response factor coactivator myocardin is required for vascular smooth muscle 
development. Proc Natl Acad Sci U S A 100:9366-70. 
97. Lincoln, T. M., N. Dey, and H. Sellak. 2001. Invited review: cGMP-dependent 
protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to 
gene expression. J Appl Physiol 91:1421-30. 
121 
98. Lincoln, T. M., X. Wu, H. Sellak, N. Dey, and C. S. Choi. 2006. Regulation of 
vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent 
protein kinase. Front Biosci 11:356-67. 
99. Lindahl, P., B. R. Johansson, P. Leveen, and C. Betsholtz. 1997. Pericyte loss and 
microaneurysm formation in PDGF-B-deficient mice. Science 277:242-5. 
100. Lockman, K., J. S. Hinson, M. D. Medlin, D. Morris, J. M. Taylor, and C. P. 
Mack. 2004. Sphingosine 1-Phosphate Stimulates Smooth Muscle Cell 
Differentiation and Proliferation by Activating Separate Serum Response Factor Co-
factors. J Biol Chem 279:42422-30. 
101. Lu, J., T. E. Landerholm, J. S. Wei, X. R. Dong, S. P. Wu, X. Liu, K. Nagata Ki, 
M. Inagaki, and M. W. Majesky. 2001. Coronary Smooth Muscle Differentiation 
from Proepicardial Cells Requires RhoA-Mediated Actin Reorganization and p160 
Rho-Kinase Activity. Dev Biol 240:404-18. 
102. Lynch, E. D., M. K. Lee, J. E. Morrow, P. L. Welcsh, P. E. Leon, and M. C. 
King. 1997. Nonsyndromic deafness DFNA1 associated with mutation of a human 
homolog of the Drosophila gene diaphanous. Science 278:1315-8. 
103. Mack, C. P., and J. S. Hinson. 2005. Regulation of smooth muscle differentiation by 
the myocardin family of serum response factor co-factors. J Thromb Haemost. 
104. Mack, C. P., and J. S. Hinson. 2005. Regulation of smooth muscle differentiation by 
the myocardin family of serum response factor co-factors. J Thromb Haemost 
3:1976-84. 
105. Mack, C. P., and G. K. Owens. 1999. Regulation of smooth muscle alpha-actin 
expression in vivo is dependent on CArG elements within the 5' and first intron 
promoter regions. Circ Res 84:852-61. 
106. Mack, C. P., A. V. Somlyo, M. Hautmann, A. P. Somlyo, and G. K. Owens. 2001. 
Smooth muscle differentiation marker gene expression is regulated by RhoA-
mediated actin polymerization. J Biol Chem 276:341-7. 
107. Mack, C. P., M. M. Thompson, S. Lawrenz-Smith, and G. K. Owens. 2000. 
Smooth muscle alpha-actin CArG elements coordinate formation of a smooth muscle 
cell-selective, serum response factor-containing activation complex. Circ Res 86:221-
32. 
122 
108. Mackay, D. J., and A. Hall. 1998. Rho GTPases. J Biol Chem 273:20685-8. 
109. MacLennan, A. J., S. J. Benner, A. Andringa, A. H. Chaves, J. L. Rosing, R. 
Vesey, A. M. Karpman, S. A. Cronier, N. Lee, L. C. Erway, and M. L. Miller. 
2006. The S1P2 sphingosine 1-phosphate receptor is essential for auditory and 
vestibular function. Hear Res 220:38-48. 
110. Madsen, C. S., J. C. Hershey, M. B. Hautmann, S. L. White, and G. K. Owens. 
1997. Expression of the smooth muscle myosin heavy chain gene is regulated by a 
negative-acting GC-rich element located between two positive-acting serum response 
factor-binding elements. J Biol Chem 272:6332-40. 
111. Maekawa, M., T. Ishizaki, S. Boku, N. Watanabe, A. Fujita, A. Iwamatsu, T. 
Obinata, K. Ohashi, K. Mizuno, and S. Narumiya. 1999. Signaling from Rho to 
the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 
285:895-8. 
112. Majesky, M. W. 2007. Developmental basis of vascular smooth muscle diversity. 
Arterioscler Thromb Vasc Biol 27:1248-58. 
113. Majesky, M. W. 2003. Vascular smooth muscle diversity: insights from 
developmental biology. Curr Atheroscler Rep 5:208-13. 
114. Manabe, I., and G. K. Owens. 2001. CArG elements control smooth muscle 
subtype-specific expression of smooth muscle myosin in vivo. J Clin Invest 107:823-
34. 
115. Martin, C. B., G. M. Mahon, M. B. Klinger, R. J. Kay, M. Symons, C. J. Der, 
and I. P. Whitehead. 2001. The thrombin receptor, PAR-1, causes transformation by 
activation of Rho-mediated signaling pathways. Oncogene 20:1953-63. 
116. McDonald, D., G. Carrero, C. Andrin, G. de Vries, and M. J. Hendzel. 2006. 
Nucleoplasmic beta-actin exists in a dynamic equilibrium between low-mobility 
polymeric species and rapidly diffusing populations. J Cell Biol 172:541-52. 
117. Medjkane, S., C. Perez-Sanchez, C. Gaggioli, E. Sahai, and R. Treisman. 2009. 
Myocardin-related transcription factors and SRF are required for cytoskeletal 
dynamics and experimental metastasis. Nat Cell Biol 11:257-68. 
123 
118. Menard, I., F. G. Gervais, D. W. Nicholson, and S. Roy. 2006. Caspase-3 cleaves 
the formin-homology-domain-containing protein FHOD1 during apoptosis to 
generate a C-terminal fragment that is targeted to the nucleolus. Apoptosis 11:1863-
76. 
119. Miano, J. M. 2003. Serum response factor: toggling between disparate programs of 
gene expression. J Mol Cell Cardiol 35:577-93. 
120. Miano, J. M., M. J. Carlson, J. A. Spencer, and R. P. Misra. 2000. Serum 
response factor-dependent regulation of the smooth muscle calponin gene [In Process 
Citation]. J Biol Chem 275:9814-22. 
121. Miano, J. M., N. Ramanan, M. A. Georger, K. L. de Mesy Bentley, R. L. 
Emerson, R. O. Balza, Jr., Q. Xiao, H. Weiler, D. D. Ginty, and R. P. Misra. 
2004. Restricted inactivation of serum response factor to the cardiovascular system. 
Proc Natl Acad Sci U S A 101:17132-7. 
122. Miki, T., K. Okawa, T. Sekimoto, Y. Yoneda, S. Watanabe, T. Ishizaki, and S. 
Narumiya. 2008. mDia2 shuttles between the nucleus and the cytoplasm through the 
Importin-alpha /beta - and CRM1-medaited nuclear transport mechanism. J Biol 
Chem. 
123. Minty, A., and L. Kedes. 1986. Upstream regions of the human cardiac actin gene 
that modulate its transcription in muscle cells: presence of an evolutionarily 
conserved repeated motif. Mol Cell Biol 6:2125-36. 
124. Miralles, F., G. Posern, A. I. Zaromytidou, and R. Treisman. 2003. Actin 
dynamics control SRF activity by regulation of its coactivator MAL. Cell 113:329-
42. 
125. Misra, R. P., V. M. Rivera, J. M. Wang, P. D. Fan, and M. E. Greenberg. 1991. 
The serum response factor is extensively modified by phosphorylation following its 
synthesis in serum-stimulated fibroblasts. Mol Cell Biol 11:4545-54. 
126. Miwa, T., and L. Kedes. 1987. Duplicated CArG box domains have positive and 
mutually dependent regulatory roles in expression of the human alpha-cardiac actin 
gene. Mol Cell Biol 7:2803-13. 
124 
127. Moseley, J. B., I. Sagot, A. L. Manning, Y. Xu, M. J. Eck, D. Pellman, and B. L. 
Goode. 2004. A conserved mechanism for Bni1- and mDia1-induced actin assembly 
and dual regulation of Bni1 by Bud6 and profilin. Mol Biol Cell 15:896-907. 
128. Muller, U., and A. Littlewood-Evans. 2001. Mechanisms that regulate 
mechanosensory hair cell differentiation. Trends Cell Biol 11:334-42. 
129. Nezami, A. G., F. Poy, and M. J. Eck. 2006. Structure of the autoinhibitory switch 
in formin mDia1. Structure 14:257-63. 
130. Niu, Z., W. Yu, S. X. Zhang, M. Barron, N. S. Belaguli, M. D. Schneider, M. 
Parmacek, A. Nordheim, and R. J. Schwartz. 2005. Conditional mutagenesis of the 
murine serum response factor gene blocks cardiogenesis and the transcription of 
downstream gene targets. J Biol Chem 280:32531-8. 
131. Norman, C., M. Runswick, R. Pollock, and R. Treisman. 1988. Isolation and 
properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos 
serum response element. Cell 55:989-1003. 
132. Numaguchi, K., S. Eguchi, T. Yamakawa, E. D. Motley, and T. Inagami. 1999. 
Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and 
intact actin filaments. Circ Res 85:5-11. 
133. Oh, J., J. A. Richardson, and E. N. Olson. 2005. Requirement of myocardin-related 
transcription factor-B for remodeling of branchial arch arteries and smooth muscle 
differentiation. Proc Natl Acad Sci U S A 102:15122-7. 
134. Oh, S. P., T. Seki, K. A. Goss, T. Imamura, Y. Yi, P. K. Donahoe, L. Li, K. 
Miyazono, P. ten Dijke, S. Kim, and E. Li. 2000. Activin receptor-like kinase 1 
modulates transforming growth factor-beta 1 signaling in the regulation of 
angiogenesis. Proc Natl Acad Sci U S A 97:2626-31. 
135. Okamoto, K., and Y. Hayashi. 2006. Visualization of F-actin and G-actin 
equilibrium using fluorescence resonance energy transfer (FRET) in cultured cells 
and neurons in slices. Nat Protoc 1:911-9. 
136. Orr, A. W., M. Y. Lee, J. A. Lemmon, A. Yurdagul, Jr., M. F. Gomez, P. D. 
Schoppee Bortz, and B. R. Wamhoff. 2008. Molecular Mechanisms of Collagen 
Isotype-Specific Modulation of Smooth Muscle Cell Phenotype. Arterioscler Thromb 
Vasc Biol. 
125 
137. Osada, M., Y. Yatomi, T. Ohmori, H. Ikeda, and Y. Ozaki. 2002. Enhancement of 
sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth 
muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun 299:483-7. 
138. Oshima, M., H. Oshima, and M. M. Taketo. 1996. TGF-beta receptor type II 
deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 
179:297-302. 
139. Otomo, T., C. Otomo, D. R. Tomchick, M. Machius, and M. K. Rosen. 2005. 
Structural basis of Rho GTPase-mediated activation of the formin mDia1. Mol Cell 
18:273-81. 
140. Owens, G. K. 1998. Molecular control of vascular smooth muscle cell differentiation. 
Acta Physiol Scand 164:623-35. 
141. Owens, G. K. 1996. Role of mechanical strain in regulation of differentiation of 
vascular smooth muscle cells. Circ Res 79:1054-5. 
142. Owens, G. K., A. A. Geisterfer, Y. W. Yang, and A. Komoriya. 1988. 
Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy 
in cultured vascular smooth muscle cells. J Cell Biol 107:771-80. 
143. Owens, G. K., M. S. Kumar, and B. R. Wamhoff. 2004. Molecular regulation of 
vascular smooth muscle cell differentiation in development and disease. Physiol Rev 
84:767-801. 
144. Owens, G. K., S. M. Vernon, and C. S. Madsen. 1996. Molecular regulation of 
smooth muscle cell differentiation. J Hypertens Suppl 14:S55-64. 
145. Palazzo, A. F., T. A. Cook, A. S. Alberts, and G. G. Gundersen. 2001. mDia 
mediates Rho-regulated formation and orientation of stable microtubules. Nat Cell 
Biol 3:723-9. 
146. Pauly, R. R., A. Passaniti, M. Crow, J. L. Kinsella, N. Papadopoulos, R. 
Monticone, E. G. Lakatta, and G. R. Martin. 1992. Experimental models that 
mimic the differentiation and dedifferentiation of vascular cells. Circulation 86:III68-
73. 
126 
147. Pederson, T., and U. Aebi. 2005. Nuclear actin extends, with no contraction in sight. 
Mol Biol Cell 16:5055-60. 
148. Pellegrin, S., and H. Mellor. 2005. The Rho family GTPase Rif induces filopodia 
through mDia2. Curr Biol 15:129-33. 
149. Peng, J., S. M. Kitchen, R. A. West, R. Sigler, K. M. Eisenmann, and A. S. 
Alberts. 2007. Myeloproliferative defects following targeting of the Drf1 gene 
encoding the mammalian diaphanous related formin mDia1. Cancer Res 67:7565-71. 
150. Peng, J., B. J. Wallar, A. Flanders, P. J. Swiatek, and A. S. Alberts. 2003. 
Disruption of the Diaphanous-related formin Drf1 gene encoding mDia1 reveals a 
role for Drf3 as an effector for Cdc42. Curr Biol 13:534-45. 
151. Percipalle, P., and N. Visa. 2006. Molecular functions of nuclear actin in 
transcription. J Cell Biol 172:967-71. 
152. Phiel, C. J., V. Gabbeta, L. M. Parsons, D. Rothblat, R. P. Harvey, and K. M. 
McHugh. 2001. Differential binding of an SRF/NK-2/MEF2 transcription factor 
complex in normal versus neoplastic smooth muscle tissues. J Biol Chem 276:34637-
50. 
153. Pipes, G. C., E. E. Creemers, and E. N. Olson. 2006. The myocardin family of 
transcriptional coactivators: versatile regulators of cell growth, migration, and 
myogenesis. Genes Dev 20:1545-56. 
154. Pipes, G. C., S. Sinha, X. Qi, C. H. Zhu, T. D. Gallardo, J. Shelton, E. E. 
Creemers, L. Sutherland, J. A. Richardson, D. J. Garry, W. E. Wright, G. K. 
Owens, and E. N. Olson. 2005. Stem cells and their derivatives can bypass the 
requirement of myocardin for smooth muscle gene expression. Dev Biol 288:502-13. 
155. Posern, G., F. Miralles, S. Guettler, and R. Treisman. 2004. Mutant actins that 
stabilise F-actin use distinct mechanisms to activate the SRF coactivator MAL. Embo 
J 23:3973-83. 
156. Posern, G., A. Sotiropoulos, and R. Treisman. 2002. Mutant actins demonstrate a 
role for unpolymerized actin in control of transcription by serum response factor. Mol 
Biol Cell 13:4167-78. 
127 
157. Posern, G., and R. Treisman. 2006. Actin' together: serum response factor, its 
cofactors and the link to signal transduction. Trends Cell Biol 16:588-96. 
158. Pruyne, D., M. Evangelista, C. Yang, E. Bi, S. Zigmond, A. Bretscher, and C. 
Boone. 2002. Role of formins in actin assembly: nucleation and barbed-end 
association. Science 297:612-5. 
159. Prywes, R., and R. G. Roeder. 1987. Purification of the c-fos enhancer-binding 
protein. Mol Cell Biol 7:3482-9. 
160. Raphael, Y., and R. A. Altschuler. 2003. Structure and innervation of the cochlea. 
Brain Res Bull 60:397-422. 
161. Risau, W. 1997. Mechanisms of angiogenesis. Nature 386:671-4. 
162. Risau, W., and I. Flamme. 1995. Vasculogenesis. Annu Rev Cell Dev Biol 11:73-
91. 
163. Romero, S., C. Le Clainche, D. Didry, C. Egile, D. Pantaloni, and M. F. Carlier. 
2004. Formin is a processive motor that requires profilin to accelerate actin assembly 
and associated ATP hydrolysis. Cell 119:419-29. 
164. Rong, J. X., M. Shapiro, E. Trogan, and E. A. Fisher. 2003. Transdifferentiation of 
mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. 
Proc Natl Acad Sci U S A 100:13531-6. 
165. Rose, R., M. Weyand, M. Lammers, T. Ishizaki, M. R. Ahmadian, and A. 
Wittinghofer. 2005. Structural and mechanistic insights into the interaction between 
Rho and mammalian Dia. Nature 435:513-8. 
166. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature 362:801-9. 
167. Sagot, I., S. K. Klee, and D. Pellman. 2002. Yeast formins regulate cell polarity by 
controlling the assembly of actin cables. Nat Cell Biol 4:42-50. 
168. Sagot, I., A. A. Rodal, J. Moseley, B. L. Goode, and D. Pellman. 2002. An actin 
nucleation mechanism mediated by Bni1 and profilin. Nat Cell Biol 4:626-31. 
128 
169. Sahai, E., A. S. Alberts, and R. Treisman. 1998. RhoA effector mutants reveal 
distinct effector pathways for cytoskeletal reorganization, SRF activation and 
transformation. Embo J 17:1350-61. 
170. Sano, H., T. Sudo, M. Yokode, T. Murayama, H. Kataoka, N. Takakura, S. 
Nishikawa, S. I. Nishikawa, and T. Kita. 2001. Functional blockade of platelet-
derived growth factor receptor-beta but not of receptor-alpha prevents vascular 
smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient 
mice. Circulation 103:2955-60. 
171. Sartorelli, V., M. Kurabayashi, and L. Kedes. 1993. Muscle-specific gene 
expression. A comparison of cardiac and skeletal muscle transcription strategies. Circ 
Res 72:925-31. 
172. Scheer, U., H. Hinssen, W. W. Franke, and B. M. Jockusch. 1984. Microinjection 
of actin-binding proteins and actin antibodies demonstrates involvement of nuclear 
actin in transcription of lampbrush chromosomes. Cell 39:111-22. 
173. Schmidt, A., and A. Hall. 2002. The Rho exchange factor Net1 is regulated by 
nuclear sequestration. J Biol Chem 277:14581-8. 
174. Schoenenberger, C. A., S. Buchmeier, M. Boerries, R. Sutterlin, U. Aebi, and B. 
M. Jockusch. 2005. Conformation-specific antibodies reveal distinct actin structures 
in the nucleus and the cytoplasm. J Struct Biol 152:157-68. 
175. Schonichen, A., M. Alexander, J. E. Gasteier, F. E. Cuesta, O. T. Fackler, and 
M. Geyer. 2006. Biochemical characterization of the diaphanous autoregulatory 
interaction in the formin homology protein FHOD1. J Biol Chem 281:5084-93. 
176. Selvaraj, A., and R. Prywes. 2003. Megakaryoblastic leukemia-1/2, a transcriptional 
co-activator of serum response factor, is required for skeletal myogenic 
differentiation. J Biol Chem 278:41977-87. 
177. Sepulveda, J. L., S. Vlahopoulos, D. Iyer, N. Belaguli, and R. J. Schwartz. 2002. 
Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs 
early cardiac gene activity. J Biol Chem 277:25775-82. 
178. Shimada, A., M. Nyitrai, I. R. Vetter, D. Kuhlmann, B. Bugyi, S. Narumiya, M. 
A. Geeves, and A. Wittinghofer. 2004. The core FH2 domain of diaphanous-related 
129 
formins is an elongated actin binding protein that inhibits polymerization. Mol Cell 
13:511-22. 
179. Shore, P., and A. D. Sharrocks. 1995. The MADS-box family of transcription 
factors. Eur J Biochem 229:1-13. 
180. Skare, P., J. P. Kreivi, A. Bergstrom, and R. Karlsson. 2003. Profilin I colocalizes 
with speckles and Cajal bodies: a possible role in pre-mRNA splicing. Exp Cell Res 
286:12-21. 
181. Skubitz, K. M., and A. P. Skubitz. 2003. Differential gene expression in 
leiomyosarcoma. Cancer 98:1029-38. 
182. Sobue, K., K. Hayashi, and W. Nishida. 1999. Expressional regulation of smooth 
muscle cell-specific genes in association with phenotypic modulation. Mol Cell 
Biochem 190:105-18. 
183. Somlyo, A. P., and A. V. Somlyo. 2000. Signal transduction by G-proteins, rho-
kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J 
Physiol (Lond) 522 Pt 2:177-85. 
184. Sotiropoulos, A., D. Gineitis, J. Copeland, and R. Treisman. 1999. Signal-
regulated activation of serum response factor is mediated by changes in actin 
dynamics. Cell 98:159-69. 
185. Staus, D. P., A. L. Blaker, J. M. Taylor, and C. P. Mack. 2007. Diaphanous 1 and 
2 regulate smooth muscle cell differentiation by activating the myocardin-related 
transcription factors. Arterioscler Thromb Vasc Biol 27:478-86. 
186. Staus, D. P., Blaker, A.L., Taylor, J.M., Mack, C.P. 2006. Diaphanous 1 and 2 
Regulate Smooth Muscle Cell Differentiation by Activating the Myocardin-Related 
Transcription Factors. Arterioscler. Thromb. Vasc. Biol. In press. 
187. Stuven, T., E. Hartmann, and D. Gorlich. 2003. Exportin 6: a novel nuclear export 
receptor that is specific for profilin.actin complexes. Embo J 22:5928-40. 
188. Sumi, T., K. Matsumoto, and T. Nakamura. 2001. Specific activation of LIM 
kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein 
kinase. J Biol Chem 276:670-6. 
130 
189. Sun, Y., K. Boyd, W. Xu, J. Ma, C. W. Jackson, A. Fu, J. M. Shillingford, G. W. 
Robinson, L. Hennighausen, J. K. Hitzler, Z. Ma, and S. W. Morris. 2006. Acute 
myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator of mammary gland 
function. Mol Cell Biol 26:5809-26. 
190. Sundberg, L. J., L. M. Galante, H. M. Bill, C. P. Mack, and J. M. Taylor. 2003. 
An endogenous inhibitor of focal adhesion kinase blocks Rac1/JNK but not 
Ras/ERK-dependent signaling in vascular smooth muscle cells. J Biol Chem 
278:29783-91. 
191. Takeya, R., K. Taniguchi, S. Narumiya, and H. Sumimoto. 2008. The mammalian 
formin FHOD1 is activated through phosphorylation by ROCK and mediates 
thrombin-induced stress fibre formation in endothelial cells. Embo J 27:618-28. 
192. Tanaka, T., D. Nishimura, R. C. Wu, M. Amano, T. Iso, L. Kedes, H. Nishida, K. 
Kaibuchi, and Y. Hamamori. 2006. Nuclear Rho kinase, ROCK2, targets p300 
acetyltransferase. J Biol Chem 281:15320-9. 
193. Tatsumoto, T., X. Xie, R. Blumenthal, I. Okamoto, and T. Miki. 1999. Human 
ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and 
involved in cytokinesis. J Cell Biol 147:921-8. 
194. Thyberg, J., K. Blomgren, U. Hedin, and M. Dryjski. 1995. Phenotypic 
modulation of smooth muscle cells during the formation of neointimal thickenings in 
the rat carotid artery after balloon injury: an electron-microscopic and stereological 
study. Cell Tissue Res 281:421-33. 
195. Tominaga, T., E. Sahai, P. Chardin, F. McCormick, S. A. Courtneidge, and A. S. 
Alberts. 2000. Diaphanous-related formins bridge Rho GTPase and Src tyrosine 
kinase signaling. Mol Cell 5:13-25. 
196. Topouzis, S., and M. W. Majesky. 1996. Smooth muscle lineage diversity in the 
chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-
mediated transcriptional responses to transforming growth factor-beta. Dev Biol 
178:430-45. 
197. Treisman, R. 1987. Identification and purification of a polypeptide that binds to the 
c-fos serum response element. Embo J 6:2711-7. 
131 
198. Treisman, R. 1986. Identification of a protein-binding site that mediates 
transcriptional response of the c-fos gene to serum factors. Cell 46:567-74. 
199. Treisman, R. 1994. Ternary complex factors: growth factor regulated transcriptional 
activators. Curr Opin Genet Dev 4:96-101. 
200. Treisman, R. 1985. Transient accumulation of c-fos RNA following serum 
stimulation requires a conserved 5' element and c-fos 3' sequences. Cell 42:889-902. 
201. Treisman, R., A. S. Alberts, and E. Sahai. 1998. Regulation of SRF activity by Rho 
family GTPases. Cold Spring Harb Symp Quant Biol 63:643-51. 
202. Turla, M. B., M. M. Thompson, M. H. Corjay, and G. K. Owens. 1991. 
Mechanisms of angiotensin II- and arginine vasopressin-induced increases in protein 
synthesis and content in cultured rat aortic smooth muscle cells. Evidence for 
selective increases in smooth muscle isoactin expression. Circ Res 68:288-99. 
203. Tyson, J., S. Bellman, V. Newton, P. Simpson, S. Malcolm, M. E. Pembrey, and 
M. Bitner-Glindzicz. 1996. Mapping of DFN2 to Xq22. Hum Mol Genet 5:2055-60. 
204. Vartiainen, M. K., S. Guettler, B. Larijani, and R. Treisman. 2007. Nuclear actin 
regulates dynamic subcellular localization and activity of the SRF cofactor MAL. 
Science 316:1749-52. 
205. Wallar, B. J., and A. S. Alberts. 2003. The formins: active scaffolds that remodel 
the cytoskeleton. Trends Cell Biol 13:435-46. 
206. Wallar, B. J., A. D. Deward, J. H. Resau, and A. S. Alberts. 2007. RhoB and the 
mammalian Diaphanous-related formin mDia2 in endosome trafficking. Exp Cell Res 
313:560-71. 
207. Wallar, B. J., B. N. Stropich, J. A. Schoenherr, H. A. Holman, S. M. Kitchen, 
and A. S. Alberts. 2006. The basic region of the diaphanous-autoregulatory domain 
(DAD) is required for autoregulatory interactions with the diaphanous-related formin 
inhibitory domain. J Biol Chem 281:4300-7. 
208. Walsh, K. 1989. Cross-binding of factors to functionally different promoter elements 
in c-fos and skeletal actin genes. Mol Cell Biol 9:2191-201. 
132 
209. Wamhoff, B. R., D. K. Bowles, O. G. McDonald, S. Sinha, A. P. Somlyo, A. V. 
Somlyo, and G. K. Owens. 2004. L-type voltage-gated Ca2+ channels modulate 
expression of smooth muscle differentiation marker genes via a rho 
kinase/myocardin/SRF-dependent mechanism. Circ Res 95:406-14. 
210. Wamhoff, B. R., K. R. Lynch, T. L. Macdonald, and G. K. Owens. 2008. 
Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell 
phenotype. Arterioscler Thromb Vasc Biol 28:1454-61. 
211. Wang, D., P. S. Chang, Z. Wang, L. Sutherland, J. A. Richardson, E. Small, P. 
A. Krieg, and E. N. Olson. 2001. Activation of cardiac gene expression by 
myocardin, a transcriptional cofactor for serum response factor. Cell 105:851-62. 
212. Wang, D. Z., S. Li, D. Hockemeyer, L. Sutherland, Z. Wang, G. Schratt, J. A. 
Richardson, A. Nordheim, and E. N. Olson. 2002. Potentiation of serum response 
factor activity by a family of myocardin- related transcription factors. Proc Natl Acad 
Sci U S A 99:14855-60. 
213. Wang, D. Z., and E. N. Olson. 2004. Control of smooth muscle development by the 
myocardin family of transcriptional coactivators. Curr Opin Genet Dev 14:558-66. 
214. Wang, Y., M. R. El-Zaru, H. K. Surks, and M. E. Mendelsohn. 2004. Formin 
homology domain protein (FHOD1) is a cyclic GMP-dependent protein kinase I-
binding protein and substrate in vascular smooth muscle cells. J Biol Chem 
279:24420-6. 
215. Wang, Y., X. R. Zheng, N. Riddick, M. Bryden, W. Baur, X. Zhang, and H. K. 
Surks. 2009. ROCK isoform regulation of myosin phosphatase and contractility in 
vascular smooth muscle cells. Circ Res 104:531-40. 
216. Wang, Z., D. Z. Wang, D. Hockemeyer, J. McAnally, A. Nordheim, and E. N. 
Olson. 2004. Myocardin and ternary complex factors compete for SRF to control 
smooth muscle gene expression. Nature 428:185-9. 
217. Wang, Z., D. Z. Wang, G. C. Pipes, and E. N. Olson. 2003. Myocardin is a master 
regulator of smooth muscle gene expression. Proc Natl Acad Sci U S A 100:7129-34. 
218. Watanabe, N., and C. Higashida. 2004. Formins: processive cappers of growing 
actin filaments. Exp Cell Res 301:16-22. 
133 
219. Watanabe, N., T. Kato, A. Fujita, T. Ishizaki, and S. Narumiya. 1999. 
Cooperation between mDia1 and ROCK in Rho-induced actin reorganization [see 
comments]. Nat Cell Biol 1:136-43. 
220. Watanabe, N., P. Madaule, T. Reid, T. Ishizaki, G. Watanabe, A. Kakizuka, Y. 
Saito, K. Nakao, B. M. Jockusch, and S. Narumiya. 1997. p140mDia, a 
mammalian homolog of Drosophila diaphanous, is a target protein for Rho small 
GTPase and is a ligand for profilin. Embo J 16:3044-56. 
221. Wei, L., W. Zhou, J. D. Croissant, F. E. Johansen, R. Prywes, A. 
Balasubramanyam, and R. J. Schwartz. 1998. RhoA signaling via serum response 
factor plays an obligatory role in myogenic differentiation. J Biol Chem 273:30287-
94. 
222. Weinhold, B., G. Schratt, S. Arsenian, J. Berger, K. Kamino, H. Schwarz, U. 
Ruther, and A. Nordheim. 2000. Srf(-/-) ES cells display non-cell-autonomous 
impairment in mesodermal differentiation. Embo J 19:5835-44. 
223. Westendorf, J. J. 2001. The formin/diaphanous-related protein, FHOS, interacts with 
Rac1 and activates transcription from the serum response element. J Biol Chem 
276:46453-9. 
224. Wilcox, J. N., E. I. Okamoto, K. I. Nakahara, and J. Vinten-Johansen. 2001. 
Perivascular responses after angioplasty which may contribute to postangioplasty 
restenosis: a role for circulating myofibroblast precursors? Ann N Y Acad Sci 
947:68-90; dicussion 90-2. 
225. Williams, C. L. 2003. The polybasic region of Ras and Rho family small GTPases: a 
regulator of protein interactions and membrane association and a site of nuclear 
localization signal sequences. Cell Signal 15:1071-80. 
226. Wirth, A., Z. Benyo, M. Lukasova, B. Leutgeb, N. Wettschureck, S. Gorbey, P. 
Orsy, B. Horvath, C. Maser-Gluth, E. Greiner, B. Lemmer, G. Schutz, J. S. 
Gutkind, and S. Offermanns. 2008. G12-G13-LARG-mediated signaling in 
vascular smooth muscle is required for salt-induced hypertension. Nat Med 14:64-8. 
227. Wu, X., Y. Yoo, N. N. Okuhama, P. W. Tucker, G. Liu, and J. L. Guan. 2006. 
Regulation of RNA-polymerase-II-dependent transcription by N-WASP and its 
nuclear-binding partners. Nat Cell Biol 8:756-63. 
134 
228. Yang, C., L. Czech, S. Gerboth, S. Kojima, G. Scita, and T. Svitkina. 2007. Novel 
roles of formin mDia2 in lamellipodia and filopodia formation in motile cells. PLoS 
Biol 5:e317. 
229. Yasuda, S., F. Oceguera-Yanez, T. Kato, M. Okamoto, S. Yonemura, Y. Terada, 
T. Ishizaki, and S. Narumiya. 2004. Cdc42 and mDia3 regulate microtubule 
attachment to kinetochores. Nature 428:767-71. 
230. Yoo, Y., X. Wu, and J. L. Guan. 2007. A novel role of the actin-nucleating Arp2/3 
complex in the regulation of RNA polymerase II-dependent transcription. J Biol 
Chem 282:7616-23. 
231. Yoshida, T., K. Kawai-Kowase, and G. K. Owens. 2004. Forced expression of 
myocardin is not sufficient for induction of smooth muscle differentiation in 
multipotential embryonic cells. Arterioscler Thromb Vasc Biol 24:1596-601. 
232. Yoshida, T., S. Sinha, F. Dandre, B. R. Wamhoff, M. H. Hoofnagle, B. E. 
Kremer, D. Z. Wang, E. N. Olson, and G. K. Owens. 2003. Myocardin is a key 
regulator of CArG-dependent transcription of multiple smooth muscle marker genes. 
Circ Res 92:856-64. 
233. Zaromytidou, A. I., F. Miralles, and R. Treisman. 2006. MAL and ternary 
complex factor use different mechanisms to contact a common surface on the serum 
response factor DNA-binding domain. Mol Cell Biol 26:4134-48. 
234. Zeidan, A., I. Nordstrom, S. Albinsson, U. Malmqvist, K. Sward, and P. 
Hellstrand. 2003. Stretch-induced contractile differentiation of vascular smooth 
muscle: sensitivity to actin polymerization inhibitors. Am J Physiol Cell Physiol 
284:C1387-96. 
235. Zhang, J., W. Zhong, T. Cui, M. Yang, X. Hu, K. Xu, C. Xie, C. Xue, G. H. 
Gibbons, C. Liu, L. Li, and Y. E. Chen. 2006. Generation of an adult smooth 
muscle cell-targeted Cre recombinase mouse model. Arterioscler Thromb Vasc Biol 
26:e23-4. 
236. Zhu, X. L., L. Liang, and Y. Q. Ding. 2008. Overexpression of FMNL2 is closely 
related to metastasis of colorectal cancer. Int J Colorectal Dis 23:1041-7. 
 
 
